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“You never know what’s around the corner. 
 It could be everything or it could be nothing. 
 You keep putting one foot in front of the other.  
And then, one day, you look back 
 and you have climbed a mountain” 
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ABSTRACT 
Bile acids, the end product of cholesterol metabolism, got researchers attention in 
the last twenty years for their ability to act as signal molecules. They are involved 
in multiple metabolic processes and, for this reason, they could be interesting lead 
compounds for the treatment of various diseases linked to metabolic syndrome. 
Due to their small chemical structure, bile acids are promiscuous molecules; 
indeed, they are able to bind both nuclear and G-protein coupled receptors, but, in 
some cases, in an unspecific manner. This promiscuity could lead to an unwanted 
activation of one of the two mentioned receptor class that could results in 
undesired side effects. For this reason, it became fundamental to understand the 
key pharmacophoric portions in that kind of molecules in order to know which 
part of them is responsible for the activation of one or both that receptors class.  
In this context, most of my Ph.D. was spent on the speculation on different bile 
acid scaffolds, where modifications were done in order understand the selectivity 
criteria behind the activation of one of the two receptors classes, improving their 
activity towards them. The modifications carried out generated a first class of 
novel selective and dual FXR, GPBAR1 (a G-protein coupled receptor) and 
LXR� agonists, in which some members could be considered as potential lead 
compounds for the treatment of several aspects of metabolic diseases. 
Furthermore, a new class of SHP (an orphan nuclear receptor) agonists was 
synthesised. This represent the first example reported in literature of synthetic 
selective agonists for this receptor, with promising results for the treatment of 
liver fibrosis.  
Finally, the last part of my Ph.D. was spent in the organic synthesis laboratories of 
the Department of Chemistry, Antwerp University, where the direct 
functionalization of the 2-aza-anthraquinone, a molecule endowed with potential 
antiplasmodial activity, was carried out. 
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CHAPTER 1: 
INTRODUCTION 
 
1.1. Metabolic syndrome 
In the civilized world characterized by a stressful life, where sedentary habits and 
unhealthy food are a common trend, the metabolic syndrome became a relevant 
factor for both citizen and public health. 
Metabolic syndrome resulted from several factors that are responsible for the 
increase of cardiovascular diseases and type II diabetes, two conditions that could 
lead to death. 1  Among these factors, insulin resistance, visceral adiposity, 
atherogenic dyslipidaemia, endothelial dysfunction, genetic susceptibility, 
elevated blood pressure, and chronic stress play a critical role in metabolic 
syndrome. Following the guidelines of World Health Organization, the incidence 
of metabolic syndrome increases dramatically when diabetes associates with one 
of the following pathologies: high blood pressure, dyslipidaemia, central obesity, 
and microalbuminuria.2 Today, more than 65% of the world population lives in 
countries where obesity is a life risk factor more than malnutrition,3 and about 20-
25% of world’s population shows the typical cluster of risk for metabolic 
syndrome, numbers that are destined to grow.4 Actually, the clinical management 
of both short and long-term effects of metabolic syndrome is difficult, because 
there is not a univocal method to improve or prevent the syndrome. One of the 
most used approaches by physicians is to treat separately the syndromes that 
constitute the metabolic disease. This approach could be useful in the treatment of 
the short-term effects of metabolic syndrome, but fails in the management of 
long-term effects. As suggested in the guidelines of the National Cholesterol 
Education Programme,5 the treatment of metabolic syndrome should consist in a 
combination of lifestyle modification, diet, physical activity, weight reduction, 
behaviour changes, pharmacological approach and bariatric surgery, as final 
choice. The last one should be actuated only when the patient does not respond 
anymore to weight loss diet or medication.6  
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Today, the pharmacological approach to the weight loss is based on two classes of 
drugs, the inhibitors of nutrient absorption and appetite suppressants. Orlistat, the 
only nutrient absorption inhibitor currently in medical use, associates with several 
side effects such as flatulence and oil leakage in the stool, which could lead to a 
poor tolerance and compliance for the long-term use.1  
Regarding dyslipidaemia, there is a single/combined pharmacological approach 
which involves statins, considered the most effective class of molecules in 
lowering LDL,5 in combination with niacin or fibrates (fenofibrate and 
gemfibrozil). Niacin, in a long-term exposition, could lead to flushing and 
hyperglycaemia,7 thus, in patients affected by diabetes, the dose of niacin should 
be kept low.8  However, although cases of myopathy and rhabdomyolysis have 
been reported, the combination between statin/niacin or statin/fibrate is generally 
considered save.9 
Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor 
blockers (ARBs) represent the first line treatment of hypertension in metabolic 
syndrome, especially in the setting of diabetes.10 Although ACE inhibitors and 
ARBs could reduce the risk of diabetes,11 a recent study suggested that the ACE 
inhibitor ramipril does not prevent the progression of diabetes in people with 
impaired glucose tolerance (IGT) or impaired fasting glucose (IFG).12  
About diabetes, the election therapy for its treatment consists in the use of oral 
hypoglycaemic agents such as metformin, thiazolidenediones, and acarbose.
13 , 14 , 15  Whereas these classes of compounds reduce the incidence of type II 
diabetes mellitus in patients affected by high hematic levels of glucose, no 
reduction in the risk of cardiovascular events in metabolic syndrome (except for 
acarbose) has been so far reported.16 
Considering that one of the most common side effect for all the above reported 
treatments is the tolerance, alternative pharmacological approaches become 
fundamental for the treatment of metabolic syndrome. In this sense, an effective 
therapeutic strategy could be the modulation of the activity of metabolic nuclear 
and G-protein coupled receptors.  
These receptors are involved in the regulation of many physiologic processes 
through different mechanisms of action that will be discussed in the next 
paragraphs. The binding of small lipophilic endogenous and exogenous molecules 
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to metabolic nuclear and G protein coupled receptors, leads to their activation or 
suppression. As result, a specific modulation of the physiologic pathway in which 
the receptor is involved, occurs. This accurate activity modulation points out 
nuclear and G protein coupled receptors as appealing pharmacological targets for 
the treatment of all the aspect composing the metabolic syndrome. 
 
1.2. Nuclear receptors 
Nuclear receptors (NRs) are a class of intracellular protein able to bind specific 
DNA sequences enhancing the transcription of the adjacent genes after the 
binding of small molecules, hormones or steroids. After ligand binding, the 
complex ligand-nuclear receptor transmigrates into the cell nucleus, and, thanks to 
the linking with other nuclear proteins, binds DNA and activates the gene 
expression. All nuclear receptors share two high conservative domains in their 
structure (Figure 1); the N-terminal domain, also called DNA binding domain, 
responsible for the binding to DNA, and a C-terminal domain, the ligand-binding 
domain (LBD), responsible of the binding between the ligand and NR. The 
binding of NR to DNA induces conformational changes that lead to release of a 
co-repressor, the recruitment of a co-activator, chromatin remodelling and finally 
the activation of the transcriptional machinery.  
Forty-eight genes coding for NRs are present in the human genome; most of them 
have been characterized during the last twenty years whereas others still require a 
de-orphanization or a complete explanation of their physiological role. One of the 
first nuclear receptors classification is based on DNA-binding properties and 
dimerization preferences. A more recent classification divided NRs in seven 
classes (from NR0 to NR6) on the base of multiple alignment procedures, 
phylogenetic-tree construction methods and other evolutionary consideration.17 In 
table 1 is reported the latest NRs classification.  
While oestrogen receptor like subfamily works as homodimer, subfamilies 1 and 
2 of NRs work as heterodimers with the retinoid X receptor (RXR). 
Among these last two subfamilies, remarkable are the peroxisome proliferated 
activated receptor (PPAR), with its two isoforms � and �, vitamin D receptor 
(VDR), retinoid acid receptor (RAR), pregnane X receptor (PXR), constitutive 
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androstane receptor (CAR), liver X receptor (LXR) and farnesoid X receptor 
(FXR). Differently from all the other mentioned receptors, PXR and CAR are 
orphan receptors, as physiological ligands have not been so far identified.  PXR 
and CAR are called xenobiotic nuclear receptors because their activation from 
xenobiotics enhances the transcription of Phase I and II enzymes, responsible of 
liver drug metabolization and elimination. 
 
 
 
 
Figure 1. Nuclear receptors structure 
 
In this thesis my attention has been focused on FXR and LXR, two NRs activated 
by bile acids (BAs) that regulate various metabolic functions. 
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 SUBFAMILY GROUP 
NR1 Thyroid Hormone Receptor-like 
•Thyroid hormone receptor 
 •Retinoic acid receptor 
 •Peroxisome proliferator-
activated receptor 
 •Rev-ErbA, RAR-related 
orphan receptor  
•Liver X receptor-like  
•Vitamin D receptor-like 
•NRs with two DNA 
binding domains 
NR2 Retinoid X Receptor-like 
•Hepatocyte nuclear factor-
4 
•Retinoid X receptor 
•Testicular receptor 
•TLX/PNR 
•COUP/EAR 
NR3 Estrogen Receptor-like 
•Estrogen receptor 
•Estrogen related receptor 
•3-Ketosteroid receptors 
NR4 Nerve Growth Factor IB-like •NGFIB/NURR1/NOR1 
NR5 Steroidogenic Factor-like •SF1/LRH1 
NR6 Germ Cell Nuclear Factor-like •GCNF 
NR0 Miscellaneous •DAX/SHP 
Table 1: NRs classification 
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1.2.1. Farnesoid X receptor (FXR) 
In 1999, FXR was deorphanized with the identification of bile acids (BA) as 
endogenous ligands.18,19,20 FXR, mostly expressed in liver and bowel, functions as 
the master sensor of BAs concentration in liver (Figure 2).21 Indeed, by a negative 
feedback mechanism, FXR reduces BAs concentration, preventing the toxic 
effects of these molecules.22 This is the consequence of three different pathways. 
First, the activation of FXR results in the gene expression of the small 
heterodimer partner (SHP), an orphan nuclear receptor that lacks DNA-binding 
domain.23 SHP dimerizes with both LRH-1 and LXR�, resulting in the inhibition 
of the expression of CYP7A1, a cytochrome involved in the de novo synthesis of 
bile acids.24 On the other hand, FXR inhibits BAs uptake in hepatocytes by the 
repression of Na+/taurocholate co-transporting polypeptide (NTCP) and organic 
anion transporting polypeptide 1 (OATP1), and stimulates their elimination in 
liver, intestine and kidney by enhancing the expression of the bile-salt exporting 
pump (BSEP), the alternative basolateral efflux transporter multi-drug resistance 3 
(MDR3) and organic solute transporters � and � (OST���).25,26 For these features, 
FXR appears to be a very attractive target for the treatment of primary biliary 
cirrhosis (PBC) and primary sclerosing cholangitis (PSC), two disorders 
characterized by impaired bile acids level in the liver and resulting from 
progressive bile duct destruction.27,28  
Beside this canonical function, FXR is also involved in maintaining lipid 
homeostasis and glucose metabolism. In fact, FXR activation results in the 
inhibition of triglyceride synthesis through the down regulation of both the 
transcription factor sterol-regulatory-element-binding protein-1c (SREBP1c) and 
its target fatty acid synthase (FAS).29 Furthermore, FXR is able to down-regulate 
gluconeogenesis by the inhibition of phosphoenol pyruvate carboxy kinase, 
glucose-6-phosphatase and fructose-1,6-biphosphatase synthesis, all involved in 
the de novo synthesis of glucose.30,31,32 
For these metabolic effects, FXR could also be an appealing target for the 
treatment of both non-alcoholic steatohepatitis (NASH) and non alcoholic fatty 
liver diseases (NAFLD). 
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Figure 2. FXR functions 
 
The potential therapeutic application of FXR agonists in the treatment of many 
metabolic pathologies increased the attention of researchers to identify 
endogenous and exogenous modulators of this receptor. Among endogenous 
ligands, the chenodeoxycholic acid (CDCA), one of the most abundant BA 
contained in the bile, represents the most potent FXR activator. Regarding 
synthetic molecules (Figure 3), high-throughput screening of several libraries of 
compounds, showed some potent synthetic FXR agonists, noteworthy GW4064, 
obeticholic acid (6-ECDCA) and fexaramine.33,34,35 
 
Figure 3. Natural and synthetic FXR agonists 
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1.2.2. Liver X receptor (LXR)  
The two isoforms of LXR (LXR� and LXR�) share about 77% aminoacid 
sequence identity, and are both activated by the same endogenous ligands. 36 
While LXR� is ubiquitously expressed, LXR� is expressed in liver, intestine, 
adipose tissue, spleen and macrophages. LXR main function is the regulation of 
lipid and cholesterol metabolism.37 Their mechanism of action (Figure 4) include 
the hetero-dimerization with RXR, leading to the activation of LXR responding 
element (LXRE), which, in turn, activates several genes involved in cholesterol 
and fatty acids metabolism such as the ATP binding cassettes A1, G5 and G8 
(ABCA1, ABCG5, ABCG8), apolipoprotein E and sterol response element 
binding protein 1 (SREBP-1c).38,39  
  
  
 Figure 4. LXR functions 
  
LXRs seem to be very appealing targets for the treatment of 
hypercholesterolemia. As reported in many papers,40,41,42,43 LXR agonists are able 
to decrease cholesterol levels and inhibit the progression of atherosclerosis in 
murine models. In another murine model of diet inducted obesity, LXR synthetic 
agonists showed to be able to improve insulin resistance and glucose tolerance, 
thorough the regulation of genes involved in glucose metabolism.44 Moreover, 
activation of LXR in macrophages inhibits the expression of inflammatory 
mediators.45 LXR seems to have also an anti-proliferative effect as its activation 
suppresses the proliferation of breast and prostatic cancer.46,47  
Unfortunately, the correlated induction of the expression of lipogenic genes leads 
to hyperglycaemia and liver steatosis; these two important side effects have 
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limited the therapeutic use of LXR agonists. The increase of lipogenesis could be 
attributed to the higher expression of SREBP-1c, the enzyme responsible of 
hepatic conversion of glucose into lipids.48,49,50,51 For the potential use in treatment 
of pathologies linked to high levels of cholesterol, diabetes and treatment of 
cancer, it is fundamental to identify LXR agonists that show no effects on 
lipogenesis.  
Both isoforms of LXR are activated by endogenous cholesterol metabolites 
(Figure 5) as 22(R)- and 24(S)-hydroxycholesterol and 24(S),25-
epoxycholesterol;52 in literature there are several natural compounds able to bind 
LXRs15 and, noteworthy, berberine, an isoquinoline alkaloid component of 
Rhizoma coptidis, has been tested for its use as anti-inflammatory, antimicrobial, 
antihypertension, antiarrhythmias, antitumor and antidiabetic agent.53,54,55  
 
Figure 5. LXR natural ligands 
 
As it will be discussed in Chapter 4, among bile acids, hyodeoxycholic acid 
(HDCA) is a weak LXR� agonist. In particular, the activation of LXR��by 
HDCA produces beneficial effects in metabolic disorders, cholesterol absorption 
and atherosclerotic plaque formation. These findings point out HDCA derivatives 
as possible lead compounds in the treatment of many metabolic disorders 
regulated by LXR�. 
 
1.3. G-protein coupled receptors 
G-protein coupled receptors (GPCRs), also called seven transmembrane domain 
receptors, are a huge class of proteins ubiquitously distributed in eukaryotes. 
These proteins are placed on the cell membrane surface and the interaction with 
an external ligand produces effects inside cytoplasm. Most of GPCRs are 
composed by seven transmembrane helices, with an N-terminal portion exposed 
outside the cell and responsible of the binding with the proper modulator, and a C-
 12
terminal domain exposed into the cytoplasm. All GPCRs are associated to a 
guanine-binding class of proteins, called G proteins, composed by three subunits 
namely �, � and �, with the last two linked together to form a ���complex, and 
acting as molecular switches inside cells. The binding of a ligand to GPCR 
induces a conformational change responsible of the exchange of GDP for GTP 
(Figure 6). Then, depending on which type of G protein (Gs, Gq or Gi) the receptor 
is associated, different types of activity are triggered. In case of Gs, the binding 
with GTP allows the release of the inhibitory G��s��subunit and the dissociation 
from the receptor itself. The activated G��subunit stimulates the membrane 
enzyme adenylate cyclase, responsible of the conversion of ATP into cAMP, a 
second messenger able to interact with PKA, a protein kinase that phosphorylates 
a large number of targets, producing various effects. Regarding Gq related 
receptors, GTP binding leads to the activation of phospholipase C (PLC). This 
enzyme catalyses the cleavage of phosphatidylinositol 4,5-biphosphate (PIP2) into 
the second messenger inositol (1,4,5) trisphosphate (IP3) and diacylglycerol 
(DAG), both responsible for an increase of intracellular Ca2+ levels. Finally, the 
Gi��protein, differently from Gs, hampers adenylate cyclase activity. Among this 
class of receptors, a part of my research activity was focused on the modulation of 
the G protein-coupled bile acid receptor 1 GPBAR1 (or TGR5), which is the first 
known GPCR able to bind bile acids. 
 
Figure 6. General activation mechanism of GPCRs 
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1.3.1 G protein-coupled bile acids receptor 1(GPBAR1)  
GPBAR1, a Gs protein-coupled receptor, also known as Takeda G receptor 5 
(TGR5), is the membrane bile acid receptor.   
 
Figure 7. GPBAR1 activation effects 
  
Discovered in 2002, the three-dimensional structure of GPBAR1 remains still 
unknown, but in 2014 a 3D homology model was proposed.56 
GPBAR1 is mainly expressed in the cell surface of liver, bowel, skeletal muscle 
cells, adipose tissue and in macrophages/monocytes,57 and depending on its tissue 
expression, it could produce different effects (Figure 7).  
In liver sinusoidal endothelial cells, as well as in biliary tree, gallbladder epithelia, 
apical membranes and primary cilium of cholangiocytes, 58 , 59 , 60  activation of 
GPBAR1 by endogenous bile acids results in the inhibition of de novo bile acids 
synthesis and their re-uptake from enterohepatic circuit as reported also for FXR. 
Consequently, GPBAR1 could be a potential target for the treatment of 
obstructive cholestasis.  
GPBAR1 is also involved in several metabolic processes. In brown adipose tissue 
and in skeletal muscle, it enhances energy expenditure and increase basal 
metabolic rate through the induction of iodothyrosine deiodinase (D2), an enzyme 
responsible of the conversion of inactive thyroid hormone T4 into the active 
thyroid hormone T3.61 Since T3 is also involved in the increasing of glucose 
 14
consumption and the increase of LDL receptors, these findings point GPBAR1 as 
potential anti-obesity target.62 
One of the most promising effects of GPBAR1 activation is on diabetes. Indeed, 
the receptor is expressed on enteroendocrine cells, ad its activation leads to the 
release of the glucagon-like peptide 1 (GLP-1). 63  This hormone acts on �-
pancreatic cells, stimulating the release of insulin and the inhibition of hepatic 
gluconeogenesis, two actions that result in regulating hematic glucose levels, 
gastrointestinal motility and sense of appetite. Experimental data, performed on 
both mice and humans, demonstrated that the activation of GPBAR1 in 
enteroendocrine cells leads to an increasing of GLP-1 hematic levels. 64 , 65 , 66 
Furthermore, other studies demonstrated that GPBAR1 agonists prevent obesity in 
mice fed with a high fat diet showing lower levels of plasma glucose.67 
The expression of GPBAR1 in macrophages and monocytes points out the role of 
GPBAR1 agonists as potential leads in inflammatory diseases. The activation of 
GPBAR1 negatively regulates the expression of several NF-κB pro-inflammatory 
targeted genes such as inducible NOS, interferon-inducible protein, and 
interleukin IL-1α.68 GPBAR1 is also expressed in Kupffer cells, and its activation 
induces the inhibition of the pro-inflammatory cytokines IL-1α, IL-1β, IL-6 and 
tumour necrosis factor-α (TNF-α).69 Several applications of potential GPBAR1 
agonists in the treatment of inflammatory diseases have been proposed. GPBAR1 
has been recently demonstrated overexpressed in patients affected by Crohn’s 
disease and in animal model of colitis. 7071  Furthermore, the anti-inflammatory 
properties of GPBAR1 could be useful for the treatment of the inflammatory 
bowel disease (IBD) and, as consequence, also in the treatment of primary 
sclerosis cholangitis (PSC), that often results from chronic IBD.72,73  
Collectively, these effects affirm GPBAR1 as an appealing target in the 
pharmacological treatment of liver disorders, especially in the metabolic 
syndrome. As reported in literature, all these effects are mediated by the binding 
of GPBAR1 with bile acids, pointing out their role in modulation of metabolic 
syndrome. 
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1.4. Bile acids (BAs) 
Bile acids (Figure 8) are the major components of bile, and their canonical 
function is to participate in lipid and vitamins absorption.  
 
  
  
Figure 8. Endogenous bile acids and hydrophobic/hydrophilic character 
 
From a chemical point of view, BAs are truncated derivatives of cholesterol,74 
with a five-carbon side chain placed in position 17 ending with a carboxylic acid 
moiety, and an hydroxyl function in position 3. Other –OH groups could be found 
at position 7 (as in CDCA and UDCA) and at position 12 (CA). The distinctive 
structural feature of bile acids is the cis junction between A/B rings producing two 
areas with different polarity (Figure 8). An hydrophilic side, composed by the 
carboxylic moiety in side chain and the –OH in position 3, and a hydrophobic 
area, resulting from the tetracyclic carbon scaffold.  
Thanks to this structural organization, bile acids can act as emulsifier molecules, 
explaining their canonical function in lipid and vitamin absorption.  
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Regarding their synthesis, bile acids represent cholesterol hepatic metabolism 
products. There are two different oxidative processes that involve different hepatic 
cytochromes, and both of them took to the synthesis of the so-called primary bile 
acids (Figure 9). 
In the first pathway (the classic pathway), CYP7A1 and CYP8B1 are involved in 
the production of cholic acid (CA), whereas, in the second pathway (the 
alternative one), CYP27A1 and CYP7B1 are responsible of the synthesis of 
chenodeoxycholic acid (CDCA).47 
Once synthesized, BAs reach the intestine, where are deoxidised by resident 
bacteria producing secondary bile acids (Figure 10) such as deoxycholic acid 
(DCA), lithocholic acid (LCA) and, in small amount, ursodeoxycholic acid 
(UDCA).  
Primary and secondary BAs could be subjected to conjugation with glycine in 
humans and taurine in mice, respectively, at C-24 by an N-acyl transferase 
enzyme; the conjugation products are stored in gallbladder, waiting to be released 
during the digestion. Most of BAs (94-98%) are re-absorbed in bowel and come 
back to liver thanks to the entero-hepatic circulation; only a small amount is 
expelled through faeces.  
Although BAs are cholesterol derivatives, they are not able to bind hormone 
receptors. The cis junction between A/B rings pushes the A ring outside the plane 
formed by B-C-D rings, and the loss of a so extended planar structure doesn’t 
allow the oxygen in position 3 to bind its counterpart in hormone receptors, 
whereas that kind of structural organization perfectly fits in BAs receptors 
previously mentioned.  
Among BAs, CDCA is the most active physiological modulator of FXR. 
Differently, LCA (together with its tauro-conjugated form) is the best 
physiological modulator of GPBAR1, showing a high selectivity towards this 
receptor. Comparing the structure of these two molecules, it is clear that the –OH 
at C-7 represents the key pharmacophoric point in activating GPBAR1. Another 
key pharmacophoric portion is the side chain; differently from cholesterol, BAs 
bear a carboxylic acid moiety, responsible of the binding with a common polar 
pocket both in FXR and GPBAR1.56 
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Figure 9. Primary BAs synthetic pathways 
 
 
Figure 10. Secondary bile acid synthetic pathways 
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In this framework, my Ph.D. research work has been mainly focused on the 
speculation of different bile acid scaffolds to find novel lead compounds in the 
treatment of one or more components of the metabolic syndrome. Chemical 
modification at C-3 and/or C-7, the length and functionalization of side chain, as 
well as at the junction between rings A/B, generated new classes of selective/dual 
agonists of FXR, GPBAR1 and LXR. Thanks to the collaboration with the 
research group of Professor Stefano Fiorucci (University of Perugia), 
pharmacological assays were performed on the new synthesized compounds. In 
particular, to address the activity of the compounds towards one of the three 
receptors, transactivation assays were performed. Compounds showing the best 
pharmacologic profile in vitro, were also tested in different ex vivo and in vivo 
experiments, in order to understand their possible applications in the treatment of 
one or more aspect of the metabolic syndrome.  
A more recent section of my work, regarded the synthesis of new synthetic 
nuclear receptor modulators. In particular, this work was focused on the synthesis 
of isoxazole derivatives as new SHP modulators, an orphan nuclear receptor 
whose activation could be useful in the treatment of liver fibrosis. Finally, the last 
part of my Ph.D. was spent in the laboratories of organic synthesis group of the 
Department of Chemistry, University of Antwerp, under the supervision of 
Professor Kourosch Abbaspour Tehrani, where my research activity was focused 
on the synthesis and the functionalization of quinone-compounds endowed with 
antiplasmodium activity.  
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CHAPTER 2: 
URSODEOXYCHOLIC ACID DERIVATIVES 
Among the endogenous bile acids, Ursodeoxycholic acid (UDCA) is a very 
interesting molecule. Generated from CDCA by a simple configuration inversion 
of the –OH at C-7, UDCA represents 3% of the total endogenous BAs. Despite its 
low concentration in human bile, today UDCA represents the only bile acid used 
in therapy. In fact, UDCA is the first choice in the pharmacological treatment of 
primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), 
intrahepatic cholestasis of pregnancy (ICP), as well as other uncommon adult and 
pediatric cholestatic conditions.75 In addition, UDCA plays a neuroprotective role 
and chemopreventive action in colon cancer.76,77,78 Although the mechanism of 
action of UDCA is still unknown, UDCA is a very safe molecule, with minimal 
side effects also when administered in high doses.  
Although UCDA and CDCA exhibit a quite common chemical structure (Figure 
11), the inversion of configuration at C-7 hydroxyl group (� in UDCA, � in 
CDCA) results in a loss of activity of UDCA towards FXR. Indeed, the 7� 
configuration pushes the –OH far from one of the most important site of 
interaction in FXR, resulting in the loss of activity.  
 
Figure 11. Structural differences between CDCA and UDCA 
 
COOH
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COOH
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Considering its safe pharmacological profile, a first set of UDCA derivatives was 
synthetized. In particular, in this frame, the influence of the side chain in receptor 
selectivity was analysed, with modifications regarding both its length and 
functionalization type. 
This modification led to a new class of GPBAR1 modulators (Figure 12), as 
demonstrated from transactivation assays. Computational studies on four 
compounds of the series have been performed to understand the binding pose in 
GPBAR1 binding pocket. Finally, a deep pharmacological evaluation was carried 
out on the best derivative of the group in order to characterize its pharmacological 
activity.  
 
Figure 12. UDCA derivatives synthetized in this study 
 
2.1. Synthesis of nor-UDCA derivatives  
The preparation of nor-UDCA derivatives (Scheme 1) started from protection of 
hydroxyl groups at position 3 and 7 through Fisher’s esterification with formic 
acid and perchloric acid on UDCA. Then, Beckmann one carbon degradation was 
performed treating compound 4 with sodium nitrite, trifluoroacetic acid (TFA) 
and trifluoroacetic anhydride (TFAA) to give the corresponding nor-nitrile 5 in 
high yield (96%). The temperature was set between 35-40 °C, preserving the two 
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formyl group from hydrolysis in the reaction mixture. The reaction proceeds with 
a concertize mechanism as shown in Figure 13. First, the reaction between the 
carboxylic acid moiety in side chain and TFA give the corresponding mixed 
anhydride, an instrumental step necessary to activate the � position at COOH 
(Figure 13, panel A). 
 
 
Scheme 1. Reagents and Conditions. a) HCOOH, HClO4; b) TFA, trifluoroacetic anhydride, 
NaNO2; c) KOH 30% in MeOH/H2O 1:1 v/v; d) p-TsOH, MeOH dry; e) DMT-MM, Et3N, taurine, 
DMF dry; f) LiBH4, MeOH dry, THF, 0 °C; g) Et3N
.SO3, DMF, 95 °C 
 
In the meantime, TFAA reacts with NaNO2 in the acid catalytic environment to 
give the trifluoroacetic nitrite (Figure 13, panel B). The trifluoroacetic nitrite 
reacted with the activated � position of the BA derivative side chain to give the 
corresponding �-nitrose anhydride (Figure 13, panel C). 
This product tautomerizes to the corresponding oxime that reacts immediately 
with TFAA. Then, the heating step induces the reaction between the two 
trifluoroacetate groups, the following electron shift forming the triple bond of 
nitrile with the elimination of CO2 (Figure 13, panel D). Treatment of 5 with 
potassium hydroxide in MeOH/H2O 1:1 gave the simultaneous hydrolysis of 
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nitrile and the de-protection at C-3 and C-7 furnishing compound 6. A first aliquot 
of 6 was treated with taurine in the presence of a coupling agent, 4-(4,6-
dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM), 
giving the amide derivative as ammonium sulphate salt. Purification on RP-18 
column followed by HPLC furnished pure 7 as sodium salt. A second aliquot of 6 
was subjected to Fisher’s esterification in side chain with MeOH and p-
toluensulfonic acid to give the corresponding methyl ester 8 that was transformed 
without purification in its corresponding alcohol 9 by treatment with LiBH4 and 
MeOH in THF. Treatment of 9 with sulfur trioxide triethylamine complex 
(Et3N·SO3) furnished a mixture of sulphate derivatives. HPLC purification gave 
three monosulphate (compounds 10, 11, 12), two disulphate (compounds 13 and 
14) and a trisulphate (15) derivatives.  
 
 
Figure 13. Reaction mechanism of Beckmann’s one carbon degradation 
 
2.2. Synthesis of bis homo-UDCA derivatives  
Key step in C-2 homologation of the side chain on UDCA was the one-pot 
Swern’s oxidation-Horner homologation. The synthetic protocol includes first the 
alcoholic protection at C-3 and C-7 with tert-butyldimethylsilyl 
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trifluoromethanesulfonate (TBSOTf) and 2,6-lutidine. Then, LiBH4 treatment 
furnished the corresponding C-24 alcohol (17) that in turn was subjected to the 
one pot Swern’s oxidation- Horner homologation. 
 
 
Scheme 2. Reagents and Conditions. a) 2,6-lutidine, t-butyldimethylsilyl 
trifluoromethanesulfonate, CH2Cl2, 0 °C; b) LiBH4, MeOH dry, THF, 0 °C; c) DMSO, oxalyl 
chloride, TEA dry, CH2Cl2, -78 °C, then methyl(triphenylphosphoranylidene)acetate; d) HCl 37%, 
MeOH; e) NaOH 5% in MeOH/H2O 1:1 v/v; f) DMT-MM, Et3N, taurine, DMF dry; g) H2, 
Pd(OH)2/C degussa type, THF/MeOH 1:1; h) NaOH 5% in MeOH/H2O 1:1 v/v; i) DMT-MM, 
Et3N, taurine, DMF dry; j) LiBH4, MeOH dry, THF, 0 °C. 
 
From a mechanistic point of view, the reaction proceeds first with the activation 
of dimethylsulfoxide (DMSO) by oxalyl chloride [(COCl)2] through the 
nucleophilic attach of the oxygen of DMSO to one of the acyl moiety of (COCl)2 
forming an intermediate positively charged on sulphur atom (Figure 14). 
 
Figure 14. DMSO activation 
 
Then, the nucleophilic attach of the alcohol (added subsequently at the reaction 
mixture) give the sulfonium ion depicted in Figure 15.  
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Figure 15. Nucleophilic attack to alcohol 
 
Finally, the addition of triethylamine (TEA) produces the de-protonation and the 
subsequent intramolecular re-arrangement affording the formation of the aldehyde 
as shown in Figure 16. 
The aldehyde was then subjected to Horner reaction with methyl 
(triphenylphosphoranylidene) acetate. The reaction was highly stereoselective, 
with the exclusive formation of E isomer 18.  
De-protection at the C-3 and C-7 carbinols by treatment with HCl 37% in MeOH, 
gave compound 19. 
A first aliquot was subjected to basic hydrolysis by treatment with NaOH 5% in 
MeOH/H2O 1:1 to give compound 20, that was treated with taurine in the same 
condition described for compound 7 furnishing the corresponding tauro-conjugate 
21. 
 
Figure 16. Deprotonation and re-arrangement 
 
A second aliquot of 19 was subjected to catalytic reduction at the side chain 
double bond by treatment with H2 and palladium hydroxide on carbon as catalyst 
to give compound 22. Following the same reaction protocols described for 
compounds 19 and 21, starting from an aliquot of 22, compounds 23 and 24 were 
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obtained. Vice versa, LiBH4 reduction of another part of 22 fournished the alcohol 
25.  
The structure-activity relationship studies were completed with the synthesis of 
UDC-OH (compound 26, scheme 3), obtained from the reduction with LiBH4 and 
MeOH of UDCA methyl ester.  
 
Scheme 3. Reagent and conditions. a) LiBH4, MeOH, THF. 
 
2.3. Pharmacological evaluations 
All the synthetized compounds were tested in transactivation assays using the 
luciferase reporter assays on HepG2 cells transfected with FXR. The results 
reported in Figure 17 indicated that none of the synthetized compounds was able 
to activate FXR, showing that independently from the length and functionalization 
of the side chain, the � configuration of hydroxyl group at C-7 plays a 
fundamental role in FXR activation. 
Of interest, transactivation assays of CREB-responsive elements in HEK-293 
cells transiently transfected with GPBAR1, showed that all the alcohols 
synthetized were able to transactivate GPBAR1 independently from the length 
and flexibility of the side chain (see compounds 9, 25 and 26). Interestingly, bis-
homoUDCA 23 and its unsaturated �24,25 analogue 20  transactivated GPBAR1, 
with compound 23 endowed with a potency comparable to taurolithocholic acid 
(TLCA), the most potent endogenous GPBAR1 agonist. Consequently, the 
elongation of the side chain on UDCA produced positive effects towards 
GPBAR1 activation but the selectivity decays with tauro-conjugation (compare 23 
with 24), proving that a further elongation on the side chain is detrimental in term 
of GPBAR1 activation. The analysis of transactivation assays suggested that 
compounds 9, 20, 23, 25 and 26 acted as selective GPBAR1 agonists, with no 
residual activity on FXR. For compounds 9 and 23, the dose–concentration 
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response curve (Figure 19) allowed the calculation of an EC50 of 24.4 and 17.2 
µM, respectively.  
For bis homo-UDCA 23, the most potent GPBAR1 agonist generated in this 
study, ex-vivo and in vivo experiments were also performed. In particular, the 
ability of compound 23 to stimulate the expression of FXR and GPBAR1 target 
genes in liver and intestine was evaluated by real time polymerase chain reaction 
(RT-PCR). 
 
Figure 17. Transactivation assays on FXR. (A) HepG2 cells were transfected with pSG5-FXR, 
pSG5-RXR, pCMV-βgal, and p(hsp27)TKLUC vectors. Cells were stimulated with compounds 3-
16 and 20-26 (10 μM). CDCA (1, 10 �M) was used as a positive control, UDCA (2, 10 �M) as 
negative control. Results are expressed as mean ± standard error; *p <0.05 vs not treated cells 
(NT). (B) HepG2 cells were transfected with pSG5-FXR, pSG5-RXR, pCMV-βgal, and 
p(hsp27)TKLUC vectors. Cells were stimulated with CDCA (1) 10 μM in combination with 3-15 
and 19-26, 50 μM. Results are expressed as mean ± standard error; *p <0.05 vs NT. #p<0.05 vs 
CDCA. °Cytotoxic at 50 μM 
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Figure 18. Transactivation assays on GPBAR1. (A) HEK293 cells were co-transfected with 
GPBAR1 and a reporter gene containing a cAMP responsive element in front of the luciferase 
gene. Twenty-four hour post transfection cells were stimulated with 1-26 (10 μM). Luciferase 
activity served as a measure of the rise in intracellular cAMP following activation of GPBAR1. 
TLCA (T, 10 �M) was used as a positive control. Results are expressed as mean ± standard error. 
*p<0.05 vs NT cells. (B) Antagonistic activity of compounds 1-26 on transactivation of cAMP 
responsive element induced by TLCA in HEK293 cells transfected with GP-BAR. Experimental 
conditions were the same described in panel A. None of the compound had an antagonistic 
activity. Concentrations used were: TLCA 10 µM while all the other compounds were tested at the 
concentration of 50 µM. Results are expressed as mean ± standard error. *p<0.05 vs NT cells. 
°Cytotoxic at 50 μM. 
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Figure 19. Concentration response-curves on GPBAR1 activation by compounds 9 and 23. 
HEK293T were transfected with GPBAR1 and stimulated with increasing concentration of 9 and 
23 (0.1, 1 and 10 �M). Results are mean ± standard error of at least 3 determination in duplicate. 
 
Compound 23 (64 mg/kg) or UDCA (60 mg/kg) were administrated to 11 weeks 
old male mice, and liver, intestine and blood were collected after 3, 6 and 24 
hours. The results reported in Figure 20 indicated that compound 23 was not able 
to induce the expression of OST� and BSEP mRNAs, two target genes for FXR 
in liver cells. Differently, compound 23 increased by two folds the expression of 
pro-glucagon-1, a classic GPBAR1 gene target.  
The activities of bis-homo UDCA (23) and its parent compound UDCA (3) were 
tested in in vivo model of cholestasis inducted by �-naphthylisothiocyanate 
(ANIT). 
 
Figure 20. In vivo administration of 23 has no effect on expression of FXR target genes in the 
liver but increases the expression of pro-glucagon 1, a GPBAR1 regulated gene.  
 
9 23
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In rodent, ANIT is a widely used chemical that simulates human intrahepatic 
cholestasis. ANIT selectively damages the intrahepatic bile ducts, causing first 
cholangitis and, subsequently, cholestasis. 
 
Figure 21.  In vivo administration of UDCA (3) and 23 alters the bile acid pool in a rodent model 
of cholestasis. Cholestasis was induced by feeding mice with ANIT alone or in combination with 
3, 15 mg/kg, or 23, 16 mg/kg, for 7 days. Blood was collected at the end of experiments and bile 
acids concentrations measured as described in the Experimental Section. (A) Analysis of body 
weight loss in control mice, mice administered ANIT, mice administered ANIT plus UDCA and 
mice administered ANIT plus 23. (B) Blood concentrations of total conjugated bile acids. (C) 
Administration of 23 caused a robust increase in tauro-muricholic acid (tMU) and tauro-cholic 
acid (tCA). 
 
Administration of ANIT induced cholestasis as confirmed by the analysis of 
plasma bile acids concentration; in particular, an increase in the total conjugated 
bile acids in comparison with not treated animals was observed (Figure 21, panel 
B and C). Furthermore, a significant weight loss was recorded in ANIT treated 
animals in comparison with not treated group (Figure 21, panel A). Regarding the 
administration of UDCA in ANIT treated animals, no significant differences in 
weight loss and bile acids concentration were observed between ANIT treated 
mice group and ANIT+UDCA treated group. In contrast, a significant increase of 
BAs concentration was observed when compound 23 was administered. In 
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particular, the amount of the tauro conjugated form of muriocholic acid, cholic 
acid and deoxycholic acid was increased in mice administered with compound 23 
(p<0.05 versus ANIT treated mice). These results demonstrated the ability of 
compound 23 in reshaping the bile acid pool in a model of ANIT inducted 
cholestasis, pointing out the use of bis-homo UDCA for the treatment of 
enterohepatic and metabolic disorders. 
 
2.4. Docking Studies  
To elucidate the structural requisites involved in the activity of the UDCA 
derivatives on GPBAR1, docking simulations have been performed on the most 
active compounds of the series (9, 23, 25 and 26), using the tridimensional model 
of GPBAR1 recently reported by the research group in which my work was 
carried out.57 The best score was obtained for compound 23, for which H-bonding 
with the Glu169 and Asn93 side chains through the 3α- and 7β-hydroxyl groups, 
respectively was found; furthermore, the C-26 side chain pointed towards the 
transmembrane helices 1, 2 and 7, interacting with the side chains of Ser21 and 
Ser270. In addition, the binding was stabilized by hydrophobic interactions 
between the steroidal scaffold and several hydrophobic residues, such as Leu71, 
Phe83, Leu174 and Trp237 (Figure 22, panel A).  
The substitution of –COOH group with an alcoholic moiety in the side chain does 
not perturb the ligand binding mode. Indeed, compound 25 (Figure 22, panel B) 
showed a comparable binding pose to that of compound 23, with the steroidal 
scaffold engaging the same H-bonds, and the hydroxyl group on the side chain H-
bonds with Ser270. Thus, the above in silico predictions are in full agreement 
with the pharmacological results, demonstrating that GPBAR1 activation resulted 
from the presence of a polar or a negatively charged group in side chain. 
In order to better understand the binding mechanism of UDCA derivatives, 
docking calculations were performed also on the alcohols 26 (Figure 22 panel C) 
and 9 (Figure 22, panel D), bearing shorter side chains (C-24 and C-23 
respectively). The results of these simulation confirmed that shorter side chains 
are allowed only if a polar end-group, able to bind Ser270 directly or through a 
water H-bond, is present on the side chain of the ligand. Another important 
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feature of the side chain is its flexibility. As confirmed by the pharmacological 
assays, compounds 19 and 20, bearing a more rigid side chain, showed a reduced 
GPBAR1activation, as well as compounds 21 and 24, where the presence of the 
amide group decreases the conformational flexibility of the ligand side chain. 
Another detrimental feature in GPBAR1 activation by UDCA derivatives is the 
presence of large groups on A and B rings. Indeed, compounds 10-15, bearing one 
or more sulfate groups, showed a loss in the activity due to the non-proper 
orientation of the ligand in the binding site.  
 
 
Figure 22. Proposed binding mode of 23 (A), 25 (B), 26 (C) and 9 (D) in the GPBAR1 homology 
model.22 Ligands are represented as cyan (23), green (25) orange (26) and yellow (9) sticks. The 
receptor is shown as grey cartoons and sticks. Hydrogens are omitted for clarity. 
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CHAPTER 3: 
CHOLANOIC ACID DERIVATIVES 
As pointed before, the exogenous regulation of GPBAR1 represents an attractive 
strategy to treat metabolic disorders such as hypercholesterolemia, 
hypertriglyceridemia, and type 2 diabetes mellitus. However, activation of 
GPBAR1 associates with potential side effects, including itching,79 cholesterol 
gallstone formation and gallbladder overfilling. 80,81 Considering the overlapping 
between FXR and GPBAR1 in their signalling pathways, selective FXR ligands 
are currently claimed as new therapeutic options in a wide range of diseases 
related to metabolic, inflammatory and immune-modulated disorders including 
type II diabetes, primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease 
(NAFLD) and nonalcoholic steatohepatitis (NASH).  
The activity of bile acids toward their receptor counterparts is structure dependent, 
with chenodeoxycholic acid (CDCA) and tauro-lithocholic acid (TLCA), being 
the most potent endogenus activators of FXR and GPBAR1, respectively.  
In recent years, the chemical manipulation on CDCA scaffold afforded several hit 
compounds with promising pharmacological profiles.82,83 
In detail, the introduction of an ethyl group at C-6 on the CDCA afforded to the 
disclosure of 6-ECDCA/OCA endowed with high potency toward FXR. 84  6-
ECDCA has been widely investigated in vitro and in vivo and in a phase III 
clinical trial in patients with non-alcoholic steatohepatitis (NASH),85 6-ECDCA 
improved several features of NASH, including inflammation and fibrosis. 
However, the positive findings were tempered by the appearance of pruritus in 
23% of patients and by an increase in total cholesterol and LDL. In addition, 
administration in PBC patients caused pruritus in approx. 50-60% that was severe 
enough to cause drug discontinuation in 40% of patients.86 Indeed, 6-ECDCA is 
also a ligand for GPBAR1,83 and therefore the above side effect might be 
associated to the activation of the membrane bile acid receptor, recently 
demonstrated bona fide to be the physiological mediator of itching in mice.80 
On the other hand, the elimination/inversion of the hydroxyl group at C-3 
represents a good strategy in shifting selectivity toward FXR.83 
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In this context, the manipulation of LCA chemical scaffold regarded the position 
3, the stereochemistry of A/B rings junction, the length and the functionalization 
of the side chain, generating the small library showed in Figure 23. 
 
 
Figure 23. Cholane derivatives generated in this frame 
 
As it will be discussed in the pharmacological section of this chapter, the 
elimination of 3�-OH from cholane scaffold generate a new class of BAs 
derivatives endowed with FXR agonistic/GPBAR1 antagonistic activity, that is, to 
the best of our knowledge, the first example reported in literature.  
 
3.1. Synthesis of 5 -Cholane derivatives  
In the following scheme the synthesis of 5�-cholanoic acid 30 and its tauro 
conjugated form 31, is reported. 
 
 
Scheme 4. Reagents and Conditions. a) p-TsOH, MeOH dry; b) p-TsCl, pyridine; c) LiBr, Li2CO3, 
DMF, reflux; d) H2 3 atm, Pd(OH)2/C degussa type, THF/MeOH 1:1; e) NaOH, MeOH:H2O 1:1 
v/v; f) DMT-MM, Et3N, taurine, DMF dry. 
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LCA was subjected to Fisher’s esterification of the carboxylic acid moiety in side 
chain and tosylation (tosyl chloride in pyridine) at C-3 hydroxyl group to give 
intermediate 28. Elimination by treatment with LiBr/LiCO3 in DMF dry, 
furnished a mixture of �2,3�and��3,4�derivatives that was hydrogenated with H2, 
Pd(OH)2 in THF/MeOH producing compound 29. Finally, basic hydrolysis 
(NaOH, MeOH/H2O) at the methyl ester on the side chain gave 5�-cholanoic acid 
30 in quantitative yield. A small aliquot of compound 30 was treated with taurine 
in the presence of DMT-MM, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-
methylmorpholinium chloride to give the amide derivative as ammonium sulfate 
salt. Purification on RP-18 column followed by HPLC furnished pure 31 as 
sodium salt.   
For the synthesis of nor-5�-cholanoic acid 37, key step was the Beckmann’s one 
carbon degradation (Scheme 5). Starting from LCA, following the same three-step 
synthetic protocol described in the scheme 1 for compounds 4-6, compound 34 
was obtained in high chemical yield. The subsequent Fisher’s esterification 
followed by tosylation, furnished intermediate 35. Elimination with LiBr/LiCO3 
and subsequent hydrogenation as detailed for compound 29, furnished compound 
36. Finally, alkaline hydrolysis of the methyl ester moiety in side chain gave nor-
5�-cholanoic acid 37. 
 
 
Scheme 5. Reagents and Conditions. a) HCOOH, HClO4; b) TFA, trifluoroacetic anhydride, 
NaNO2; c) KOH 30% in MeOH/H2O 1:1 v/v; d) p-TsOH, MeOH dry; e) p-TsCl, pyridine; f) LiBr, 
Li2CO3, DMF, reflux; g) H2 3 atm, Pd(OH)2/C degussa type, THF/MeOH 1:1; h) NaOH, 
MeOH:H2O 1:1 v/v. 
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3.2. Synthesis of 5 -Cholane derivatives  
For the synthesis of 5�-cholane derivatives, the methyl ester of Hyodeoxycholic 
acid, obtained by Fisher’s esterification of HDCA, was used as starting material 
(Scheme 6). 
 
Scheme 6. Reagents and Conditions.  a) p-TsCl, pyridine; b) CH3COOK, DMF/H2O 9:1, reflux; 
(c) H2, Pd/C, THF/MeOH 1:1, room temperature; d) NaOH 5% in MeOH/H2O 5:1 v/v%; e) DMT-
MM, Et3N, taurine, DMF dry; f) LiBH4, MeOH dry, THF, 0 °C; g) Et3N
.SO3, DMF, 95 °C
 
 
Tosylation at position 3 and 6 was followed by double elimination with 
CH3COOK in DMF/H2O. The obtained diene 40 was then subjected to 
hydrogenation in the same operative condition described for compound 29 
furnishing compound 41. Due to the steric hindrance of the methyl-19, the attack 
of H2 proceeds to the � face of the plane formed by A and B rings, affording the 
required A/B trans ring junction, exclusively. A portion of compound 41 was then 
subjected to alkaline hydrolysis furnishing 5�-cholanoic acid 42 that in turn was 
conjugated with taurine in the same condition described for compound 31, giving 
compound 42. Treatment of another aliquot of compound 41 with LiBH4 in 
MeOH/THF produced the reduction of the methyl ester on the side chain 
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furnishing 5�-cholan-23-ol 44. A small aliquot of 44 was then sulphated in side 
chain, giving compound 45. 
 
3.3. Pharmacological evaluations 
The activity of the synthesized compounds was tested in a luciferase reporter 
assay using HepG2 and HEK-293T cells transfected with FXR and GPBAR1, 
respectively. Among this small library, the activity of 5�-cholanoic acid 30 is 
comparable to that of CDCA, the most potent endogenous FXR agonist (Figure 
24). 
 
Figure 24. Transactivation assays on FXR. A, HepG2 cells were transfected with pSG5-FXR, 
pSG5-RXR, pCMV-βgal, and p(hsp27)TKLUC vectors. 24 hours post transfection cells were 
stimulated with compounds 30-45 (10 μM). CDCA (1, 10 �M) was used as a positive control. 
Results are expressed as mean ± standard error; *p <0.05 versus not treated cells (NT). B, HepG2 
cells were transfected as described in A. 24 hours post transfection cells were stimulated with 10 
�M CDCA alone or in combination with 50 �M compounds 30-45. *p <0.05 versus not treated 
cells (NT). #p<0.05 versus CDCA stimulated cells.  
 
Interestingly, also its 5-epimer, 5�-cholanoic acid 42, showed a considerable 
activity towards FXR, indicating that in absence of the hydroxyl groups at C-3 
and C-7, a flat BA scaffold is able to activate FXR. Nor-5�-cholanoic acid 37 was 
inactive at 10 �M but, at 50 �M and in presence of CDCA, it showed a four-fold 
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higher activity compared to that of compound 1, indicating that also compound 37 
could be an FXR modulator.  
Transactivation assay on HEK-293T cells transiently transfected with the 
membrane bile acid receptor GPBAR1 (Figure 25), showed that, except 
compound 45, none of the synthesized compound acted as GPBAR1 agonist, 
indicating that the elimination of the hydroxyl group at C-3 position on LCA is 
detrimental in terms of GPBAR1 activation and therefore represents a good 
strategy in shifting the activity of bile acid derivatives towards FXR. 
 
Figure 25. Transactivation assays on GPBAR-1. A, HEK-293T cells were co-transfected with 
GPBAR-1 and a reporter gene containing a cAMP responsive element in front of the luciferase 
gene. 24 hours post transfection, cells were stimulated with compounds 30-45 (10 μM). TLCA (2, 
10 �M) was used as a positive control. Results are expressed as mean ± standard error. *p < 0.05 
versus not treated cells (NT). B, HEK-293T cells were transfected as described in A. 24 hours post 
transfection cells were stimulated with 10 �M TLCA (2) alone or in combination with 50 �M 
compounds 30-45. *p <0.05 versus not treated cells (NT). #p<0.05 versus TLCA stimulated cells. 
 
Of interest are the data showed in Figure 25, panel B. When administrated in 
presence of TLCA, 5�-cholanoic acid 30, nor 5�-cholanoic acid 37 or 5�-
cholanoic acid 42 inhibited GPBAR1 activation caused by its endogenous ligand. 
These three compounds represented the first example of dual FXR 
agonists/GPBAR1 antagonistic. To further confirm the antagonistic profile of 5�-
cholanoic acid 30 and 5�-cholanoic acid 42, their concentration-response curve 
on GPBAR1 was analyzed. As shown in Figure 26, both compounds inhibited 
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TLCA-transactivation of GPBAR1 in a dose dependent fashion with IC50 values 
of 28 and 22 �M, respectively. 
 
 
Figure 26. Concentration-response curve of 30 and 42 on GPBAR1. GPBAR1 activity was 
measured in HEK-293T cells cotransfected with GPBAR1 and a reporter gene containing a cAMP 
responsive element in front of the luciferase gene (CRE). Twenty-four h post transfection, cells 
were stimulated with increasing concentrations of each compound: range from 1 to 50 μM. Results 
are expressed as mean ± standard error.  
 
Compound 30, the most active molecule synthesized in this study, was evaluated 
in the recruitment of FXR and GPBAR1 target genes. RT-PCR results confirmed 
that it was able to induce the expression of FXR target genes SHP, OST� and 
BSEP (Figure 27). At the same time, the expression of pro-glucagon mRNA 
resulted inhibited when compound 30 was administrated to GLUTAg cells, 
confirming again the FXR agonist/GPBAR1 antagonist profile of compound 30. 
Very recently, the effect of compound 30 has been evaluated on human gastric 
adenocarcinomas cells in which GPBAR1 is expressed in several 
adenocarcinomas and its activation by secondary bile acids increases intestinal 
cell proliferation. Activation of GPBAR1 in gastric cancer cells triggers the EMT 
(epithelial-mesenchymal transition, a process involved in metastasis) and 
acquisition of aggressive phenotype.87  
These effects were inhibited by the administration of 5�-cholanoic acid 30,87 and 
these results highlight the potential beneficial effects of GPBAR1 antagonism in 
the management of advanced gastric cancer. Furthermore, these outcomes could 
shed light on the complex biological pathways under GPBAR1 control.  
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Figure 27. In vitro pharmacological evaluation of compound 30 effect on FXR and GPBAR1 
target genes. (A-C) Real-time PCR analysis of mRNA expression of FXR target genes BSEP (A), 
SHP (B), and OSTα (C) in HepG2 cells primed with 10 μM compound 30. CDCA (1) was used as 
positive control (10 μM). (D) Real-time PCR analysis of mRNA expression of GPBAR1 target 
gene pro-glucagon in Glutag cells stimulated with 10 μM TLCA alone or in combination with 50 
μM compound 30. Values are normalized relative to GAPDH mRNA and are expressed relative to 
those of not treated cells (NT), which are arbitrarily set to 1: *p < 0.05 vs NT. #p<0.05 vs TLCA 
stimulated cells 
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CHAPTER 4: 
HYODEOXYCHOLIC ACID DERIVATIVES 
As mentioned in the Introduction section, the activation of LXR� could be a 
promising therapeutic strategy for the treatment of hypercholesterolemia, 
inflammation and the regulation of glycaemia. Unluckily, synthetic LXR� 
agonists cause the activation of lipogenic enzymes with consequent accumulation 
of triglycerides, hampering their potential use in cardiovascular diseases. Despite 
their side effects, extensive efforts have been made in the investigation of new 
synthetic LXR� modulators. 
Beside some oxysterols [22(R)- and 24(S)-hydroxycholesterol and 24(S),25-
epoxycholesterol], only few examples of BAs capable of activate LXR�� are 
reported; among them, one of the most interesting molecule is the hyodeoxycholic 
acid (HDCA, 46).88  
 
HDCA is a secondary bile acid generated by the C-6 hydroxylation of LCA.89 It is 
present only in traces in human bile but it is the main component of hog bile.90 
HDCA is a weak LXR� agonist,91 showing favourable outcomes in the treatment 
of metabolic disorders in rodent models.92, In addition, as reported by Shih et al.,93 
a diet enriched in HDCA reduced the absorption of cholesterol and increases the 
HDL-mediated outgoing of cholesterol from macrophages and foam cells, in LDL 
receptor-knockout mice. As consequence, a protective effect against 
atherosclerotic plaques formation is achieved. Furthermore, the administration of 
HDCA in mice produced hypolipidemic effects as confirmed by the inhibition of 
the expression of sterol regulatory element binding protein 1c (SREPB1c), acetyl-
CoA carboxylase (ACoA synthase), fatty acid synthase (FAS), and stearoyl-CoA 
desaturase (S-CoA Des) genes in liver.94 
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HDCA also exhibits a weak but interesting activity on GPBAR1 with an EC50 of 
31.6 �M.95 The LXRα/GPBAR1 activity of HDCA could trace new roads towards 
the synthesis of a novel class of potential dual agonists. Considering that both 
receptors regulate the same physiological processes, a potential dual agonist could 
be a promising molecule for the treatment of metabolic/inflammatory disorders 
with a novel mechanism of action.  
The key step for the synthesis of potential HDCA dual agonists was the analysis 
of the ligand-binding site of both LXR� and GPBAR1. LXR� binding pocket is 
rather amphipathic, allowing the accommodation of both polar and non-polar 
moieties, 96 while GPBAR1 exhibits a small lipophilic cavity that could represent 
a target for small hydrophobic side chains (Figure 28).  
 
Figure 28. Binding pockets of LXR� (panel A) and GPBAR1 (panel B) 
 
For this reason, hydrophobic side chains, differing for length, flexibility and 
ramification, have been introduced on HDCA scaffold as showed in Figure 29.  
 
Figure 29. HDCA side chain derivatives 
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A second set of modification (Figure 30) regarded HDCA steroidal scaffold; in 
particular, the role of A/B rings junction and the hydroxyl group at C-6, as well as 
the configuration at C-3 in the selectivity towards LXR� and/or GPBAR1 
receptors were investigated. Pharmacological evaluations showed several 
compounds endowed with LXR� or GPBAR1 agonist activity. Noteworthy, 
compound 65 represents the first example of dual LXR�/GPBAR1 agonist. 
 
Figure 30. Cholane scaffold and side chain modifications 
 
Furthermore, a deep pharmacological evaluation on this compound has been 
performed in order to evaluate the effects of the dual LXR�/GPBAR1 activation 
on mice metabolism. 
 
4.1. Side chain modifications 
In the preparation of the first class of HDCA derivatives (Figure 29), two sets of 
reactions were performed. First, Wittig reaction on protected aldehydes 50 and 61, 
using various phosphorus ylides, allowed the elongation of the side chain, both on 
HDCA and on nor-HDCA. On the other hand, shorter side chains were prepared 
through an oxidative decarboxylation reaction, furnishing C-22 derivatives.  
The starting material for the synthesis of aldehyde 50 was HDCA (46) and the 
synthetic scheme is reported below (Scheme 7) 
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Scheme 7. Reagents and conditions: a) p-TsOH, MeOH dry, quantitative yield; b) 2,6-lutidine, t-
butyldimethylsilyltrifluoromethanesulfonate, CH2Cl2, 0 °C, quantitative yield; c) LiBH4, MeOH 
dry, THF, 0 °C, 56%; d) DMSO, oxalyl chloride, TEA dry, CH2Cl2, -78 °C, quantitative yield. 
 
The carboxylic acid moiety was subjected to Fisher’s esterification, furnishing the 
corresponding methyl ester 47. Then, hydroxyls protection with TBS, followed by 
reduction of the ester in side chain, afforded the alcohol 49. After purification, 
compound 49 was oxidised by Swern procedure to the corresponding aldehyde 
50. On this intermediate, Wittig reactions were performed using several type of 
phosphorus ylides, as methyl triphenylphosphonium iodide, isopropyl 
triphenylphosponium iodide, isobutyl triphenylphosponium iodide and benzyl 
triphenylphosphonium iodide, followed by –OH deprotection, producing 
compounds 51, 52, 53, 54 and 55, respectively (Scheme 8). Using isobutyl 
triphenylphosponium iodide and benzyl triphenylphosphonium iodide, a 
diasteromeric mixture of cis/trans isomers was obtained, but, differently from 
compounds 54 and 55, the mixture of cis/trans 53 was tested as such. 
 
Scheme 8. Reagents and conditions. a) n-BuLi, methyl/isopropyl/isobutyl/phenyl 
triphenylphosponium iodide, THF dry, r.t.; b) HCl 37%, MeOH; c) H2, Pd(OH)2 degussa type, 
THF:MeOH dry 1:1. 
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Aiming at the synthesis of more flexible derivatives, �24,25 unsaturation in side 
chain was hydrogenated in catalytic conditions, furnishing compound 56 (from 
51), 57 (from 52), 58 (from 53) and 59 from the mixture of 54 and 55.  
For the synthesis of shorten side chains, HDCA was subjected to Beckmann’s one 
carbon degradation (Scheme 9). Following the same operative condition reported 
in Scheme 1, steps a-d, HDCA was converted in the corresponding truncated 
methyl ester. Then, as reported for the methyl ester 47, compound 60 was 
converted into its corresponding protected aldehyde 61. 
 
Scheme 9. Reagents and conditions: a) HCOOH, HClO4; b) TFA, trifluoroacetic anhydride, 
NaNO2; c) KOH 30% in MeOH/H2O 1:1 v/v; d) p-TsOH, MeOH dry; e) 2,6-lutidine, t-
butyldimethylsilyltrifluoromethanesulfonate, CH2Cl2, 0 °C; f) LiBH4, MeOH dry in THF dry; g) 
DMSO, oxalyl chloride, TEA dry, CH2Cl2, -78 °C; h) n-BuLi, methyl/isopropyl 
triphenylphosphonium iodide, THF dry, r.t.; i) HCl 37%, MeOH; j) H2, Pd(OH)2 degussa type, 
THF/MeOH 1:1. 
 
Again, two Wittig reactions, using methyl triphenylphosphonium iodide and 
isopropyl triphenylphosponium iodide, followed by acid deprotection, furnished 
�23,24 unsaturated derivatives 62 and 63. Hydrogenation in catalytic condition of 
an aliquot of compounds 62 and 63 afforded derivatives 64 and 65, respectively. 
Bis-norHDCA derivatives were obtained starting from HDCA by an oxidative 
decarboxylation procedure (Scheme 10). The first step was the protection of 
hydroxyl groups through a simple acetylation. Then, the oxidative 
decarboxylation was performed using Cu(OAc)2  and Pb(OAc)4 with a free radical 
mechanism. 
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Scheme 10. Reagents and conditions: a) Ac2O, pyridine; b) Cu(OAc)2 H2O, Pb(OAc)4 in toluene 
dry/pyridine dry; c) CH3ONa, CHCl3 dry/MeOH dry 5:3 v/v; d) H2, Pd(OH)2 degussa type, THF 
dry/MeOH dry 1:1 v/v. 
 
The reaction of compound 66 with Pb(OAC)4 furnished an interchange of ester 
groups as reported in the following Figure 31. 
 
Figure 31. Insertion of Pb(OAc)4 
 
Then, a free radical mechanism started with the formation of the intermediate 
radical R• (Figure 32) 
 
Figure 32. Radical R• formation 
 
The following reaction step was then catalyzed by Cu(OAc)2, allowing the 
oxidation of the intermediate radical to carbocation; in this condition, the loss of a 
proton furnished the corresponding alkene 67. 
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Figure 33. Carbocation and alkene formation 
 
Deprotection at C-3 and C-6 with CH3ONa furnished compound 68; then, the 
reduction of the side chain double bond on an aliquot of 68 afforded derivative 69. 
 
4.2. Steroidal scaffold modifications 
The analysis of the structural requirement for the synthesis of potential dual 
LXR�/GPBAR1 agonists was extended to the steroidical scaffold.  
The effects of the 6-OH removal were analysed through the synthesis of novel 
lithocholic acid derivatives, introducing several apolar side chains on LCA, the 
corresponding 6-deoxy HDCA analogue, using a synthetic procedure reported in 
Scheme 11.  
 
Scheme 11. Reagents and conditions: a) p-TsOH, MeOH dry; b) 2,6-lutidine, t-
butyldimethylsilyltrifluoromethanesulfonate, CH2Cl2, 0 °C; c) LiBH4, MeOH dry, THF, 0 °C; d) 
DMSO, oxalyl chloride, TEA dry, CH2Cl2, -78 °C; e) n-BuLi, methyl/isopropyl 
triphenylphosponium iodide, THF dry, r.t.; f) HCl 37%, MeOH; g) H2, Pd(OH)2 degussa type, 
THF:MeOH dry 1:1. 
 
Aldehyde 70 was synthesized as reported for compound 50 (Scheme 7). Two 
Wittig reactions, using methyl triphenylphosphonium iodide and isopropyl 
triphenylphosponium iodide, followed by –OH deprotection, furnished the 
unsaturated compounds 71 and 72, respectively. An aliquot of both compounds 71 
and 72 was then subjected to catalytic double bond reduction, affording 
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compounds 73 and 74, respectively. The LCA analogues of compounds 68 and 69 
were obtained following the same protocol described in Scheme 10 starting from 
LCA (Scheme 12). 
 
 
Scheme 12. Reagents and conditions: a) Ac2O, Pyr; b) Cu(OAc)2 H2O, Pb(OAc)4 in toluene 
dry/pyridine dry; c) CH3ONa, CHCl3 dry/MeOH dry 5:3 v/v; d) H2, Pd(OH)2 degussa type, THF 
dry/MeOH dry 1:1 v/v. 
 
LCA was first subjected to acetylation at the 3-OH then, the oxidative 
decarboxylation produced compound 76. The following deprotection furnished 
compound 77 that was in turn hydrogenated, giving compound 78. 
The synthesis of 3�, 5�-LCA derivatives started from HDCA and is showed in 
Scheme 13.  
Applying the same set of four reactions described in a previous work,97 a first 
aliquot of HDCA was converted into the methyl ester of 3�, 5�-LCA (compound 
79). 
In detail, the inversion of configuration at C-3 and C-5 was realized through a 
double tosylation on the methyl ester of HDCA, and subsequent 
inversion/elimination with CH3COOK in refluxing DMF. The so obtained �5,6 
intermediate was hydrogenated in catalytic condition to give compound 79. 
Following the same synthetic procedure described in Scheme 11 for LCA, 
compound 79 was converted into the corresponding protected aldehyde 80, that 
was then subjected to Wittig reactions (with methyl triphenylphosphonium iodide 
and isopropyl triphenylphosponium iodide); the following deprotection furnished 
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compounds 81 and 82. These compounds were subjected to catalytic 
hydrogenation to give compounds 83 and 84, respectively. 
A second aliquot of 79 was instead subjected to the shortening protocol as 
described in Scheme 12 for LCA. Thus, the methyl-3�-hydroxy-5�-cholanoate 79 
was first subjected to basic hydrolysis of the side chain methyl ester. Then, 
acetylation at C-3 followed by oxidative decarboxylation furnished compound 85. 
Deprotection afforded compound 86, that was subjected to double bond 
hydrogenation, giving compound 87. 
 
Scheme 13. Reagents and conditions: a) p-TsOH, MeOH dry; b) p-TsCl, pyridine; c) CH3COOK, 
DMF/H2O 9:1, reflux; c) H2, Pd/C, THF/MeOH 1:1, room temperature; e) 2,6-lutidine, t-
butyldimethylsilyltrifluoromethanesulfonate, CH2Cl2, 0 °C; f) LiBH4, MeOH dry, THF, 0 °C; g) 
DMSO, oxalyl chloride, TEA dry, CH2Cl2, -78 °C; h) n-BuLi, methyl/isopropyl 
triphenylphosponium iodide, THF dry, r.t.; i) HCl 37%, MeOH; j) H2, Pd(OH)2 degussa type, 
THF:MeOH dry 1:1; k) NaOH, MeOH/H2O 1:1 v/v, reflux; l) Ac2O,pyridine; m) Cu(OAc)2 H2O, 
Pb(OAc)4 in toluene dry/pyridine dry; n) CH3ONa, CHCl3 dry/MeOH dry 5:3 v/v; o) H2, Pd(OH)2 
degussa type, THF dry/MeOH dry 1:1 v/v. 
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4.3. Pharmacological evaluations 
Luciferase reporter assay on HepG2 and HEK-293T cells transfected with LXR�, 
��and GPBAR1 receptors, respectively, was used to evaluate the activity of the 
synthesized compounds. The well-known agonists GW396598 and TLCA (Figure 
34) were used as positive controls for LXR�, �� and GPBAR1, respectively. 
 
Figure 34. Chemical structures of GW3965 and TLCA 
 
As reported in Figure 35, the introduction of a hydrophobic side chain on the 
hyodeoxycholane scaffold produces beneficial effects on the activation of LXR� 
receptor. 
The analysis of the biological activity of compounds 51-69 suggested that 
pharmacological profile of these HDCA derivatives was strictly depended on the 
length and the flexibility of the side chain. Although there is no linear correlation 
between the size of the side chain and the activity towards LXR�, it is possible to 
affirm that too long (compounds 54 and 55) or too short (compounds 62, 64, 68 
and 69) side chains produced detrimental effects in LXR� activation. Concerning 
the flexibility, compounds with a less rigid side chain showed a better activity 
compared to their unsaturated analogues. On the contrary, the elimination of the 
hydroxyl group at C-6, the inversion of configuration of 3-OH and trans A/B ring 
junction, produced detrimental effects on LXR� activation (see derivatives 71-
87), suggesting that these features are necessary for the receptor activation. 
Consequently, compounds endowed with the best activity were 57, 59 and 65, 
with an efficacy of 73%, 63% and 109%, respectively.  
Regarding GPBAR1 activation, their behaviour was the opposite of what 
described for LXR���Figure 36���
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Figure 35. Transactivation assays on LXR . Activity toward LXR� in a reporter assay was 
assessed in HepG2 cells transfected with an LXRα responsive element (LRE) cloned upstream to 
the luciferase gene. For calculation of efficacy data, maximal transactivation of LRE caused by 
each compound (10 μM) was compared to maximal transactivation caused by GW3965 (10 μM) 
and by HDCA (10 μM). 
 
 
 
Figure 36. Transactivation assays on GPBAR1. Activity toward GPBAR1 in a reporter assay 
was assessed in HEK-293T cells transfected with a cAMP responsive element (CRE) cloned 
upstream to the luciferase gene. For calculation of efficacy data, maximal transactivation of CRE 
caused by each compound (10 μM) was compared to maximal transactivation caused by TLCA 
(10 μM) and by HDCA (10 μM). 
 
The elimination of the hydroxyl group at C-6, as well as the inversion of 
configuration at C-3 and the trans A/B ring junction, produced beneficial effects 
on GPBAR1 activation, identifying compounds 78 and 86 as the best selective 
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GPBAR1 agonists generated in this study. Furthermore, compounds presenting a 
double bond in side chain showed a better activity compared to their saturated 
analogues, suggesting that, in presence of a trans A/B ring junction, a saturated 
side chain produces beneficial effects. HDCA scaffold derivatives did not show a 
significant activity towards GPBAR1, except compound 65, the first and the only 
dual LXR�/GPBAR1 agonist generated in this study. Finally, transactivation 
assays on LXR� (Figure 37) and FXR (not shown) indicated that none of 
synthesized compounds was a LXR�/FXR agonist, confirming their selectivity 
towards LXR� and GPBAR1.  
 
Figure 37. Transactivation assay on LXR Activity towards LXR� in a reporter assay was 
assessed in HepG2 cells transfected with an LXRα responsive element (LRE) cloned upstream to 
the luciferase gene. For calculation of efficacy data, maximal transactivation of LRE caused by 
each compound (10 μM) was compared to maximal transactivation caused by GW3965 (10 μM) 
and by HDCA (10 μM). 
 
For the most interesting compounds, dose response experiments were carried out 
(not shown) and the calculated EC50 are reported in Table 2.  
The pharmacological analysis on compound 65 continued with the evaluation of 
the recruitment of LXR� and GPBAR1 target genes through RT-PCR. HepG2 
and Glutag cells were stimulated with GW3965, TLCA and HDCA (10 μM) and 
with increasing concentration of compound 65 (1, 5, 10, 25, 50 µM). As expected, 
compound 65 was able to induce the expression of ABCA1 and SREBP1c, two 
target genes of LXR�, as well as pro-glucagon, a target gene of GPBAR1 (Figure 
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38). This behavior was a further confirmation of the crucial role exerted by 
compound 65 in both LXR�/GPBAR1 activity modulation.  
 
Compound GPBAR1 LXR  
 Affinity ( M)* Affinity ( M) 
Selective LXR  agonists 
51  2.7±0.65 
52  5.1±0.43 
53  6.99±0.31 
54  8.2± 0.16 
59  12.4±0.41 
   
GPBAR1/LXR  dual agonists 
63 4.2±0.79 22.3±3.05 
65 4.9±0.2  3.2±0.03 
   
Selective GPBAR1 agonists 
62 3.7±0.38  
68 2.54±0.015  
72 5.9±0.055  
73 6.8±0.08  
78 0.91±0.092  
81 7.6±0.71  
82 1±0.062  
86 4.9±0.06    
87 1.98±0.145  
Table 2. EC50 of the most interesting compounds 
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 Figure 38. Real-Time PCR analysis of mRNA expression on LXRα and GPBAR1 target 
genes. ABCA1 (A) and SREBP1c (B) expression in HepG2 cells primed with increasing 
concentration of compound 65 (1, 5, 10 and 25 μM). GW3965 and HDCA were used as positive 
controls. C) Pro-glucagon expression in Glutag cells stimulated with increasing dose of compound 
65 (1, 10, 25 and 50 μM). TLCA and HDCA were used as a positive control. Values are 
normalized to GAPDH and are expressed relative to those of not treated cells (NT) which are 
arbitrarily settled to 1. The relative mRNA expression is expressed as 2(-ΔΔCt). 
 
In vivo and ex vivo experiments were performed in order to evaluate whether the 
administration of compound 65 could lead to lipid accumulation in liver, the most 
common side effect shown by almost all LXR��synthetic agonists. As reported in 
Figure 39, panel A, administration of 65 (30 mg/kg) to C57BL6 mice for two 
weeks, did not produce any significant increase of plasmatic levels of AST, 
cholesterol and triglycerides. These results were confirmed by the analysis of liver 
histology, where no differences between the control group and mice treated with 
65 in the hepatocytes shape were observed. In the Figure 39, panel B, the results 
of RT-PCR assayed on liver tissue after administration of 65, were reported. As 
expected, administration of 65 did not affect the expression of steatosis markers 
genes such as FAS, SREBP1c, CD36 and PPARs. Finally, administration of 65 
resulted in an expression increase of GPBAR1 target genes GLP1 and Fgf21 in 
terminal ileum, confirming the dual activity of this compound. 
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Figure 39. Effects of compound 65 on hepatic lipid metabolism and on terminal ileum after 
administration on intact mice. C57BL6 mice were treated with 65 (30 mg/Kg daily per os) for 
two weeks. Results are the mean ± SE of 3-5 mice per group; *p<0.05 versus control mice. A) 
Serum levels of AST, total cholesterol and triglycerides; B) Relative hepatic mRNA expression of 
GLP-1, FGF21, FXR and LXRα genes in terminal ileum; C) Relative hepatic mRNA expression of 
genes involved in fatty acids metabolism (FASN, SREBP1C, CD36) and genes for nuclear 
receptors (PPARα, PPARγ, LXR α); D) Hematoxilin and Eosin liver staining. 
 
4.4. Molecular modelling. 
Computational studies were then performed on compound 65, in order to 
understand the structural features of its interaction with LXR� and GPBAR1 
receptors. 
Using the same GPBAR1 homology model that was used for compound 23 (see 
Chapter 2),57 the docking pose of 65 in GPBAR1 binding pocket was modelled as 
reported in Figure 40. As shown in Figure 40, panel B, the best score model of 
compound 65•GPBAR1 complex exibited similar structural feature as compound 
23 (bis-homoUDCA, chapter 2) did. Despite this, some differences were found. In 
particular, the apolar side chain occupied a small lipophilic pocket formed by 
Ala66, Leu68 and Leu71 on TM2, a different site of interaction in comparison to 
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compounds bearing a polar side chain. This binding pose was further stabilized by 
the interaction of 3�-OH with Glu169 on TM5 and some hydrophobic interaction 
between bile acid scaffold and the side chains of Leu71, Phe96, Leu174 and 
Trp237.  
 
 
Figure 40. Proposed binding mode of 65 in GPBAR1 and in LXRα. (A) Docking pose in the 
homology model of GPBAR1. (B) Conformation obtained from MD simulations within the LXRα 
LBD (PDB code: 3IPU). Compound 65 is represented as cyan sticks. GPBAR1 and LXRα are 
shown as grey and orange cartoons, respectively. Amino acids important for ligand binding are 
depicted as sticks. Non-polar hydrogens are omitted for clarity. 
 
Regarding the binding pose of 65 with LXR�, docking simulations have been 
performed using the crystal structure of the receptor ligand-binding domain (PDB 
code: 3IPU).99 For this receptor, two possible binding poses, A and B, have been 
obtained. As reported in Figure 41, panel A, the hydrophobic chain of 65 is 
oriented towards the helices 11 and 12 of LXRα, whereas the 3α- and 6α-hydroxyl 
groups interact with the residues of the �-sheet close to H1. The binding mode B 
(Figure 41, panel B) showed that compound 65 is oriented in the opposite way in 
comparison to the binding mode A. In particular, the 3α-OH and 6α-OH groups 
are oriented towards His421 of helix 11, whereas the hydrophobic side chain 
extends towards the ligand binding pocket in the space between H4 and H1. In 
order to understand which of the two described binding pose was more stable, 100 
ns molecular dynamics (MD) calculations were performed. The conservation of 
the interactions engaged by the ligand with the protein and the geometrical 
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stability of the ligand were evaluated through computing the root mean square 
displacement (rmsd) of its heavy atoms relative to their starting position. 
 
Figure 41. Binding poses A (A) and B (B) of 65 (cyan sticks) in the LXRα LDB (PDB code: 
3IPU) as predicted by docking calculations. LXRα is shown as orange cartoons. Amino acids 
important for ligand binding are highlighted as sticks. Non-polar hydrogens are omitted for clarity  
 
Figure 42. The rmsd plot of the heavy atoms of 65 during the MD simulations of binding modes A 
(black) and B (red) to LXRα. Prior to the rmsd calculations, trajectory frames were aligned using 
the coordinates of the Cα carbons of the receptor helices. Since binding mode B showed early to 
be unstable, its simulation was stopped at 70 ns. 
The higher value of rmsd in binding mode B suggested that the complex between 
the binding pocket and compound 65 was not stable during the simulation. On the 
other hand, rmsd value for the binding mode A remained constant for all the 
simulation, suggesting that this kind of binding pose was more stable than the 
other one. In the binding pose A, as also shown in Figure 40, panel B, while the 3-
OH moiety established H-bond interactions with the Ser264 side chain, the 
steroidal scaffold sets favourable contacts with lipophilic residues such as Phe257, 
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Phe315 and Phe326. Both 3-OH and 6-OH moieties are able to form water-
mediated interactions with the side chains of Arg232, Glu267 and Glu301. 
Regarding the side chain of 65, it pointed toward a deep lipophilic pocket defined 
by the helices 3, 4, 6, 11, and 12 forming hydrophobic interactions with Phe254, 
Phe335, Leu435, Leu439 and Trp443. These interactions allowed Trp443 to 
interact with His421 through a cation-� interplays. This receptor conformation is 
well recognized as fundamental for the activation of nuclear receptors, because it 
allowed the C-terminal helix to be in the right conformation for the binding of a 
co-activator, resulting in the activation of gene transcription.101 Finally, the above 
described binding mode of 65 within LXR is comparable to the one reported for 
some oxysterols and with the mutagenesis data, suggesting a functional role of 
Glu267 in the binding of oxysterols to LXRs.101 
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CHAPTER 5: 
SHP AGONISTS 
In parallel to the synthesis of BAs derivatives as potential leads for the treatment 
of metabolic disease, a more recent part of my research activity was focused on 
the investigation of new synthetic chemical entities active in the treatment of liver 
fibrosis. In particular, the target of this study was the small (or short) heterodimer 
partner (SHP). SHP is an orphan nuclear receptor presenting a unique structure; 
differently from other NRs, SHP lacks the classical DNA binding domain (DBD), 
while seems to contain a putative ligand binding domain (LBD).100 This structural 
deficiency does not allow SHP to directly bind DNA. Consequently, this receptor 
interacts with the LBD of other nuclear receptors and, in this way, SHP exerts its 
functions. SHP generally works as a negative regulatory co-factor, interacting 
both with NRs, like the farnesoid X receptor (FXR), estrogen receptor (ER), 
hepatocyte nuclear factor (HNF) 4, androgen receptor (AR), estrogen related 
receptor (ERR), liver receptor homolog-1 (LRH-1), liver X receptor (LXR), 
glucocorticoid receptor (GR), pregnane X receptor (PXR), retinoid X receptor 
(RXR), thyroid hormone receptor (THR), constitutive androstane receptor (CAR), 
and with other non nuclear transcriptional factors like NF-�B, c-Jun, SREBP-1c, 
and the forkhead transcription factor HNF3. 101,102  
Three mechanisms of inhibition have been hypothesized for SHP. The first, as in 
the case of the estrogen receptor, involves a competition with the co-activator for 
the binding with the C-terminal activation factor (AF-2) on the receptor.102 A 
second mechanism of inhibition involves the recruitment of a co-repressor, as 
happens in the inhibition of cholesterol 7α-hydroxylase (CYP7A1).103 The third 
involves the interaction of SHP with the surface of the NR or the transcriptional 
factor and in this way, the binding to DNA results hindered, like in the inhibition 
of RXR/RAR heterodimer complex formation.102  
SHP mRNA is predominantly expressed in liver, but it is also present in heart, 
pancreas, spleen, small intestine of human adults, adrenal cortex and 
stomach.102,103 The wide expression of SHP, together with the large number of its 
interacting partners, suggests that this receptor is involved in a number of 
physiological processes. Among them and in the context of metabolic pathologies, 
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one of the main SHP function is the regulation of bile acids homeostasis. Indeed, 
as mentioned in the Introduction, the activation of FXR induces an overexpression 
of SHP that negatively regulates the expression of CYP7A1 and sterol 12 
hydroxylase (CYP8B1) through the inhibition of LRH-1 and HNF4�� 104 
Furthermore, SHP has a role in cholesterol metabolism, glucose homeostasis and, 
interestingly, SHP seems to play an important role against hepatic carcinoma.105 
As discovered in 2014 from the research group of Professor Fiorucci, the 
activation of SHP seems to have beneficial effects in the reversion of liver 
fibrosis.106 Fibrosis represents the natural consequence of a chronic liver injury. It 
is caused by a continuous remodelling of the extracellular matrix (ECM) due to an 
accumulation of type I collagen, proteoglycans, carbohydrates and other 
extracellular proteins. 107  With the persistence of this condition, the fibrosis 
develops into cirrhosis and, as final stage, could turn into hepatic carcinoma. A 
key role in the development of liver fibrosis is played by the activation of the 
hepatic stellate cells (HSC). Their activation, caused by a chronic liver injury, 
results into their trans-differentiation to myofibroblast-like cells, responsible of 
the overexpression of the ECM genes, as well as matrix-degrading enzymes and 
their respective inhibitors.106 The nature of chronic liver injury could range from a 
persistent inflammation status, alcohol abuse, parasites, obesity, cholestasis, 
autoimmune attack and metabolic disorders. In the context so far described, it was 
shown that the activation of SHP results in the inhibition of the trans-
differentiation of HSC into myofibroblast, with the reduction of 70% of type 1 
collagen.108 These data point out SHP as a potential pharmacological target for the 
treatment of liver fibrosis, one of the consequence of metabolic disease.  
Actually, a specific endogenous ligand for SHP is not still found. Some retinoic 
acid related molecules (like all trans retinoic acid ATRA) bind SHP, while among 
synthetic compounds, (E)-4-[3-(1-Adamantyl)-4′-hydroxyphenyl]-3-
chlorocinnamic acid (3-Cl-AHPC) is a weak SHP agonist, despite its anticancer 
activity (Figure 43).108 
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Figure 43. SHP known agonists 
 
Analysing these two structures, it is possible to highlight two common features: a 
carboxylic ending moiety and a cyclic portion on the opposite side of the 
molecule. The difference between these molecules lies in the spacer separating 
these two moieties. The same structural features are present in GW4064, a well-
known FXR agonist (Figure 44).  
 
Figure 44. GW4064 
 
In this molecule, the carboxylic moiety is separated from an isooxazole ring by an 
aromatic spacer, like in 3-Cl-AHPC.  
Keeping in mind these considerations, it was thought that a structural 
simplification of GW4064 could produce new SHP agonists (Figure 45). Holding 
unchanged the 3-(2,6-chlorophenyl)-5-sopropyl-isooxazole, different side chains, 
ending with a polar moiety, were introduced in position 4. These modifications 
furnished the first set of specific SHP agonists, as demonstrated by the 
pharmacological assays. Among them, a deep pharmacological analysis was 
performed on compound 92, demonstrating its potential application in the 
treatment of liver fibrosis, cholestasis and liver inflammation.  
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Figure 45. 3-(2,6-dichlorophenil)-5-isopropil isooxazole derivatives 
 
5.1. Side chain modifications of 3-(2,6-dichlorophenil)-5-isopropil 
isooxazole. 
Following a procedure reported in literature, 109  the synthesis of the 3-(2,6-
dichlorophenyl)-5-isopropylisoxazole-4-carboxylate ethyl ester 91 started from 
2,6-dichlorobenzaldehyde (Scheme 14)  
 
Scheme 14. Reagents and conditions: a) NH2OH•HCl, NaOH in ethanole; b) N-
chlorosuccinimmde in DMF dry; c) ethyl isobutyryl acetate, sodium ethoxide, in THF dry. 
 
The starting material was converted into the corresponding hydroxylamine 89 by 
the treatment with NH2OH•HCl in alkaline conditions. Then, the chlorination of 
intermediate 89 furnished the instrumental functional group for the reaction of 
cyclization with ethyl isobutyryl acetate, yielding 3-(2,6-dichlorophenyl)-5-
isopropylisoxazole-4-carboxylate ethyl ester 91 in high chemical output. As 
reported in Scheme 15, an aliquot of 91 was hydrolyzed in alkaline condition to 
the corresponding carboxylic acid 92 (ISO-COOH), whereas another portion of 91 
was subjected to reduction using diisobutyl aluminum hydride (DIBAL-H) 
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furnishing the alcohol 93, a key intermediate for the synthesis of the elongated 
side chain analogues. Swern oxidation, followed by Horner C-2 homologation on 
compound 93 furnished the ethyl ester 94 that was in turn hydrolyzed to the 
corresponding carboxylic acid 95 by the treatment with LiOH. Finally, an aliquot 
of compound 94 was reduced with DIBAL-H furnishing the unsaturated alcohol 
96. With the aim to keep unchanged the unsaturation both in the ester hydrolysis 
and in the ester reduction, the use of two mild reagents, like LiOH and DIBAL-H 
respectively, was necessary. Stronger condition, like using NaOH or with LiBH4, 
respectively, would have reduced also the double bond. Applying the same 
synthetic protocol described for compound 91, an aliquot of 94 was hydrolyzed to 
the corresponding carboxylic acid 95, while a second aliquot was reduced to yield 
the alcohol 96 that was in turn converted in ethyl ester 97 by Swern-Horner 
reaction. 
 
Scheme 15. Reagents and conditions: a) NaOH 5% in MeOH/H2O 1:1 v/v; b) DIBAL-H in THF, 
Toluene; c) DMSO, oxalyl chloride, TEA dry, CH2Cl2, -78° C; d) LiOH, TEPA, THF dry; e) 
LiOH, THF: H2O 1:1 v/v; f) DIBAL-H in THF, Toluene; g) DMSO, oxalyl chloride, TEA dry, 
CH2Cl2, -78° C; h) LiOH, TEPA, THF dry. 
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5.2. Pharmacological evaluations 
To assess if the synthesized compounds were SHP agonists, transactivation assays 
were performed. HepG2 cells transfected with responsive elements of SHP were 
stimulated with compounds 91-97 (10 �M and 50 �M) and with ATRA, used as 
positive control. As shown in Figure 46, compounds 91, 92 and 96 acted as SHP 
agonists, although their activity is lower than ATRA. Interestingly, the EC50 
calculated for compounds 91 and 92 were similar to that of ATRA (9.6 μM, 8.9 
μM and 8.6 μM, respectively). Further pharmacological analysis has been 
performed on ISO-COOH (92), the best derivative synthesized. First, the activity 
of ISO-COOH on HSC was evaluated and, in particular, the effects on �SMA and 
COL1�1 genes were assessed. Administration of ISO-COOH (92) to rat 
overexpressing SHP resulted into a decrease of α-Smooth muscle actin (αSMA) 
and Collagen Type I Alpha (COL1α) mRNAs, as assessed by RT-PCR (Figure 47, 
panels C and D). In wild type HSC, administration of ISO-COOH did not produce 
any significant effect, confirming that an overexpression of SHP was necessary to 
estimate the activity of 92 (Figure 47, panels A and B).  
 
 
Figure 46. Transactivation assay on SHP ligand binding domain. HepG2 cells were transiently 
transfected with the fusion protein SHP/GAL4 and with the reporter vector pGL4.35. 24 hours 
post-transfection Cells were stimulated with 10 μM or 50 μM compounds 91–97 and with 10 or 50 
μM all trans retinoic acid (ATRA), used as a positive control. Results are expressed as the mean 
Å} standard error (*p < 0.05 vs not treated cells (NT). Concentration−response curves for 
compounds 91 and 92 (ISO-COOH). HepG2 cells transiently transfected with the fusion protein 
SHP/GAL4 and with the reporter vector pGL4.35 were stimulated with increasing concentrations 
of compounds 91 and 92 (1, 10 and 50 μM). ATRA (1, 10 and 50 μM) was used as a positive 
control to evaluate the SHP ligand binding domain activity. 
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Then, the same experiments were performed on human HSC (Figure 48). In 
human HSC-LX2, the administration of CDCA was necessary to overexpress 
SHP. Since the concentration of SHP in human HSC in physiological condition is 
low, its increased expression is achieved through the activation of FXR. Indeed, 
stimulation of FXR with an agonist, like CDCA, resulted into an overexpression 
of SHP.108 Co-administration of 92 and CDCA resulted in a decrease of αSMA 
and COL1α genes levels both in LX2 wild type cells and LX2 overexpressing 
SHP cells.  
 
 
Figure 47. SHP agonism reverses the pro-fibrotic phenotype induces by TGFβ1 in rat HSC. 
Rat HSC-T6 and HSC-T6 overexpressing SHP were used. (A,B). Serum starved HSC-T6 were 
stimulated 18 hours with 10 ng/ml TGFβ1 alone or in combination with 50 μM ISO-COOH. At the 
end of stimulation the relative mRNA expression of αSMA and COL1α1 was assayed by Real-
Time PCR. (C,D) Serum starved HSC-T6 overexpressing SHP were stimulated 18 hours with 10 
ng/ml TGFβ1 alone or in combination with 50 μM ISOCOOH. At the end of stimulation the 
relative mRNA expression of αSMA and COL1α1 was assayed by Real-Time PCR. Values are 
normalized relative to GAPDH mRNA and are expressed relative to those of not treated cells 
(NT), which are arbitrarily set to 1. *p < 0.05 vs NT; #p < 0.05 vs TGFβ1. 
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The effects of compound 92 were also investigated in vivo in a model of liver 
fibrosis inducted in mice by two weeks treatment with CCl4 (Figure 49). Again, 
the administration of CDCA was necessary to stimulate SHP expression. In 
particular, it has been reported that the administration of CDCA in CCl4 treated 
mice results in an overexpression of SHP without reducing liver fibrosis. 110 
Treatment with CCl4 increased the levels of AST and bilirubin, and the treatment 
with CDCA worsened these conditions. On the other hand, co-administration of 
CDCA and 92 resulted in a decrease of these values. A morphometric analysis of 
liver sections confirmed these findings (Figure 50).  
 
 
Figure 48. SHP agonism reverses the pro-fibrotic phenotype induced by TGFβ1 in human 
HSC. HSC-LX2 and HSC-LX2 overexpressing SHP were used. (A,B). Serum starved HSC-LX2 
were activated with 10 ng/ml TGFβ1 and stimulated 18 hours with 50 μM CDCA and ISO-COOH 
50 μM or with a combination of both agents. At the end of stimulation the relative mRNA 
expression of αSMA and COL1α1 was assayed by Real-Time PCR. (C,D) Serum starved HSC-
LX2 overexpressing SHP were exposed to 10 ng/ml TGFβ1 for 18 h alone or in combination with 
50 μM CDCA and 50 μM ISO-COOH or with a combination of both agents. At the end of the 
study cells were harvested and relative mRNA expression of αSMA and COL1α1 assayed by Real-
Time PCR. Values were normalized relative to GAPDH mRNA and not treated cells (NT) were 
arbitrarily set to 1. *p < 0.05 vs NT; #p < 0.05 vs TGFβ1. 
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Imaging of liver sections coloured with two different techniques shows that while 
the treatment with CCl4 increased the number of bridging fibrosis, co-treatment 
with CDCA and 92 almost restored the liver in physiological conditions. The 
same did not happen treating mice with CDCA alone. Furthermore, RT-PCR 
analysis showed that the treatment with CDCA alone aggravated the fibrotic 
condition (Figure 51). On the contrary, co-treatment of CDCA and ISO-COOH 
improved this condition, as demonstrated by the reduction of �SMA, COL1�1, 
TGF� and IL1-� gene levels. 
 
 
Figure 49. SHP activation protects against liver fibrosis in the CCl4 model. Effect of 
compound 92 on AST, Albumin and Bilirubin in mice rendered cirrhotic by administration of 
CCl4. Mice were administered CCl4 for 3 weeks and after the first week of treatment randomized 
to receive CDCA, 5 mg/kg/day, alone or in combination with ISO-COOH, 30 mg/kg/day. 
 
Since ISO-COOH seems to inhibit and to regress liver fibrosis only when 
administrated with CDCA, another model of liver fibrosis was set up using ANIT 
to demonstrate that the activity of compound 92 is independent from the presence 
of CDCA. Administration of ANIT induced an immune response that causes the 
injury of small intrahepatic bile ducts, bile duct regeneration and, finally, liver 
fibrosis and cholestasis, as described in Chapter 2. The hepatic injury was 
confirmed by morphometric analysis of a liver section (Figure 52, panels B and 
C), while cholestasis was confirmed by the evaluation of hematic levels of AST 
and alkaline phosphatase. 
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Figure 50. SHP activation protects against liver fibrosis in the CCl4 model. (A) Hematoxylin 
and eosin (H&E) staining. (B) Syrius red staining. (C) Image J quantification of Syrius red 
staining. 
 
While administration of CDCA alone did not reverse the fibrotic condition 
inducted by ANIT, compound 92, alone or in combination with CDCA, enhanced 
the reversion of liver fibrosis. Then, the expression of various genes involved in 
liver fibrosis, cholestasis and liver inflammation was screened (Figure 53). The 
data suggested that the administration of 92, alone or in combination with CDCA, 
resulted in the reduction of �SMA and COL1�1 mRNAs expression, whereas 
administration of CDCA resulted in the increase their expression. Furthermore, 
compound 92 restored the physiological levels of OST-�, BSEP and NTCP, three 
canonical FXR target genes involved in bile acid uptakes and detoxification by 
hepatocytes. Finally, administration of 92, alone or with CDCA, resulted in the 
reduction of the pro-inflammatory IL-1β and MCP-1 mRNAs, whereas CDCA 
alone did not produce any positive effects. All these data demonstrate that the 
administration of ISO-COOH results in a number of positive effects like 
preventing liver fibrosis, cholestasis and liver inflammation, pointing out SHP as 
an important physiological mediator of metabolic pathology. 
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Figure 51. SHP activation protects against liver fibrosis in the CCL4 model. Effect of CDCA 
(5 mg/kg) or ISO-COOH (30 mg/kg) on fibrotic genes in CCl4-treated mice. The relative hepatic 
mRNA expression of αSMA, COL1α1, TGFβ1, IL1β, FXR, SHP and BSEP was assayed by Real-
Time PCR. Results are the mean Å} SE of 4–6 mice per group. *p < 0.05 versus naïve mice. #p < 
0.05 versus CCl4 alone. 
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Figure 52. SHP agonism protects against liver fibrosis development in a mice model of 
cholestasis. (A) Effect of ISO-COOH on AST and Alkaline phosphatase in mice administered α-
naphthyl-isothiocyanate (ANIT), 10 mg/kg per os for 4 weeks. Mice were randomized after 2 
weeks to receive CDCA (5 mg/kg) alone or in combination with ISO-COOH (30 mg/Kg), or ISO-
COOH alone (30 mg/Kg), for two additional weeks. Data shown are: (B) Hematoxylin and eosin 
(H&E) staining. (C) Syrius red staining. (D) Image J quantification of Syrius red staining. Results 
are the mean Å} SE of 6–9 mice per group. *p < 0.05, **p < 0.005, ***p < 0.0005. 
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Figure 53. SHP activation protects against liver injury by modulating the expression of 
inflammatory genes. Effect of ISO-COOH on fibrosis, bile acid metabolism and inflammatory 
genes was assessed in mice administered α-naphthyl-isothiocyanate (ANIT), 10 mg/kg per os for 4 
weeks. Mice were randomized after 2 weeks of ANIT to receive CDCA (5 mg/kg) alone or in 
combination with ISO-COOH (30 mg/Kg), or ISOCOOH alone (30 mg/Kg), for two additional 
weeks. The relative hepatic mRNA expression of αSMA, COL1α1, TGFβ1, IL1β, MCP1, NTCP, 
FXR, SHP, OSTα and BSEP was assayed by Real-Time PCR. Results are the mean Å} SE of 6–9 
mice per group. *p < 0.05, **p < 0.005, ***p < 0.0005. 
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CHAPTER 6: 
2-AZAANTHREAQUINONE: TOTAL SYNTHESIS AND 
FUNCTIONALIZATION 
The last part of my Ph.D. was spent in the laboratories of Organic Synthesis of the 
Antwerp University, under the supervision of Professor Kourosch Abbaspour 
Tehrani, where the research activity was focused on the synthesis of the 2-
azaanthraquinone, a benz[g]isoquinoline, and its direct functionalization. 
Among natural compounds, the 2-aza-pyronaphtalenquinones are a very 
interesting class of molecules due to their different biological activities. Extracted 
from different kind of organism, and in spite of their pyranonaphthoquinones 
analogues, 2-azaanthraquinones (2-AAQs) have rarely been isolated.111 Examples 
of 2-AAQs (Figure 54) are Bostrycoidin and 9-O-Methylbostrycoidin, both 
isolated from several fungi of the Fusarium species,112 and both endowed with 
antibiotic activity, 113 , 114  Tolypocladin, isolated from the mycelium of 
Tolypocladium inflatum, showing metal-chelating properties,115,116  and, finally, 
the benz[g]isoquinoline-5,10 dione itself, obtained from Psychotria camponutans 
and Mitracarpus scaber, endowed with biologic activity against Plasmodium 
falciparum and Staphylococcus aureus, two multidrug resistant pathogens.117  
 
Figure 54. Naturally occurring 2-AAQs 
 
Beside these antiplasmodial activities, 2-AAQs are intercalating DNA binding 
agents, attracting the researchers interest in cancer chemotherapy.118 Under this 
respect, examples of synthetic 2-AAQs acting as DNA intercalating molecules are 
the pixantrone and the benzo-fused isoquinolinedione derivative BFI (Figure 
55).119,120 Studies on these molecules demonstrated that the planar aromatic ring is 
an essential feature for the intercalation, showing the highest activity with three or 
four conjugated cyclic systems. Finally, the presence of an N-heterocyclic moiety 
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seems to enhance the intercalation due to the formation of further H-bonds with 
DNA.121 These features seems also to reduce the toxic effects related to other 
quinolone antitumor agents; indeed, while the mixantrone shows toxic dose-
related side effects such as myelosuppresion and cardiotoxicity,122 pixantrone, its 
N-heterocyclic analog, showed a reduced toxicity.116  
 
Figure 55. 2-AAQs with anticancer activity 
 
These findings underline the importance of the 2-AAQs scaffold as potential lead 
for new anticancer molecules.  
In this chapter, a new method for the functionalization of the benz[g]isoquinoline-
5,10 dione N-heterocyclic ring with nucleophiles was investigated, leading to the 
synthesis of new 2-AAQ analogues . 
 
6.1. Total synthesis of 2-AAQ 
In literature, a number of methods for the synthesis of the 2-AAQ are reported;111 
one the most frequently used approach is the Diels Alder condensation between 
the isoquinoline-5,8-dione and a suitable substitute cyclohexa-1,3-diene, 
furnishing substitute 2-AAQs on the homocyclic moiety (Figure 56).123  
 
Figure 56. Diels-Alder condensation 
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Another classic approach to the synthesis of substitute 2-AAQs involves the use 
of a Fridel-Craft reaction between a substitute benzene and methylpyridine-4,5-
dicarboxylic anhydride (Figure 57) .124  
 
Figure 57. Fridel-Craft approach 
 
Professor Tehrani research group developed a new synthetic strategy for the 
synthesis of the benz[g]isoquinoline through an intramolecular Hack reaction 
between a protected allylamino moiety and a bromine instrumental function 
(unpublished results). The synthetic procedure (Scheme 16) started from the 
commercially available Menadione (98); the first step was the conversion of the 
chetonic moieties in their alcoholic analogues 99. In this way, the subsequent 
esterification with dimethyl sulphate and sodium methoxyde of that alcoholic 
moieties resulted in the protection of the two chetonic groups, limiting their 
reactivity in the next steps (Scheme 16, step b). Intermediate 100, was then 
subjected to bromination in position 3 using molecular Bromine (intermediate 
101). A second bromination on benzylic position was performed using N-
bromosuccinimide (NBS), furnishing intermediate 102. The methyl bromine of 
102 was then alkylated using a protected allylamine, furnishing compound 103 
(Scheme 16, step e), a suitable substrate for a modified intramolecular Hack 
cyclization. In particular, the use of Cs2CO3 and tert-
butyldicyclohexylphosphonium tetrafluoroborate represent the novelties proposed 
by professor Tehrani research group. This reaction furnished the N-protected 
intermediate 104, that was in turn subjected to a one-step N-deprotection and 
aromatic oxidation furnishing intermediate 105. Finally, the re-oxidation of the 
methyl ester moieties using cerium ammonium nitrate (CAN) provided the 2-
AAQ 106. Although the higher number of synthetic steps compared to the other 
methods reported in literature, this synthesis furnished the desired product in high 
chemical yields and with just one purification step.  
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Scheme 16. Reagents and conditions. a) Na2S2O4, H2O, EtOAC; b) dimethyl sulphate, NaOMe, 
iPrOH, 63 °C; c) Br2, DCM, 0 °C; d) NBS, (E)-Azobis(isobutyronitrile), EtOAc, reflux; e) NaH, 
N-Ethenylacetamide, DMSO, 2-bromo-3-(bromomethyl)-1,4-dimethoxynaphthalene; f) Pd(OAc)2, 
tert-Butyldicyclohexylphosphonium tetrafluoroborate, Cs2CO3, DMF, 130 °C; g) NaOH, air, 
MeOH, reflux; h) CAN, CAN/H2O 2:1 v/v, 0 °C. 
 
6.2. 2-AAQ functionalization 
Given the poor reactivity of 2-AAQ pyridine moiety, an intermediate reaction step 
was necessary to enhance the nucleophilic/electrophilc character of the 
heteroarene portion. One of the most used synthetic protocol for pyridine 
position-2 functionalization is the nucleophilic displacement of the corresponding 
2-halopyridine; unfortunately, this strategy often gives low yields.125 The use of 
Palladium as catalysts in a C2-metalated heteroarene cross-coupling improves the 
yields, but harsh condition or specific ligands are often required.126 Another well-
known strategy to enhance pyridine reactivity towards both nucleophiles and 
electrophilic agents involves its conversion in the corresponding N-oxide (Figure 
58). 127  In the last decade, this activation method has drawn the attention of 
researchers for its versatility in the synthesis of the 2 and 4 substituted pyridine 
derivatives.  
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Figure 58. Electrophilic (A) and nucleophilic (B) behaviour of pyridine N-oxide 
 
There are many different methods for the oxidation of pyridine, most of them 
require the use of peracids or peroxides as oxygen atom donors.128 The products 
obtained are often stable, and this simple activation method offers a number of 
synthetic opportunities for the synthesis of 2 and 4 substitute pyridine derivatives. 
Consequently, using meta-chloroperbenzoic acid (mCPBA), the reaction with 
benz[g]isoquinoline-5,10-dione (106) furnished the stable N-oxide 107 (Scheme 
18) that was used as substrate for the direct functionalization with nucleophiles.  
 
Scheme 18. Reagent and conditions. mCPBA 1.2 eq, DCM, 72 h , rt. 
 
In order to further exalt the electrophilic character of positions 1 or 3 in 
benz[g]isoquinoline-5,10-dione N-oxide, the use of an activating agent became 
necessary. In this way, the addition of a generic nucleophilic agent under mild 
condition could be enhanced.  
After a screening of the related literature, two methods of nucleophilic addition on 
compound 107, were tested. In the first one, bromotripyrrolidinophosphonium 
hexafluorophosphate (PyBroP) as activating agent for the addition of primary and 
secondary amine, was used.129 The second one was based on the work of Crisenza 
et al. which use a Brønsted acid (like p-toluensolfonic acic) as catalyst for the C-2 
alkenylations on pyridine N-oxide scaffold. 130  Both methods have been 
investigated in order to achieve both the nucleophilic substitution and the de-
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oxygenation in a single step. Unfortunately, both the reactions failed in the 
synthesis of the desired product, catalyzing only the de-oxygenation of 2-AAQ N-
oxide. Although a further investigation about the reasons behind this failure was 
not performed, one possible explanation lays in the electron withdrawing effect 
played by the central quinone ring (Figure 59).  
 
Figure 59. Resonance structures of 2-AAQ N-oxide 
 
When the electrons shifted from the N-oxide oxygen to the ketone in position 5, 
the activating agent binds this moiety, resulting in a missed enhancement of the 
electrophilic properties of the heteroarene. Consequently, a new literature search 
about other N-oxide activation methods started. After analysing different 
procedures implicating the use of inorganic and organic metal catalysts, the work 
of Zhu et al. was considered appropriate for the purpose of a direct nucleophilic 
functionalization.131 In this paper, copper iodide (CuI) was proposed as catalyst in 
a one-pot direct amination of quinoline and isoquinoline N-oxides by 
dehydrogenative C−N coupling. Copper ion worked as a Lewis acid in –CH 
activation of position 2 in quinoline N-oxide scaffold; finally, the presence of O2 
was necessary to re-oxidize the copper and complete the catalytic cycle. The 
mechanism of reaction reported in the paper suggested that the N-oxide oxygen 
was not involved in the process of amination, so this method have been applied 
for the nucleophilic substitution in position 1 or 3 of benz[g]isoquinoline-5,10-
dione N-oxide scaffold. Using piperidine as nucleophilic agent, the same 
operative conditions described in Zhu’s work were applied (Table 3). In 16 h, the 
reaction furnished 11.9% yield, with the 9% of the 3-monoaminated product 
(compound 108) and the 2.9% of the 3,4-diaminated (compound 110), efficiently 
separated by silica gel chromatography. The substitution in position 3 was 
confirmed by the 1H NMR spectrum, where the presence of two singlets at ��8.88 
and ��7.60, instead of one singlet and two doublet (as in 2-AAQ N-oxide), 
suggesting that one proton was missing. The correlation in HMBC (Figure 60) 
between H-1 and H-4 with C-3, and between the �-N protons of piperidine (� 
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3.52) and the carbon at � 158.6 (C-3), established that the amination had to be 
necessary in position 3. Regarding compound 110, the double substitution was 
confirmed by the presence of only one singlet at � 8.6. Thanks to the HMBC 
correlations (Figure 60) between the proton at � 3.34 with the carbons at � 158, 
and the proton at � 3.14 with the carbon at � 148.3, it was possible to position the 
two piperidine moieties on carbons 3 and 4, respectively. The NOESY correlation 
between protons at � 3.34 and � 3.14 confirmed the adjacency of the two 
piperidine moieties, as suggested from HMBC.  
 
Figure 60. Principal HMBC (red) and NOESY (blue) correlations of compounds 108 and 110 
 
Interestingly, although the total yield was quite low, the presence of the expected 
1-monoaminated product was not detected, probably because the reactivity of H-1 
resulted limited for the steric hindrance given by the presence of the N-oxide 
oxygen and the ketone in position 10; on the other hand, the 3,4-diaminated 
product suggested that an amination in position 4 took place. Furthermore, the 
presence of both the de-oxygenated 3-monoaminated and 3,4-diaminated product 
was observed.  
Several reaction conditions were then investigated, in order to improve the yields 
of the nucleophilic addition (table 3). 
Using different type of solvents, the total yields were always constant 
(approximately 18%), with the exception of entry 3, where it raised to 55% (12% 
of compound 108 and 33% of compound 110). After long time stirring (entry 5) 
or in case of piperidine excess (entry 6), beside the formation of compounds 108 
and 110, the presence of the 1,3,4-triaminated 2-AAQ (compound 114, Figure 
61), was observed. 
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Entry Solvent Amine Time CuI Additive 
Yields 
of 108 
Yields 
of 109 
Yields 
of 110 
1a,b Toluene 8 eq. 16h 
0.1 
eq. 
- 9% - 2.9% 
2a DMSO 8 eq. 16h 
0.1 
eq. 
- 15.7% - 3.8% 
3c DMF 8 eq. 16 h 
0.1 
eq. 
- 12.5% - 33.6% 
4 CH3CN 8 eq. 16 h 
0.1 
eq. 
- 9.5% - - 
5c,d Toluene 6 eq. 
10 
days 
0.1 
eq. 
- 9.8% - 5% 
6a,b,c Piperidine Excess 16 h 
0.1 
eq. 
- - - 4.4% 
7 Toluene 8 eq. 16 h 
0.1 
eq. 
Cs2CO3  
1 eq. 
31.6% - 60% 
8 Toluene 8 eq. 5 h - 
Cs2CO3  
1 eq. 
- - - 
9 Toluene 2 eq. 16 h - 
Cs2CO3  
1 eq. 
- - - 
10 Toluene 4 eq. 16 h - 
Cs2CO3  
1 eq. 
- - - 
11 Toluene 8 eq. 72 h - 
Cs2CO3  
1 eq. 
5.2% - 23% 
12 Toluene 8 eq. 5 h 
0.1 
eq. 
Cs2CO3  
1 eq. 
10.2% 13.6% 52.9% 
13e Toluene 1 eq. 4 h 
0.1 
eq. 
Cs2CO3  
1 eq. 
8.5% 32% 26% 
Table 3. Optimizing reaction parameters for the condensation of benz[g]isoquinoline-5,10-dione 
N-oxide with piperidine; a 3-monoaminated de-oxygenated side product; b 3,4-diaminated de-
oxygenated side product; c 1,3,4-triaminated de-oxygenated side product; d 2-AAQ side product; e 
2-AAQ N-oxide side product 
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This result suggested that also the substitution in position 1 could be obtained if 
harsh reaction condition (like a large excess of pyridine or the long reaction time) 
was set. 
 
Figure 61. Structure of compound 114 
 
Trying to improve the yields, it was thought that the addition of a base, like 
caesium carbonate (Cs2CO3), could promote the removal of the proton in position 
1, 3 or 4. The results obtained in entry 7 were surprising; adding Cs2CO3, the total 
yield increased to 92% (32% of 108 and 60% of 110), without the presence of any 
side products. Considering the yields improvements by adding Cs2CO3, the effects 
of this additive were tested without CuI. Data reported in entries 8-11 show that 
Cs2CO3 alone did not produce any effect, unless it was let reacting for a longer 
time (entry 11). However, yields were not comparable with entry 7. With the 
scope of getting more insights about the mechanism of substitution, the reaction 
time and the amount of amine were evaluated in presence of CuI and Cs2CO3. 
Surprisingly, reducing the reaction time and/or working with stoichiometric 
amount of amine (entries 12 and 13), the 4-monosubstitute product 109 was 
obtained. The substitution in position 4 was confirmed by the analysis of mono 
and 2D NMR experiments (Figure 62). Two singlets at � 8.48 and � 8.18 in 1H 
NMR were found, suggesting that these two protons should not be adjacent. 
HMBC experiment positioned the piperidine moiety on carbon 4 as a correlation 
between the protons at � 3.18 with carbon at � 150.36 was found; the couplings of 
H-1��� 8.48) with C-� 181.5, C-� 134.6, C-� 132.9 and C-� 118, and the couplings 
of H-3 (� 8.18) with C-1 (� 130), C-4 (� 150.36) and the quaternary carbon at � 
118 confirmed the right placement of the piperidine moiety in position 4. 
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Figure 62. Principal HMBC correlation of compound 109 
 
Comparing the yields of compounds 109 and 110 with the reaction time in entries 
7, 12 and 13, it was possible to get some insights about the mechanism of reaction 
of the different substitutions. Yields of compound 110 arise from 26% (entry 13) 
to 52% (entry 12) first, and finally to 60% (entry 7), whereas the amount of 109 
decreases from 32% in entry 13 to 0% (entry 7); these results indicated that 
compound 109 was totally converted in compound 110 as long as the reaction 
proceeded. Regarding compound 108, its presence could be justified by the attach 
of CuI to the position 3 of 2-AAQ N-oxide in parallel to the reaction in position 4. 
The substitution in position 4 could be explained considering the contribution of 
Mori-Quiroz et al. work; 132  in this paper, a direct coupling of primary and 
secondary amines with an alkylquinone was proposed for the synthesis of 
benzylic amines. The reaction mechanism hypothesized the alkylquinone 
tautomerization, with the formation of a methide intermediate that immediately 
reacted with the amine (Figure 63). The presence of a base (triethyl amine) was 
necessary for the formation of the methide intermediate.  
 
Figure 63. Amination by enolisation reported by Mori-Quiroz et al. 
 
Treating benz[g]isoquinoline 5,10 dione N-oxide with CuI in presence of Cs2CO3, 
the tautomerization of the ketone in position 10 could enhance the 
dehydrogenative coupling in position 4. Interestingly, the use of Cs2CO3 alone 
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failed in the synthesis of mono and diaminated products (entries 8-10), indicating 
a pivotal role for the Cu+ in the mechanism of amination. On the other hand, 
without the addition of Cs2CO3, a small amount of compounds 108 and 110 was 
obtained, indicating that probably the counter ion I(-) could be involved in the 
dehydrogenative coupling in position 3 and 4, but with a lower efficiency 
compared to Cs2CO3. 
Finally, the treatment of intermediate 108, 109 and 110 with phosphorus 
threechloride (PCl3) furnished their de-oxygenated analogues (compounds 111, 
112 and 113, respectively) in quantitative yields (Scheme 19). 
 
Scheme 19. Reagents and Conditions. PCl3 1.2 eq., DCM, r.t. 
 
In conclusion, a new easy, cheap and versatile method for the direct 
functionalization of the 2-AAQ was developed. Although the reaction is not 
selective, the 3 and 4 monoaminated products (108 and 109 respectively) could be 
obtained in decent yields, whereas the 3,4 diaminated product 110 could be 
synthetized in good chemical output. These reaction conditions could be applied 
for a screening of other secondary amines, and in other types of reaction like 
olefination, sulfonylation, alkylation, and acetoxylation, aiming at the synthesis of 
libraries of compounds that could be tested for their antiplasmodial and 
antitumoral activities. 
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CONCLUSIONS 
During this Ph.D., my research activity was mainly focused on the synthesis of 
new potential lead compounds for the treatment of many factors composing the 
so-called metabolic syndrome. Among them, insulin resistance, visceral adiposity, 
atherogenic dyslipidaemia, endothelial dysfunction, genetic susceptibility, 
elevated blood pressure, and chronic stress play a critical role in metabolic 
syndrome. Although the clinical management of both short and long-term effects 
of metabolic syndrome yet exists, the necessity to find new pharmacological 
approaches to these syndromes lays in the side effects showed by the drugs used 
in the actual therapies. In this sense, the interaction between small molecules and 
metabolic nuclear and G-protein coupled receptors could represent a valid 
alternative. These receptors are involved in a number of metabolic physiological 
processes, and their activation or activity repression by a specific ligand 
accurately regulates the pathway in which receptor is involved in and, in many 
case, side effects are avoid.  
Among nuclear and GPCR modulators, bile acids represent a very interesting 
class of molecules. Beside their role in lipid and vitamin absorption, in the last 
twenty years their ability to modulate the activity of both NR and GPCR, working 
as signalling molecules was shown. The main targets of BAs are FXR, LXR� 
(two NR) and GPBAR1 (a GPCR). These receptors are involved in the regulation 
of many physiological processes including BAs, lipid and glucose homeostasis, 
pointing out their modulation through BAs interaction as a new potential 
therapeutic approach in the treatment of some aspects composing the metabolic 
syndrome. As BAs are promiscuous molecules, interacting at the same time with 
more than one receptor, in this work, a deep speculation on BAs scaffold has 
performed in order to understand the structural features necessary for a specific 
modulation of one or more of the mentioned receptors.  
The manipulation of UDCA side chain generated a first set of selective GPBAR1 
agonists, with compound 23, bis-homo UDCA, as the most active compound 
synthesized. Pharmacological evaluation on 23 showed that this compound could 
be a promising lead for the treatment of diabetes, as confirmed by the selective 
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increasing expression of proglucagon 1, a GPBAR1 target, in the small intestine, 
while it had no effect on FXR target genes in the liver. Furthermore, 
administration of compound 23 in vivo resulted in a significant reshaping of bile 
acid pool in a rodent model of cholestasis, thus demonstrating that compound 23 
is a  potential hit for the treatment of enterohepatic and metabolic disorders. 
On the other hand, GPBAR1 is the physiological mediator of cholestatic itching, a 
very heavy side effect in patients affected by cholestasis. Considering that the 
elimination of the hydroxyl group at C-3 from CDCA resulted in a decrease of 
GPBAR1 activity, shifting the selectivity towards FXR, the activity of 5� and 5�-
cholane derivatives was evaluated. Interestingly, the elimination of the hydroxyl 
group at C-3 from LCA resulted in the synthesis of the first class of dual FXR 
agonists/GPBAR1 antagonists. On the best of our knowledge, this result 
represents the first example of cholanoic acid derivatives able to antagonize 
GPBAR1, opening a new pharmacologic approach in the treatment of all the 
pathologies where GPBAR1 activation is associated with severe side effects. 
As reported in literature, HDCA is an interesting molecule for its ability to weakly 
activate both LXR� and GPBAR1. Guided by the structural information on the 
binding site of the two mentioned targets, a rational lead optimization towards the 
synthesis of novel LXR�/GPBAR1 dual agonists was performed. These data 
suggested that the introduction of apolar side chains could be accepted in both 
receptors binding pockets. Consequently, a first set of HDCA apolar derivatives 
was synthesized. A second pattern of modification regarded the tetracyclic core of 
HDCA, where the influence of the elimination of the hydroxyl group at C-6 and 
the inversion in A/B rings junction on LXR�/GPBAR1 activation was evaluated. 
Among the library of HDCA derivatives obtained, compound 65 was the only 
LXR�/GPBAR1 dual agonist, as confirmed from pharmacologic evaluations. 
Interestingly, in vivo administration of 65 did not result in the expression of 
lipogenic enzymes, the most common side effect of LXR� agonists so far 
synthetized, probably for the contemporary activation of GPBAR1. These data 
point out on the double LXR�/GPBAR1 activation as a new potential therapeutic 
strategy for the treatment of metabolic disorders including diabetes, chronic 
inflammatory states and neurodegenerative diseases.  
 87
Beside the bile acids speculation, a more recent and small part of my Ph.D. 
research activity was focused on the synthesis of new SHP modulators as 
potential leads in the treatment of liver fibrosis. Modification of 3-(2,6-
dichlorophenil)-5-isopropil isooxazole side chain afforded a small library of 
compounds, among which compound 92 showed the best activity. Deep 
pharmacologic analysis, both in vitro and in vivo, on compound 92 showed its 
potential application in the treatment of liver fibrosis.  
Finally, the last part of my Ph.D. was spent in the laboratories of Organic 
Synthesis of the University of Antwerp, where my research activity was focused 
on the direct functionalization of the 2-AAQ through –CH catalytic activation. 
During that period, a new, cheap and easy method for the nucleophilic addition in 
position 3 and/or 4 of 2-AAQ was developed and optimized. These reaction 
conditions could be applied to a large number of nucleophiles, opening a new 
synthetic way to the functionalization of benz[g]isoquinoline without the use of 
halogen (for classic cross coupling reaction).  
In conclusion, the results of this work underline that the interaction of small 
molecules and metabolic nuclear and G-protein coupled receptors could be a very 
promising strategy for the treatment of all the pathologies composing the 
metabolic syndrome. In this scenario, bile acids play a pivotal role, since their 
involvement in different metabolic physiologic processes. In this work, it was 
demonstrated that simple modifications to BAs scaffold could generate specific 
lead compounds for the treatment of one or more pathologies composing the 
metabolic disease.  
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EXPERIMENTAL SECTION 
 
I. General procedures. 
 
Chemistry 
Specific rotations were measured on a Jasco P-2000 polarimeter. High-
resolution ESI-MS spectra were performed with a Micromass Q-TOF mass 
spectrometer. NMR spectra were obtained on Varian Inova 400 and Varian 
Inova 500 NMR spectrometers (1H at 400 MHz and 500 MHz, 13C at 100MHz 
and 125 MHz) equipped with a Sun hardware and recorded in CDCl3 (�H = 
7.26 and �C = 77.0 ppm) and CD3OD (�H = 3.30 and �C = 49.0 ppm). J are in 
hertz and chemical shifts (�) are reported in ppm and referred to CHCl3 and 
CHD2OD as internal standards. HPLC was performed using a Waters Model 
510 pump equipped with Waters Rheodine injector and a differential 
refractometer, model 401. Reaction progress was monitored via thin-layer 
chromatography (TLC) on Alugram® silica gel G/UV254 plates. Silica gel 
MN Kieselgel 60 (70-230 mesh) from Macherey-Nagel Company was used for 
column chromatography. All chemicals were obtained from Sigma-Aldrich, 
Inc. Solvents and reagents were used as supplied from commercial sources 
with the following exceptions. Tetrahydrofuran, dichloromethane, 
diisopropylamine and triethylamine were distilled from calcium hydride 
immediately prior to use. Methanol was dried from magnesium methoxide as 
follow. Magnesium turnings (5 g) and iodine (0.5 g) are refluxed in a small 
(50-100 mL) quantity of methanol until all of the magnesium has reacted. The 
mixture is diluted (up to 1 L) with reagent grade methanol, refluxed for 2-3 h 
then distilled under nitrogen. All reactions were carried out under argon 
atmosphere using flame-dried glassware. 
The purity of all of the intermediates, checked by 1H NMR, was greater than 
95%.  
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II. Experimental section Ursodeoxycholic acid derivatives. 
 
3α, 7 -diformyloxy-5 -cholan-24-oic acid (4). A solution of ursodeoxycholic 
acid 3 (550 mg, 1.3 mmol) in 10 mL of 90% formic acid containing 25 �L of 
70% perchloric acid was stirred at 47-50 °C for 12 h. The temperature of the 
heating bath was lowered to 40 °C, then 5 mL of acetic anhydride was added 
over 10 min and the mixture was stirred for 10 min more. The solution was 
cooled to room temperature, poured into 50 mL of water and extracted with 
diethyl ether. The organic layers were washed with water to neutrality, dried 
over Na2SO4, and evaporated to give 570 mg of 4 (96%). An analytic sample 
was obtained by silica gel chromatography eluting with CH2Cl2:MeOH 9:1. 
Selected 1H NMR (400 MHz CD3OD): � 8.03 (1H, s), 7.98 (1H, s), 4.89 (1H, 
m), 4.80 (1H, m), 0.98 (3H, s), 0.93 (3H, d, J = 6.5 Hz), 0.69 (3H, s); 13C 
NMR (100 MHz CD3OD): ��178.1, 163.0, 162.5, 74.9, 74.8, 56.6, 56.4, 44.8, 
43.5, 41.3, 41.2, 40.7, 36.6, 35.4 (2C), 35.1, 34.1, 34.0, 32.3, 32.0, 29.5, 27.6, 
23.6, 22.3, 18.9, 12.5; HRMS-ESI m/z 449.2907 [M+H]+, C26H41O6 requires 
449.2903. 
3α, 7 -diformyloxy-24-nor-5β-cholan-23-nitrile (5). Crude 4 (500 mg, 1.1 
mmol), 1.7 mL of cold trifluoroacetic acid, and 466 �L (3.3 mmol) of 
trifluoroacetic anhydride were stirred at 0-5 °C until dissolution. Sodium nitrite 
(83 mg, 1.2 mmol) was added in small portions. After the addition was 
complete, the reaction mixture was stirred first at 0-5 °C for 1 h, then at 38-40 
°C for 8 h. On completion, the reaction was neutralized with NaOH 2 N, then 
the product was extracted with 50 mL of diethyl ether (3x50 mL), followed by 
washing with brine and dried over anhydrous Na2SO4. The ether was removed 
under reduced pressure to afford 440 mg of 5 (96%), that was subjected to next 
step without any purification. An analytic sample was obtained by silica gel 
chromatography eluting with n-hexane: ethyl acetate 8:2. Selected 1H NMR 
(400 MHz CD3OD): � 8.04 (1H, s), 7.99 (1H, s), 4.87 (1H, m), 4.73 (1H, m), 
1.12 (3H, d, J = 6.5 Hz), 0.98 (3H, s), 0.71 (3H, s); 13C NMR (100 MHz 
CD3OD): ��163.1, 162.6, 120.3, 74.8 (2C), 56.4, 55.5, 44.8, 43.2, 41.2, 40.9, 
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40.6, 35.4, 35.1, 34.6, 34.1, 34.0, 30.9, 29.3, 27.6, 25.1, 23.6, 22.3, 19.8, 12.5; 
HRMS-ESI m/z 416.2807 [M+H]+, C25H38NO4 requires 416.2801. 
24-nor-ursodeoxycholic acid (6). Crude compound 5 (400 mg, 1.0 mmol) was 
refluxed in ca. 50 mL of methanol-water 1:l with 30% KOH. After stirring for 
48 h, the basic aqueous solution was neutralized with HCl 6 N. Then methanol 
was evaporated and the residue was extracted with AcOEt (3x50mL). The 
combined organic layers were washed with brine, dried and evaporated to 
dryness to give white solid residue, that was purified by silica gel 
chromatography, eluting with CH2Cl2:MeOH 9:1 (355 mg, 97%). 
[�]25D=+11.0 (c 0.41, CH3OH); selected 1H NMR (400 MHz CD3OD): ��3.44 
(2H, m), 0.98 (3H, d, J = 6.5 Hz), 0.93 (3H, s), 0.71 (3H, s). 13C NMR (100 
MHz CD3OD): ��177.3, 72.1, 71.9, 57.5, 56.6, 44.8, 44.5, 44.0, 42.5, 41.4, 
40.7, 38.6, 38.0, 36.1, 35.2, 34.9, 31.0, 29.7, 27.9, 23.9, 22.4, 20.2, 12.7; 
HRMS-ESI m/z 379.2844 [M+H]+, C23H39O4 requires 379.2848. 
3 , 7 -dihydroxy-24-nor-5 -cholan-23- oyl taurine sodium salt (7). 
Carboxylic acid 6 (20 mg, 0.1 mmol) in DMF dry (2 mL) was treated with 
DMT-MM (41 mg, 0.2 mmol) and triethylamine (174 �L, 1.3 mmol) and the 
mixture was stirred at room temperature for 10 min. Then to the mixture was 
added taurine (37 mg, 0.3 mmol). After 1h, the reaction mixture was 
concentrated under vacuo and dissolved in water (5 mL). The solution was 
poured over a C18 silica gel column. Fraction eluted with H2O/MeOH 99:1 
gave a mixture that was further purified by HPLC on a Nucleodur 100-5 C18 
(5 �m; 4.6 mm i.d. x 250 mm) with MeOH/H2O (60:40) as eluent (flow rate 1 
mL/min), to give 7 mg (28%) of compound 7 (tR=12.4 min); [�]25D=-4.8 (c 
0.15, CH3OH); selected 1H NMR (400 MHz CD3OD): � 3.58 (2H, t, J = 6.6 
Hz), 3.48 (2H, m), 2.95 (2H, t, J = 6.6 Hz), 0.97 (3H, d, ovl), 0.96 (3H, s), 0.71 
(3H, s); HR ESIMS m/z 484.2735 [M-Na]-, C25H42NO6S requires 484.2732. 
Methyl 3 7 -dihydroxy-24-nor-5β-cholan-23-oate (8). The compound 6 
(100 mg, 0.3 mmol) was dissolved in 30 mL of dry methanol and treated with 
p-toluenesulfonic acid (251 mg, 1.3 mmol). The solution was left to stand at 
room temperature for 5h. The mixture was quenched by addition until the 
neutrality of NaHCO3 saturated solution. Most of the solvent was evaporated, 
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and the residue was extracted with EtOAc. The combined extract was washed 
with brine, dried with Na2SO4, and evaporated to give 8 as amorphous solid 
(100 mg, 97% yield). An analytic sample was obtained by silica gel 
chromatography eluting with CH2Cl2:MeOH 95:5. [�]25D=+19.8 (c 0.22, 
CHCl3); selected 1H NMR (400 MHz CDCl3): � 3.60 (3H, s), 3.51 (2H, m), 
0.92 (3H, d, J = 6.3 Hz), 0.88 (3H, s), 0.65 (3H, s). 13C NMR (100 MHz 
CDCl3): ��173.8, 71.0, 70.9, 55.7, 54.9, 51.3, 43.6, 43.4, 42.4, 41.3, 39.9, 39.1, 
37.1, 37.0, 34.8, 33.9, 33.6, 30.0, 28.6, 26.7, 23.3, 21.0, 19.5, 12.0; HRMS-ESI 
m/z 393.3009 [M+H]+, C24H41O4 requires 393.3005. 
24-nor-5 -cholan-3 , 7 - triol (9). To a solution of 8 (90 mg, 0.2 mmol) 
in dry THF (5 mL) at 0 °C under argon were added LiBH4 (0.8 mL, 2 M in 
THF, 1.6 mmol) and dry methanol (65 μl, 1.6 mmol) and the resulting mixture 
was stirred for 3 h at 0 °C. The mixture was quenched by addition of NaOH (1 
M, 1.4 mL) and then allowed to warm to room temperature. Ethyl acetate was 
added and the separated aqueous phase was extracted with ethyl acetate (3×30 
mL). The combined organic phases were washed with water, dried (Na2SO4) 
and concentrated. Purification by silica gel (CH2Cl2:MeOH 97:3) gave 
compound 9 as a colorless oil (85 mg, quantitative yield). [�]25 D=+23.7 (c 
0.18, CH3OH); 1H NMR (400 MHz CD3OD): δ 3.60 (1H, m ovl), 3.51 (1H, 
m), 3.50 (2H, m), 0.97 (3H, d, ovl), 0.96 (3H, s), 0.72 (3H, s). 13C NMR (100 
MHz CD3OD): � 72.1, 71.9, 60.8, 57.5, 57.1, 44.8, 44.5, 44.0, 41.6, 40.7, 39.9, 
38.6, 38.0, 36.1, 35.2, 34.1, 31.0, 29.8, 27.9, 23.9, 22.4, 19.5, 12.6; HRMS-ESI 
m/z 365.3053 [M+H]+, C23H41O3 requires 365.3056. 
3 , 7 - dihydroxy-24-nor-5 -cholan-23-yl- 23-sodium sulfate (10), 7 23- 
dihydroxy-24-nor-5 -cholan-3 -yl-3-sodium sulfate (11), 3 23- 
dihydroxy-24-nor-5 -cholan-7 -yl-7-sodium sulphate (12), 7 -hydroxy-24-
nor-5 -cholan-3 , 23-diyl- 3, 23-sodium disulfate (13), 3 -hydroxy-24-nor-
5 -cholan-7 , 23-diyl- 7, 23-sodium disulfate (14) and 24-nor-5 -cholan-
3 , 7 , 23-tryl-3, 7, 23-sodium trisulfate (15). The triethylamine-sulfur 
trioxide complex (253 mg, 1.4 mmol) was added to a solution of compound 9 
(50 mg, 0.1 mmol) in DMF dry (5 mL) under an argon atmosphere, and the 
mixture was stirred at 95 °C for 24 h. The solution was then concentrated 
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under vacuum. To the solid dissolved in methanol (15 mL) was added three 
drops of HCl 37% v/v and the mixture was stirred for 3h at room temperature. 
At the end of reaction, silver carbonate was added to precipitate chloride. Then 
the reaction mixture was centrifuged and the supernatant was concentrated in 
vacuo. The residue was poured over a RP18 column. Fraction eluted with 
H2O/MeOH 99:1 gave a mixture that was further purified by HPLC on a 
Nucleodur 100-5 C18 (5 �m; 4.6 mm i.d. x 250 mm) with MeOH/H2O (35:65) 
as eluent (flow rate 1 mL/min), to give 3.7 mg (4%) of compound 15 (tR = 5 
min); fraction eluted with H2O/MeOH 95:5 and with H2O/MeOH 9:1 gave a 
mixture that was purified as previously to afford respectively 8.7 mg (11 %) of 
compound 13 (tR = 15 min) and 7 mg (9%) of compound 14 (tR = 14 min). 
Fraction eluted with H2O/MeOH 75:25 gave a mixture that was further 
purified by HPLC on a Nucleodur 100-5 C18 (5 �m; 4.6 mm i.d. x 250 mm) 
with MeOH/H2O (65:35) as eluent (flow rate 1 mL/min), to give 15 mg (23 %) 
of compound 12 (tR = 7 min). Fraction eluted with H2O/MeOH 7:3 gave a 
mixture that was further purified as previously to give 5 mg (8%) of compound 
10 (tR = 8.4 min) and 4 mg (6 %) of compound 11 (tR = 6.4 min). 
3 , 7 - dihydroxy-24-nor-5 -cholan-23-yl- 23-sodium sulfate (10): 
[�]25D=+35.8 (c 0.69, CH3OH); 1H NMR (400 MHz CD3OD): δ 4.04 (2H, m), 
3.48 (2H, m), 1.00 (3H, d, J = 6.5 Hz), 0.97 (3H, s), 0.72 (3H, s). HR ESIMS 
m/z 443.2469 [M-Na]-, C23H39O6S requires 443.2467. 7 23- dihydroxy-24-
nor-5 -cholan-3 -yl-3-sodium sulfate (11): [�]25D=+11.4 (c 0.04, CH3OH); 
1H NMR (400 MHz CD3OD): δ 4.23 (1H, m), 3.48 (3H, m), 0.98 (3H, d, J = 
6.4 Hz), 0.97 (3H, s), 0.72 (3H, s). HR ESIMS m/z 443.2462 [M-Na]-, 
C23H39O6S  requires 443.2467. 
3 23- dihydroxy-24-nor-5 -cholan-7 -yl-7-sodium sulfate (12): 
[�]25D=+7.8 (c 0.19, CH3OH); 1H NMR (400 MHz CD3OD): δ 4.29 (1H, m), 
3.61 (1H, m), 3.51 (2H, m), 0.97 (3H, s), 0.96 (3H, d, ovl), 0.70 (3H, s). HR 
ESIMS m/z 443.2465 [M-Na]-, C23H39O6S requires 443.2467. 
7 -hydroxy-24-nor-5 -cholan-3 , 23-diyl- 3, 23-sodium disulfate (13): 
[�]25D=+0.3 (c 0.23, CH3OH); 1H NMR (400 MHz CD3OD): δ 4.23 (1H, m), 
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4.04 (2H, m), 3.48 (1H, m), 1.00 (3H, d, J = 6.6 Hz), 0.97 (3H, s), 0.72 (3H, s). 
HR ESIMS m/z 545.1859 [M-Na]-, C23H38NaO9S2 requires 545.1855. 
3 -hydroxy-24-nor-5 -cholan-7 , 23-diyl- 7, 23-sodium disulfate (14): 
[�]25D=+0.5 (c 0.15, CH3OH); 1H NMR (400 MHz CD3OD): δ 4.29 (1H, m), 
4.05 (2H, m), 3.50 (1H, m), 0.99 (3H, d, J = 6.5 Hz), 0.97 (3H, s), 0.71 (3H, s). 
HR ESIMS m/z 545.1857 [M-Na]-, C23H38NaO9S2 requires 545.1855. 
24-nor-5 -cholan-3 , 7 , 23-tryl-3, 7, 23-sodium trisulfate (15): 
[�]25D=+13.3 (c 0.03, CH3OH); 1H NMR (400 MHz CD3OD): δ 4.31 (1H, m), 
4.23 (1H, m), 4.04 (2H, m), 1.00 (3H, d, J = 6.4 Hz), 0.98 (3H, s), 0.71 (3H, s). 
HR ESIMS m/z 647.1247 [M-Na], C23H37Na2O12S3 requires 647.1243.  
5β-cholan-3 , 7 , 24-triol (16). At a solution of methyl 3�, 7�-dihydroxy-5β-
cholan-24-oate (50 mg, 0.1 mmol) in THF dry (10 mL) were added at 0 °C dry 
methanol (51 μl, 1.3 mmol) and LiBH4 (300 �L, 2M in THF, 1.3 mmol). After 
1h, the mixture was quenched by addition of NaOH (1 M, 240 �L) and then 
allowed to warm to room temperature. Ethyl acetate was added and the 
separated aqueous phase was extracted with ethyl acetate (3×30 mL). The 
combined organic phases were washed with water, dried (Na2SO4) and 
concentrated. Purification by silica gel (CH2Cl2/MeOH 9:1) gave compound 16 
as colourless oil (42 mg, 93%). [�]25D=+54.7 (c 0.36, CHCl3); selected 1H 
NMR (400 MHz CD3OD): δ 3.51 (4H, m), 0.97 (3H, d, ovl), 0.97 (3H, s), 0.72 
(3H, s). 13C NMR (100 MHz CD3OD): � 72.1, 71.9, 63.6, 57.6, 56.8, 44.8, 
44.5, 44.0, 41.6, 40.7, 38.6, 38.0, 37.0, 36.1, 35.2, 33.3, 31.0, 30.3, 29.7, 27.9, 
23.9, 22.4, 19.4, 12.6; HRMS-ESI m/z 379.3215 [M+H]+, C24H43O3 requires 
379.3212. 
3 , 7 -di(tert-butyldimethylsilyloxy)-5β-cholan-24-ol (18). 2,6-lutidine (2.8 
mL, 20 mmol) and tert-butyldimethylsilyltrifluoromethanesulfonate (1.7 mL, 6 
mmol) were added at 0 °C to a solution of methyl 3�, 7�-dihydroxy-5β-cholan-
24-oate (800 mg, 2 mmol) in 30 mL of CH2Cl2. After 2 h stirring at 0 °C, the 
reaction was quenched by addition of aqueous NaHSO4 (1M, 100 mL). The layers 
were separated and the aqueous phase was extracted with CH2Cl2 (3×100 mL). 
The combined organic layers were washed with NaHSO4, water, saturated 
aqueous NaHCO3, and brine and evaporated in vacuo to give 1.3 g of methyl 3�, 
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7�-di(tert-butyldimethylsilyloxy)-5β-cholan-24-oate in the form of colourless 
needles, that was subjected to next step without any purification. To a solution of 
methyl ester (1 g, 1.6 mmol) in dry THF (30 mL), at 0 °C dry methanol (453 μL, 
11.2 mmol) and LiBH4 (5.6 mL, 2M in THF, 11.2 mmol) was added. The 
resulting mixture was stirred for 2 h at 0 °C. The mixture was quenched by 
addition of 1M NaOH (3.2 mL) and then ethyl acetate. The organic phase was 
washed with water, dried (Na2SO4) and concentrated. Purification by silica gel 
(hexane/ethyl acetate 99:1 and 0.5% TEA) gave 3�, 7�-di(tert-
butyldimethylsilyloxy)-5β-cholan-24-ol (18) as a white solid (1.2 g, quantitative 
yield over two steps).  
Methyl 3 , 7 -di(tert-butyldimethylsilyloxy)-25, 26-bis-homo-5β-chol-24-en-
26-oate (19). DMSO (2 mL, 28 mmol) was added dropwise for 15 min to a 
solution of oxalyl chloride (7 mL, 14 mmol) in dry dichloromethane (50 mL) at -
78 °C under argon atmosphere. After 30 min a solution of alchol 23 (1.2 g, 2 
mmol) in dry CH2Cl2 was added via cannula and the mixture was stirred at -78 °C 
for 30 min. Et3N (2.8 mL, 20 mmol) was added dropwise. After 1 h, 
methyl(triphenylphosphoranylidene)acetate (2.1 g, 3 mmol) was added and the 
mixture was allowed to warm to room temperature. NaCl saturated solution was 
added and the aqueous phase was extracted with diethyl ether (3×100 mL).  The 
combined organic phases were washed with water, dried (Na2SO4) and 
concentrated. Purification by silica gel (hexane-ethyl acetate 95:5 and 0.5% TEA) 
gave compound 19 as a colourless oil (1 g, 76%); [�]25D=+45.0 (c 0.70, CH3OH); 
1H NMR (400 MHz CDCl3): δ 6.94 (1H, dt, J = 7.3, 15.5 Hz), 5.78 (1H, d, J = 
15.5 Hz), 3.66 (3H, s), 3.64 (1H, m), 3.50 (1H, br s), 0.92 (3H, d, J = 6.5 Hz), 0.90 
(3H, s), 0.86 (18H, s), 0.62 (3H, s), 0.04 (6H, s), 0.03 (6H, s). 13C NMR (100 MHz 
CDCl3): ��167.0, 150.0, 120.9, 72.7, 72.5, 55.5, 54.9, 51.3, 43.9, 43.7, 42.8, 39.9, 
38.8, 37.9, 37.8, 35.3 (2C), 35.1, 34.3, 34.1, 30.9 (2C), 30.8, 28.9, 27.3, 26.4 (3C), 
25.9 (3C), 23.5, 21.2, 18.6, 12.1, -2.8, -3.4, -4.6 (2C); HRMS-ESI m/z 661.5050 
[M+H]+, C39H73O4Si2 requires 661.5047.  
Methyl 3 , 7 -dihydroxy-25, 26-bis-homo-5β-cholan-26-oate (23). A solution 
of compound 24 (500 mg, 0.76 mmol) in THF dry/EtOH dry (5 mL/5 mL, v/v) 
was hydrogenated in presence of Pd(OH)2 5% wt on activated carbon Degussa 
type (5 mg). The flask was evacuated and flushed first with argon and then with 
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hydrogen. After 12 h, the reaction was complete. The catalyst was filtered through 
celite, and the recovered filtrate was concentrated under vacuum to give the 
methyl ester, which was dissolved in methanol (40 mL). At the solution was added 
1 mL of HCl 37% v/v. After 1h, silver carbonate was added at the solution to 
precipitate chloride. Then the reaction mixture was centrifuged and the supernatant 
was concentrated in vacuo to give compound 23 as colourless amorphous solids 
(330 mg, quantitative yield). An analytic sample was purified by HPLC on a 
Nucleodur 100-5 C18 (5 �m; 4.6 mm i.d. x 250 mm) with MeOH/H2O (92:8) as 
eluent (flow rate 1 mL/min), to give compound 23 (tR=13 min). [�]25D=+41.8 (c 
0.15, CH3OH); selected 1H NMR (400 MHz CDCl3): δ 3.67 (3H, s), 3.59 (2H, m), 
2.30 (2H, dt, J = 2.5, 7.5 Hz), 0.95 (3H, s), 0.91 (3H, d, J = 6.5 Hz), 0.67 (3H, s). 
13C NMR (100 MHz CDCl3): 167.1, 71.3 (2C), 55.7, 55.1, 51.4, 43.8, 43.7, 42.4, 
40.1, 39.2, 37.3, 36.8, 35.5 (2C), 34.9, 34.2, 34.1, 30.4, 28.7, 26.9, 25.7, 25.4, 
23.4, 21.2, 18.7, 12.1. HRMS-ESI m/z 435.3479 [M+H]+, C27H47O4 requires 
435.3474. 
3 , 7 -dihydroxy-25, 26-bis-homo-5β-cholan-26-oic acid (24). A portion of 
compound 23 (200 mg, 0.46 mmol) was hydrolyzed with NaOH (184 mg, 4.6 
mmol) in a solution of MeOH: H2O 1:1 v/v (20 mL). The mixture was stirred for 4 
h at reflux. The resulting solution was then acidified with HCl 6N and extracted 
with ethyl acetate (3 x 50 mL). The collected organic phases were washed with 
brine, dried over Na2SO4 anhydrous and evaporated under reduced pressure to 
give compound 24 (115 mg, 60%). An analytic sample was purified by HPLC on a 
Nucleodur 100-5 C18 (5 �m; 4.6 mm i.d. x 250 mm) with MeOH/H2O (95:5) as 
eluent (flow rate 1 mL/min), to give compound 24 (tR = 5 min). [�]25D=-9.0 (c 
0.04, CH3OH); selected 1H NMR (500 MHz CD3OD): δ 3.47 (2H, m), 2.27 (2H, 
dt, J = 3.4, 7.4 Hz), 0.96 (3H, s), 0.94 (3H, d, J = 6.5 Hz), 0.70 (3H, s). 13C NMR 
(125 MHz CD3OD): ��178.2, 72.1, 71.9, 57.6, 56.7, 44.8, 44.5, 44.0, 41.6, 40.7, 
38.6, 38.0, 36.9, 36.8, 36.1, 35.3, 35.2, 30.9, 29.8, 27.9, 26.7, 26.6, 23.9, 22.4, 
19.3, 12.7; HRMS-ESI m/z 421.3315 [M+H]+, C26H45O4 requires 421.3318. 
3 , 7 -dihydroxy-25, 26-bis-homo-5β-cholan -26-oyl taurine sodium salt (25). 
Carboxylic acid 24 (20 mg, 0.1 mmol) in DMF dry (5 mL) was treated with DMT-
MM (39 mg, 0.1 mmol) and triethylamine (164 �L, 1.2 mmol) and the mixture 
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was stirred at room temperature for 10 min. Then to the mixture was added taurine 
(35 mg, 0.3 mmol). After 3h, the reaction mixture was concentrated under vacuo 
and dissolved in water (5 mL). The solution was poured over a C18 silica gel 
column. Fraction eluted with H2O/MeOH 95:5 gave a mixture that was further 
purified by HPLC on a Nucleodur 100-5 C18 (5 �m; 4.6 mm i.d. x 250 mm) with 
MeOH/H2O (45:55) as eluent (flow rate 1 mL/min), to give 12 mg (45%) of 
compound 25 (tR=12.4 min); [�]25D=+108.3 (c 0.06, CH3OH); selected 1H NMR 
(400 MHz CD3OD): δ 3.59 (2H, t, J = 6.5 Hz), 3.47 (2H, m), 2.96 (3H, t, J = 6.5 
Hz), 2.18 (2H, t, J = 7.4 Hz), 0.96 (3H, s), 0.94 (3H, d, J = 6.2 Hz), 0.71 (3H, s). 
HRMS-ESI m/z 526.3200 [M-Na]-, C28H48NO6S requires 526.3202. 
25, 26-bis-homo-5β-cholan-3 , 7 , 26-triol (26). To a solution of compound 23 
(50 mg, 0.11 mmol) in THF dry (10 mL) were added at 0 °C dry methanol (31 μl, 
0.8 mmol) and LiBH4 (382 �L, 2 M in THF, 0.8 mmol). After 1h, the mixture was 
quenched by addition of NaOH (1M, 220 �L) and then allowed to warm to room 
temperature. Ethyl acetate was added and the separated aqueous phase was 
extracted with ethyl acetate (3×30 mL). The combined organic phases were 
washed with water, dried (Na2SO4) and concentrated. Purification by silica gel 
(CH2Cl2/MeOH 9:1) gave compound 26 as a colourless oil (35 mg, 77%); 
[�]25D=+41.8 (c 0.21, CH3OH); selected 1H NMR (400 MHz CD3OD): δ 3.53 (2H, 
t, J = 6.5 Hz), 3.48 (2H, m), 0.95 (3H, s), 0.94 (3H, d, ovl), 0.70 (3H, s). 13C NMR 
(100 MHz CD3OD): ��72.1, 71.9, 63.0, 57.5, 56.7, 44.7, 44.4, 44.0, 41.6, 40.7, 
38.5, 37.9, 37.2, 37.0, 36.1, 35.2, 33.7, 30.9, 29.8, 27.9, 27.4, 27.1, 23.9, 22.4, 
19.4, 12.7; HRMS-ESI m/z 407.3520 [M+H]+, C26H47O3 requires 407.3525. 
Methyl 3 , 7 -dihydroxy-25, 26-bis-homo-5β-chol-24-en-26-oate (20). To 
compound 19 (180 mg, 0.3 mmol), dissolved in methanol (30 mL), 1 mL of HCl 
37% v/v was added and the mixture was stirred for 2 h at room temperature. At the 
end of reaction, silver carbonate was added to precipitate chloride. Then the 
reaction mixture was centrifuged and the supernatant was concentrated in vacuo to 
give 120 mg (quantitative yield) of the desired compound 20 as colourless 
amorphous solids. An analytic sample was purified by HPLC on a Nucleodur 100-
5 C18 (5 �m; 4.6 mm i.d. x 250 mm) with MeOH/H2O (92:8) as eluent (flow rate 
1 mL/min), to give compound 20 (tR=14 min). [�]25D=+45.0 (c 0.70, CH3OH); 1H 
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NMR (400 MHz CDCl3): δ 6.93 (1H, dt, J = 6.6, 15.7 Hz), 5.79 (1H, d, J = 15.7 
Hz), 3.64 (3H, s), 3.58 (2H, m), 0.92 (3H, s), 0.91 (3H, d, J = 6.4 Hz), 0.65 (3H, 
s). 13C NMR (100 MHz CDCl3): ��167.2, 150.1, 120.4, 71.1, 71.0, 55.9, 55.1, 51.4, 
43.7, 43.6, 42.5, 40.2, 39.3, 37.3, 37.1, 35.4, 34.9, 34.3, 34.0, 30.2, 29.0, 28.7, 
26.9, 23.4, 21.2, 18.5, 12.2; HRMS-ESI m/z 433.3323 [M+H]+, C27H45O4 requires 
433.3318. 
3 , 7 -dihydroxy-25, 26-bis-homo-5β-chol-24-en-26-oic acid (21). A portion of 
compound 20 (100 mg, 0.23 mmol) was hydrolyzed with NaOH (93 mg, 2.3 mmol) 
in a solution of MeOH: H2O 1:1 v/v (20 mL). The mixture was stirred for 1h at reflux. 
The resulting solution was then acidified with HCl 6N and extracted with ethyl 
acetate (3 x 50 mL). The collected organic phases were washed with brine, dried 
over Na2SO4 anhydrous and evaporated under reduced pressure to give compound 
21 (89 mg, 93% yield). An analytic sample was purified by HPLC on a Nucleodur 
100-5 C18 (5 �m; 4.6 mm i.d. x 250 mm) with MeOH/H2O (95:5) as eluent (flow 
rate 1 mL/min), to give compound 21 (tR=5 min). [�]25D= +203.0 (c 0.39, 
CH3OH); selected 1H NMR (400 MHz CDCl3): δ 7.07 (1H, dt, J = 7.0, 15.0 Hz), 
5.81 (1H, d, J = 15.0 Hz), 3.60 (2H, m), 0.94 (3H, s), 0.94 (3H, d, ovl), 0.67 (3H, 
s). 13C NMR (100MHz CD3OD): δ 170.7, 151.6, 122.7, 72.1, 71.9, 57.5, 56.6, 
44.8, 44.5, 44.0, 41.6, 40.7, 38.6, 38.0, 36.8, 36.1, 35.6, 35.2, 31.0, 29.9, 29.7, 
27.9, 23.9, 22.4, 19.1, 12.7. HRMS-ESI m/z 419.3163 [M+H]+, C26H43O4 requires 
419.3161. 
3 , 7 -dihydroxy-25, 26-bis-homo-5β-chol-24-en-26-oyl taurine sodium salt 
(22). Carboxylic acid 21 (10 mg, 0.024 mmol) in DMF dry (2 mL) was treated 
with DMT-MM (20 mg, 0.1 mmol) and triethylamine (87 �L, 0.6 mmol) and the 
mixture was stirred at room temperature for 10 min. Then to the mixture was 
added taurine (18 mg, 0.1 mmol). After 2 h, the reaction mixture was concentrated 
under vacuo and dissolved in water (5 mL). The solution was poured over a C18 
silica gel column. Fraction eluted with H2O/MeOH 95:5 gave a mixture that was 
further purified by HPLC on a Nucleodur 100-5 C18 (5 �m; 4.6 mm i.d. x 250 
mm) with MeOH/H2O (45:55) as eluent (flow rate 1 mL/min), to give 3.5 mg 
(26%) of compound 22 (tR=15.8 min); [�]25D=+52.1 (c 0.08, CH3OH); selected 1H 
NMR (400 MHz CD3OD): δ 6.73 (1H, dt, J = 6.5, 14.0 Hz), 5.89 (1H, d, J = 14.0 
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Hz), 3.65 (2H, t, J = 7.0 Hz), 3.47 (2H, m), 2.98 (2H, t, J = 7.0 Hz), 0.97 (3H, d, 
ovl), 0.96 (3H, s), 0.71 (3H, s). HRMS-ESI m/z 524.3043 [M-Na]-, C28H46NO6S 
requires 524.3046. 
Animal studies. All studies were approved by the Animal Study Committee of the 
University of Perugia (Italy). Mice were maintained in a temperature controlled 
facility with a 12-hour light/dark cycle and were given free access to food and 
water. C57BL/6j mice were obtained from Charles River Breeding Laboratories 
(Monza-Italy). Mice (n = 5,6) were orally administered for seven days with 30 
mg/kg dose of �-naphthylisothiocyanate (ANIT) in methylcellulose 1%, a 
chemical agent that cause a specific damage to biliary epithelial cells leading to 
bile duct injury and cell proliferation ultimately causing intrahepatic cholestasis. 
Animals were administered with C2 or C16 at the dose of 15 mg/kg. At the end of 
the experiment serum and liver samples were collected. During the experiment 
mice were daily weight. 
In another experimental section C57BL/6j mice were treated 6 hours with C2 (60 
mg/Kg, IP) or with C16 (64 mg/Kg, IP). At the end of the treatments mice were 
sacrificed and liver samples were collected to perform Real-Time PCR analysis. 
Transactivation assay. For FXR mediated transactivation, HepG2 cells were 
plated in a 24 well-plate and transfected with 100 ng of pSG5-FXR, 100 ng of 
pSG5-RXR, 200 ng of the reporter vector p(hsp27)-TK-LUC containing the FXR 
response element IR1 cloned from the promoter of heat shock protein 27 (hsp27) 
and with 100 ng of pGL4.70 (Promega), a vector encoding the human Renilla 
gene. For GP-BAR1 mediated transactivation, HEK-293T cells were plated in a 24 
well-plate and transfected with 200 ng of pGL4.29 (Promega), a reporter vector 
containing a cAMP response element (CRE) that drives the transcription of the 
luciferase reporter gene luc2P, with 100 ng of pCMVSPORT6-human GP-BAR1, 
and with 100 ng of pGL4.70. At 24 h post-transfection, cells were stimulated 18 h 
with 10 �M CDCA, TLCA and synthetized compounds. After treatments, cells 
were lysed in 100 μL of lysis buffer (25 mM Tris-phosphate, pH 7.8; 2 mM DTT; 
10% glycerol; 1% Triton X-100), and 20 μL of cellular lysate was assayed for 
luciferase activity using the luciferase assay system (Promega). Luminescence was 
measured using Glomax 20/20 luminometer (Promega). 
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Real-Time PCR. Real-Time PCR was performed as previously described.  
Forward and reverse primer sequences were the following:  
mouse GAPDH, ctgagtatgtcgtggagtctac  and  gttggtggtgcaggatgcattg;  
mOST�, cagtggacatagccctcacc and gaccaaagcagcagaacaca;  
mBSEP, aaatcggatggtttgactgc and tgacagcgagaatcaccaag;  
mPro-glucagon, tgaagacaaacgccactcac and caatgttgttccggttcctc. 
Bile acids determination. Stock solutions of bile acids (tMu, tCA, tDCA, 
tCDCA, tHCA) were prepared separately in methanol at the concentration of 10 
mmol/L, and stored at −20 °C. The appropriate amounts of each bile acid stock 
solution was added into pooled samples ranging a five-points calibration curve 
from 5 nM to 50 μM.   
Aliquots of 100 μL of each cell lysate were deproteinized with 1 mL of cold 
acetonitrile with 5% of NH4OH vortexing for 1 min. After centrifugation at 16000 
g for 10 min, the clear supernatant was transferred to a new vial, snap frozen and 
lyophilized. The samples were then re-dissolved in methanol-water (2:1, v/v) for 
tauro-conjugated bile acids determination. A bile acids extraction yield of 95% has 
been measured using bile acids standards addition in blank samples before and 
after deproteinization procedure. 
Liquid chromatography and mass spectrometry. For LC–MS/MS analysis, 
chromatographic separation was carried out on the HPLC–MS system LTQ XL 
ThermoScientific equipped with Accelera 600 Pump and Accelera AutoSampler 
system. The mixture was separated on a Jupiter 5u C18 column from Phenomenex 
(150X2.00 mm) and the column flow rate was set at 200 µl/min. Tauro-conjugated 
bile acids were separated using a methanol-aqueous ammonium acetate (NH4OAc) 
gradient. Mobile phase A was 5% methanol in water containing 2mM ammonium 
acetate at pH 7, mobile phase B was methanol, containing ammonium acetate at 
2mM. The gradient started at 30 % B and increased to 100% B in 20 min, kept at 
100% B for 5 min then decreased to 30% B in 1 min and kept at 30% B for 10 
min. ESI was performed in negative ion mode, the ion source temperature was set 
at 280 °C.  The tune page parameters were automatically optimized injecting 
taurocholic acid at 1 μM as standard. The MS/MS detection was operated in MRM 
mode using a collision energy of 20 (arbitrary units), the observed transitions 
were: tauromuricholic acid (t-MCA) at 13.5 min MRM of 514.28 Th�514.28 Th, 
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taurohyocholic acid (t-HCA) at 15.6 min MRM of 498.29 Th�498.29 Th, 
taurocholic acid (t-CA) at 16.6 min MRM of 514.28 Th�514.28 Th, 
taurochenodeoxycholic acid (t-CDCA) at 18.5 min MRM of 498.29 Th�498.29 
Th, and taurodeoxycholic acid (t-DCA) at 18.9 min MRM of 498.29 Th�498.29 
Th. 
Molecular Docking. The AutoDock4.2 software package was used to perform 
molecular docking calculations in the three-dimensional model of hGP-BAR1 and 
in the crystal structure of the FXR-LBD from Rattus Norvegicus (rFXR) in 
complex with 6-ethylchenodeoxycholic acid (6-ECDCA) and the GRIP-1 co-
activator peptide, NID-3 (PDB code 1osv). rFXR-LBD shares the 95% of 
homology with that of the human FXR-LBD (hFXR-LBD), with all of the residues 
in the ligand binding pocket conserved among the two species. Ligands 
tridimensional structures were generated with the Maestro Build Panel. For each 
ligand, an extensive ring conformational sampling was performed with the OPLS-
AA force field and a 2.0 Å rmsd cutoff using MacroModel (version 9.9) as 
implemented in Maestro 9.3. All conformers were then refined using LigPrep as 
implemented in Maestro 9.3. Protonation states at pH 7.0 were assigned using 
Epik. Protein structure was prepared through the Protein Preparation Wizard 
through the graphical user interface of Maestro 9.3. Water molecules were 
removed and hydrogen atoms were added and minimized using the OPLS-2005 
force field. Ligands and receptor structures were converted to AD4 format files 
using ADT, and the Gesteiger-Marsili partial charges were then assigned. Grid 
points of 70 × 70 × 70 for FXR and of 65 × 80 × 55 for GP-BAR1 with a 0.375 Å 
spacing were calculated around the binding cavity using AutoGrid4.2. Thus, 100 
separate docking calculations were performed for each run. Each docking run 
consisted of 10 million energy evaluations using the Lamarckian genetic algorithm 
local search (GALS) method. Otherwise default docking parameters were applied. 
Docking conformations were clustered on the basis of their rmsd (tolerance = 2.0 
Å) and were ranked based on the AutoDock scoring function. 
All the residue labels were taken from crystal structure of rFXR-LBD with PDB 
ID 1osv and the wild-type amino acidic sequence of human GP-BAR1. 
All figures were rendered using PyMOL (http://www.pymol.org). 
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1H NMR (400 MHz, CD3OD) of compound 16 
 
 
13C NMR (100 MHz, CD3OD) of compound 16 
 
 
 103
1H NMR (400 MHz, CD3OD) of compound 9 
 
  
13C NMR (100 MHz, CD3OD) of compound 9 
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1H NMR (400 MHz, CD3OD) of compound 10 
 
 
 
 
 
1H NMR (400 MHz, CD3OD) of compound 11 
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1H NMR (400 MHz, CD3OD) of compound 12 
 
 
 
 
 
1H NMR (400 MHz, CD3OD) of compound 13 
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1H NMR (400 MHz, CD3OD) of compound 14 
 
  
1H NMR (400 MHz, CD3OD) of compound 15 
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1H NMR (400 MHz, CD3OD) of compound 6 
 
 
 
 
 
13C NMR (100 MHz, CD3OD) of compound 6 
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1H NMR (400 MHz, CD3OD) of compound 7 
 
  
 
1H NMR (400 MHz, CDCl3) of compound 8 
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13C NMR (100 MHz, CDCl3) of compound 8 
 
  
 
1H NMR (400 MHz, CD3OD) of compound 26 
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13C NMR (100 MHz, CD3OD) of compound 26 
 
 
 
 
1H NMR (400 MHz, CDCl3) of compound 23 
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13C NMR (100 MHz, CDCl3) of compound 23 
 
 
 
 
 
1H NMR (500 MHz, CD3OD) of compound 24 
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13C NMR (125 MHz, CD3OD) of compound 24 
 
 
 
 
 
 
1H NMR (400 MHz, CD3OD) of compound 25 
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1H NMR (400 MHz, CDCl3) of compound 20 
 
  
 
13C NMR (100 MHz, CDCl3) of compound 20 
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1H NMR (400 MHz, CDCl3) of compound 21 
 
 
 
 
 
13C NMR (100 MHz, CD3OD) of compound 21 
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1H NMR (400 MHz, CD3OD) of compound 22 
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III. Experimental section Cholanoic acid  derivatives. 
 
Methyl 3α-tosiloxy-5β-cholan-24-oate (28). To a solution of lithocholic acid 2 (2 
g, 5.3 mmol), dissolved in 50 mL of dry methanol was added p-toluenesulfonic 
acid (4.5 g, 26.5 mmol). The solution was left to stand at room temperature for 1 h. 
The mixture was quenched by addition until the neutrality of NaHCO3 saturated 
solution. After the evaporation of the methanol, the residue was extracted with 
ethyl acetate. The combined extract was washed with brine, dried with Na2SO4, 
and evaporated to give the methyl ester 27 as amorphous solid (2.1 g, quantitative 
yield). 
At the solution of the methyl ester 27 (2 g, 5.1 mmol) in dry pyridine (30 mL), 
tosyl chloride (4.9 g, 25.6 mmol) was added, and the mixture was stirred at room 
temperature for 8 h. It was poured into cold water (50 mL) and extracted with 
CH2Cl2 (3 × 50 mL). The combined organic phases were washed with saturated 
NaHCO3 solution (50 mL) and water (50 mL), dried (Na2SO4) and concentrated to 
give 2.6 g of 28 as a white solid (92%). [�]D25= +59.5 (c 0.02, CH3OH); selected 
1H NMR (500 MHz, CDCl3): δ 7.77 (2H, d, J = 8.2 Hz), 7.31 (2H, d, J = 8.2 Hz), 
4.43 (1H, m), 3.64 (3H, s), 2.32 (1H, m), 2.19 (1H, m), 0.88 (3H, d, J = 6.6 Hz), 
0.86 (3H, s), 0.60 (3H, s); HR ESIMS m/z 545.3309 [M + H]+, C32H49O5S requires 
545.3301. 
Methyl 5β-cholan-24-oate (29). Lithium bromide (800 mg, 9.2 mmol) and lithium 
carbonate (680 mg, 9.2 mmol) were added to a solution of compound 28 (2.5 g, 4.6 
mmol) in dry DMF (30 mL), and the mixture was refluxed for 2 h. After cooling to 
room temperature, the mixture was slowly poured into saturated NaHCO3 solution 
(50 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layer 
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was washed successively with water, and then dried over anhydrous MgSO4 and 
evaporated to dryness to give 1.7 g of oily residue (quantitative yield), that was 
subjected to next step without any purification. 
A solution of compound previously obtained (1.7 g, 4.6 mmol) in THF dry/MeOH 
dry (10 mL/10 mL, v/v) was hydrogenated in presence of Pd(OH)2 20% wt on 
activated carbon Degussa type (30 mg) in PARR apparatus. The flask was 
evacuated and flushed first with argon and then with hydrogen (about 5 atm). After 
12 h, the reaction was complete. The mixture was filtered through celite, and the 
recovered filtrate was concentrated to give 1.7 g of crude product. Purification by 
silica gel (hexane/ethyl acetate 95:5) gave compound 29 as a colourless oil (1.27 g, 
74%). [�]25D=-3.0 (c 0.03, CH3OH); selected 1H NMR (400 MHz, CDCl3): δ 3.68 
(3H, s), 2.37 (1H, m), 2.24 (1H, m), 0.94 (3H, d, ovl), 0.93 (3H, s), 0.66 (3H, 
s).13C NMR (100 MHz, CDCl3): δ 175.2, 56.9, 56.3, 51.8, 44.0 (2C), 40.8, 40.6, 
37.9, 36.2, 35.7, 31.4 (2C), 28.5, 27.8, 27.6, 27.4, 26.9 (2C), 24.6, 21.6, 21.2, 18.6, 
12.4. HR ESIMS m/z 375.3267 [M+H]+, C25H43O2 requires 375.3263. 
5 -cholan-24-oic acid (30). Compound 29 (500 mg, 1.3 mmol) was hydrolyzed 
with a methanol solution of sodium hydroxide (5%, 5 mL) in H2O (5 mL) 
overnight under reflux. The resulting solution was then concentrated under 
vacuum, diluted with water, acidified with HCl 6 N and extracted with ethyl 
acetate (3x50 mL). The collected organic phases were washed with brine, dried 
over Na2SO4 anhydrous and evaporated under reduced pressure to give 480 mg of 
compound 30 (quantitative yield). An analytic sample was obtained by HPLC on a 
Nucleodur 100-5 C18 (5 �m; 10 mm i.d. x 250 mm) with MeOH/H2O (999.5:0.5) 
as eluent (flow rate 3 mL/min, tR=21 min); 
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[�]25D=+13.3 (c 0.32, CHCl3); selected 1H NMR (400 MHz CDCl3): δ 2.39 (1H, 
m), 2.26 (1H, m), 0.93 (3H, d, J = 6.6 Hz), 0.91 (3H, s), 0.66 (3H, s). 13C NMR 
(100 MHz CDCl3): δ 179.1, 56.8, 56.2, 50.6, 43.9, 43.0, 40.7, 40.5, 37.8, 36.1 
(2C), 35.6 (2C), 31.1, 28.4, 27.7, 27.5, 27.3, 26.8, 24.5, 21.6, 21.0, 18.5, 12.3. HR 
ESIMS m/z 359.2956 [M-H]-, C24H39O2 requires 359.2950. 
5 -cholan-24-oyl taurine sodium salt (31). Compound 30 (50 mg, 0.1 mmol) in 
DMF dry (3 mL) was treated with DMT-MM (77.5 mg, 0.3 mmol) and 
triethylamine (70 µL, 0.5 mmol) and the mixture was stirred at room temperature 
for 10 min. Then to the mixture was added taurine (15 mg, 0.2 mmol). After 24 h, 
the reaction mixture was concentrated under vacuo and dissolved in water (5 mL). 
The mixture was purified by HPLC on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. 
x 250 mm) with MeOH/H2O (83:17) as eluent (flow rate 1 mL/min), to give 3.5 
mg of compound 31 (tR=11 min); [�]25D=+22.5 (c 0.05, CH3OH); selected 1H 
NMR (400 MHz, CD3OD): δ 3.58 (2H, t, J = 7.0 Hz), 2.95 (2H, t, J = 7.0 Hz), 
2.24 (1H, m), 2.08 (1H, m), 0.95 (3H, d, ovl), 0.94 (3H, s), 0.68 (3H, s). HR 
ESIMS m/z 480.3150 [M-Na]-, C27H46NO4S requires 480.3153. 
3α-formyloxy-5 -cholan-24-oic acid (32). A solution of lithocholic acid 2 (500 
mg, 1.3 mmol) in 10 mL of 90 % formic acid containing 25 �L of 70% perchloric 
acid was stirred at 47-50 °C for 12 h. The temperature of the heating bath was 
lowered to 40 °C, then 5 mL of acetic anhydride was added and the mixture was 
stirred for 15 min. The solution was cooled to room temperature, poured into 50 
mL of water and extracted with diethyl ether. The organic layers were washed 
with saturated NaHCO3 solution (50 mL) and water to neutrality, dried over 
Na2SO4, and evaporated to give 540 mg of 32 (quantitative yield). An analytic 
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sample was obtained by silica gel chromatography eluting with CH2Cl2:MeOH 
9:1. Selected 1H NMR (400 MHz CD3OD): � 8.04 (1H, s), 4.85 (1H, m), 2.39 
(1H, m), 2.25 (1H, m), 0.93 (3H, s), 0.92 (3H, d, J = 6.7 Hz), 0.65 (3H, s); 13C 
NMR (100 MHz CD3OD): ��178.1, 160.8, 74.4, 56.5, 55.9, 41.9, 40.5, 40.2, 40.1, 
35.8 (3C), 35.4 (2C), 32.3, 30.8, 30.7, 28.2, 27.0, 26.3, 24.2, 23.4, 20.8, 18.2, 
12.1; HRMS-ESI m/z 405.2997 [M+H]+, C25H41O4 requires 405.2999. 
3α- formyloxy-24-nor-5β-cholan-23-nitrile (33). Crude 32 (500 mg, 1.2 mmol), 
3.8 mL of cold trifluoroacetic acid, and 1 mL (7.2 mmol) of trifluoroacetic 
anhydride were stirred at 0 °C until dissolution. Sodium nitrite (248 mg, 3.6 
mmol) was added at the solution. The reaction mixture was stirred first at 0-5 °C 
for 1 h, then at 45-50 °C for 3 h. When the reaction was completed, it was 
neutralized with NaOH 2 N, then the product was extracted with 50 mL of diethyl 
ether (3 x 50 mL), followed by washing with brine and dried over anhydrous 
Na2SO4. The ether was removed under reduced pressure to afford 380 mg of 33 
(85%), that was subjected to next step without any purification.  
24-nor-lithodeoxycholic acid (34). Compound 33 (350 mg, 0.94 mmol) was 
refluxed in ca. 50 mL of methanol-water 1:1 with 30% KOH. After 2 h, the basic 
aqueous solution was neutralized with HCl 6 N. Then methanol was evaporated 
and the residue was extracted with ethyl acetate (3 x 50mL) and then with CH2Cl2 
(3 x 50 mL). The organic layers were washed with brine, dried and evaporated to 
dryness to give white solid residue, that was purified by silica gel 
chromatography, eluting with CH2Cl2:MeOH 9:1 (340 mg, quantitative yield). An 
analytic sample was purified by HPLC on a Nucleodur 100-5 C18 (5 �m; 4.6 mm 
i.d. x 250 mm) with MeOH/H2O (95:5) as eluent (flow rate 1 mL/min), to give 
compound 34 (tR=10.5 min). [�]25D=+21.9 (c 0.58, CH3OH); selected 1H NMR 
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(400 MHz CD3OD): ��3.54 (1H, m), 2.41 (2H, m), 1.00 (3H, d, J = 7.0 Hz), 0.94 
(3H, s), 0.71 (3H, s). 13C NMR (100 MHz CD3OD): ��178.0, 72.5, 57.9, 57.5, 
43.6, 42.5, 41.9, 41.4, 37.2, 37.1, 36.5, 35.7, 34.9, 31.1, 29.3, 28.3, 27.6, 25.2, 
23.9, 21.9, 19.9, 12.5; HRMS-ESI m/z 363.2895 [M+H]+, C23H39O3 requires 
363.2899. 
24-nor-5 -cholanoic acid (37). Compound 37 (210 mg, 75% over five steps) was 
synthesized, starting from compound 34 (300 mg, 0.8 mmol) as described in 
Scheme 2, by an analogous procedure to that detailed above for compound 30. An 
analytic sample was obtained by HPLC on a Nucleodur 100-5 C18 (5 �m; 10 mm 
i.d. x 250 mm) with MeOH/H2O (999.5:0.5) as eluent (flow rate 3 mL/min, tR=20 
min); [�]D25= +24.6 (c 0.03, CH3OH); selected 1H NMR (400 MHz CD3OD): δ 
2.41 (1H, m), 1.00 (3H, d, J = 6.0 Hz), 0.95 (3H, s), 0.72 (3H, s); 13C NMR (100 
MHz CD3OD): ��178.0, 58.0, 57.6, 45.2, 44.0, 42.8, 41.9, 41.5, 38.7, 37.3, 36.5, 
35.0, 29.3, 28.6, 28.4, 28.2, 27.7, 25.3, 24.8, 22.4, 21.9, 20.0, 12.5; HR ESIMS 
m/z 347.2947 [M + H]+, C23H39O2 requires 347.2950. 
Methyl cholan-3,5-dien-24-oate (40). To a solution of the ditosylate 39 (500 mg, 
0.7 mmol) in water (3 ml) and N,N’-dimethylformamide (DMF; 27 ml) was added 
CH3COOK (206 mg, 2.1 mmol) and the mixture was refluxed for 36 h. The 
solution was cooled at room temperature, then water and ethyl acetate were added 
and the separated aqueous phase was extracted with ethyl acetate (3 × 20 mL). 
The combined organic phases were washed with water, dried (Na2SO4) and 
concentrated. Purification by silica gel eluting with hexane-ethyl acetate (99:1) 
gave the diene 40 (200 mg, 78%). selected 1H NMR (400 MHz CD3OD): δ 5.92 
(1H, d, J = 9.7 Hz), 5.58 (1H, d, J = 11.3 Hz), 5.38 (1H, m), 3.66 (3H, s), 2.34 
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(1H, m), 2.22 (1H, m), 0.94 (3H, d, J = 5.8 Hz), 0.92 (3H, s), 0.70 (3H, s); 13C 
NMR (100 MHz CD3OD): ��174.8, 141.5, 129.1, 125.2, 123.2, 57.0, 55.8, 51.5, 
48.4, 43.4, 39.8, 35.4, 33.8, 31.9, 31.8, 31.7, 31.0, 30.9, 28.1, 24.2, 23.9, 23.0, 
20.9, 18.8, 12.0. HR ESIMS m/z 371.2947 [M + H]+, C25H39O2 requires 371.2950. 
Methyl 5 -cholan-24-oate (41). A solution of compound 40 (150 mg, 0.4 mmol) 
in methanol (5 mL) and dry THF (5 mL) was added in an oven-dried 50 mL flask, 
that was charged with 10% palladium on carbon (10 mg). The flask was evacuated 
and flushed first with argon and then with hydrogen. The reaction was stirred at 
room temperature under H2 (1 atm) for 1 h. The mixture was filtered through 
celite, and the recovered filtrate was concentrated to give 147 mg of compound 41 
(quantitative yield). [�]25D=-2.9 (c 2.54, CH3OH); selected 1H NMR (400 MHz 
CDCl3): δ 3.66 (3H, s), 2.34 (1H, m), 2.21 (1H, m), 0.91 (3H, d, J = 6.4 Hz), 0.77 
(3H, s), 0.64 (3H, s); 13C NMR (100 MHz CDCl3): ��176.0, 56.9, 56.2, 55.0, 51.6, 
47.3, 40.4, 39.0 (2C), 35.7 (3C), 32.5, 31.4, 31.3, 29.4, 29.3, 28.4, 27.2, 24.5, 
22.6, 21.2, 18.6, 12.5, 12.4; HR ESIMS m/z 375.3269 [M+H]+, C25H43O2 requires 
375.3263.  
5 -cholan-24-oic acid (42). Compound 41 (50 mg, 0.1 mmol) was hydrolyzed 
with a methanol solution of sodium hydroxide (5%, 5 mL) in H2O (1 mL) 
overnight under reflux. The resulting solution was then concentrated under 
vacuum, diluted with water, acidified with HCl 6 N and extracted with ethyl 
acetate (3 x 30 mL). The collected organic phases were washed with brine, dried 
over Na2SO4 anhydrous and evaporated under reduced pressure to give compound 
42 (40 mg, 87%). An analytic sample was obtained by HPLC on a Nucleodur 
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100-5 C18 (5 �m; 4.6 mm i.d. x 250 mm) with MeOH/H2O (92:8) as eluent (flow 
rate 1 mL/min, tR=12 min); 
[�]25D=+17.7 (c 0.14, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 2.31 
(1H, m), 2.20 (1H, m), 0.94 (3H, d, J = 6.2 Hz), 0.81 (3H, s), 0.69 (3H, s). HR 
ESIMS m/z 359.2953 [M-H]-, C24H39O2 requires 359.2950. 
5 -cholan-24-oyl-taurine sodium salt (43). Compound 42 (10 mg, 27.8 x 10-3 
mmol) in DMF dry (3 mL) was treated with DMT-MM (16 mg, 58.2 x 10-3 mmol) 
and triethylamine (70 µL, 0.5 mmol) and the mixture was stirred at room 
temperature for 10 min. Then to the mixture was added taurine (15 mg, 0.2 
mmol). After 24 h, the reaction mixture was concentrated under vacuo and 
dissolved in water (5 mL). The mixture was purified by HPLC on a Nucleodur 
100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (83:17) as eluent 
(flow rate 1 mL/min), to give 3.5 mg (27 %) of compound 43 (tR=10.4 min); 
[�]25D=+37. (c 0.03, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.58 (2H, 
t, J = 7.0 Hz), 2.96 (2H, t, J = 7.0 Hz), 2.24 (1H, m), 2.09 (1H, m), 0.95 (3H, d, J 
= 6.2 Hz), 0.82 (3H, s), 0.69 (3H, s). HR ESIMS m/z 452.2840 [M-Na]-, 
C25H42NO4S requires 452.2835. 
5 -cholan-24-ol (44). Dry methanol (40 µL, 0.9 mmol) and LiBH4 (470 �L, 2 M 
in THF, 0.9 mmol) were added to a solution of the compound 43 (50 mg, 0.11 
mmol) in dry THF (10 mL) at 0 °C under argon and the resulting mixture was 
stirred for 2 h at 0 °C. The mixture was quenched by addition of NaOH (1 M, 260 
�L) and then allowed to warm to room temperature. Ethyl acetate was added and 
the separated aqueous phase was extracted with ethyl acetate (3×15 mL). The 
combined organic phases were washed with water, dried (Na2SO4) and 
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concentrated. Purification by silica gel eluting with CH2Cl2:MeOH (85:15) gave 
the alcohol 44 as a white solid (45 mg, quantitative yield). An analytic sample 
was obtained by HPLC on a Nucleodur 100-5 C18 (5 �m; 4.6 mm i.d. x 250 mm) 
with MeOH/H2O (92:8) as eluent (flow rate 1 mL/min, tR=17.6 min); [�]25D=+5.5 
(c 1.14, CH3OH); selected 1H NMR (400 MHz CDCl3): δ 3.51 (2H, m), 0.87 (3H, 
d, J = 6.3 Hz), 0.72 (3H, s), 0.60 (3H, s).13C NMR (100 MHz CDCl3): ��63.6, 
56.6, 56.1, 54.7, 47.0, 42.6, 40.1, 38.6, 35.6, 35.5 (2C), 32.2, 31.8, 29.3, 29.0 
(2C), 28.2, 26.8, 24.2, 22.2, 20.8, 18.6, 12.2, 12.1; HR ESIMS m/z 347.3318 
[M+H]+, C24H43O requires 347.3314. 
5 -cholan-24-yl-24-triethylammonium solfate (45). At a solution of compound 
44 (10 mg, 0.1 mmol) in DMF dry (3 mL) was added triethylamine-sulfur trioxide 
complex (26 mg, 0.1 mmol) under an argon atmosphere, and the mixture was 
stirred at 95 °C for 12 h. Most of the solvent was evaporated and the residue was 
poured over a RP18 column to remove excess SO3·NEt3. Fraction eluted with 
MeOH:H2O 1:1 gave a mixture that was further purified by HPLC on a Nucleodur 
100-5 C18 (5 �m; 4.6 mm i.d. x 250 mm) with MeOH:H2O (90:10) as eluent (flow 
rate 1 mL/min), to give 1.4 mg of compound 10 (18%, tR= 5 min). [�]25D=-26.7 (c 
0.02, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.95 (2H, t, J = 6.7 Hz), 
0.94 (3H, d, J = 6.5 Hz), 0.81 (3H, s), 0.69 (3H, s). HR ESIMS m/z 425.2730 [M-
Na]-, C24H41O4S requires 425.2726. 
Luciferase reporter gene assay. To evaluate FXR mediated transactivation, 
HepG2 cells were transfected with 100 ng of pSG5-FXR, 100 ng of pSG5-RXR, 
200 ng of the reporter vector p(hsp27)-TK-LUC containing the FXR response 
element IR1 cloned from the promoter of heat shock protein 27 (hsp27) and with 
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100 ng of pGL4.70 (Promega), a vector encoding the human Renilla gene. To 
evaluate GPBAR1 mediated transactivation, HEK-293T cells were transfected 
with 200 ng of pGL4.29 (Promega), a reporter vector containing a cAMP 
response element (CRE) that drives the transcription of the luciferase reporter 
gene luc2P, with 100 ng of pCMVSPORT6-human GPBAR1, and with 100 ng of 
pGL4.70. At 24 h post-transfection, cells were stimulated 18 h with 10 �M 
CDCA, TLCA and the synthetized compounds. In another experimental setting, at 
24 hours post-transfection cells were stimulated with 50 �M of synthetized in 
combination with 10 �M CDCA (1) or TLCA (2). To calculate the IC50 versus 
GPBAR1, a dose response curve was performed in HEK-293T transfected as 
described above and stimulated 18 h with 1, 5, 25 and 50 �M compounds 30 and 
42. After treatments, 10 μL of cellular lysates were read using Dual Luciferase 
Reporter Assay System (Promega Italia srl, Milan, Italy) according manufacturer 
specifications using the Glomax20/20 luminometer (Promega Italia srl, Milan, 
Italy). Luciferase activities were assayed and normalized with Renilla activities. 
Real-Time PCR. Total RNA was isolated from HepG2 or Glutag cells using the 
TRIzol reagent according to the manufacturer’s specifications (Invitrogen). One 
microgram of purified RNA was treated with DNase-I and reverse transcribed 
with Superscript II (Invitrogen). For Real Time PCR, 10 ng template was 
dissolved in 25 μL containing 200 nmol/L of each primer and 12.5 μL of 2X 
SYBR FAST Universal ready mix (Invitrogen). All reactions were performed in 
triplicate, and the thermal cycling conditions were as follows: 2 min at 95 °C, 
followed by 40 cycles of 95 °C for 20 s and 60 °C for 30 s in iCycler iQ 
instrument (Biorad). The relative mRNA expression was calculated and expressed 
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as 2−(ΔΔCt). Forward and reverse primer sequences were the following, 
respectively:  
human GAPDH, gaaggtgaaggtcggagt and catgggtggaatcatattggaa;  
human OSTα, tgttgggccctttccaatac and ggctcccatgttctgctcac;  
human BSEP, gggccattgtacgagatcctaa and tgcaccgtcttttcactttctg;  
human SHP, gctgtctggagtccttctgg and ccaatgatagggcgaaagaagag;  
mouse GAPDH, ctgagtatgtcgtggagtctac and gttggtggtgcaggatgcattg;  
mouse Pro-glucagon, tgaagacaaacgccactcac and caatgttgttccggttcctc. 
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1H NMR (400 MHz, CDCl3) of compound 30 
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1H NMR (400 MHz, CD3OD) of compound 37 
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1H NMR (400 MHz, CD3OD) of compound 42 
 
 
 
 
 
1H NMR (500 MHz, CD3OD) of compound 43 
 
 
  
 129
1H NMR (400 MHz, CDCl3) of compound 44 
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IV. Experimental section Hyodeoxycholic acid derivatives. 
 
Compound 50. To a solution of HDCA (6 g, 15.3 mmol) in 50 mL of dry 
methanol, p-toluenesulfonic acid (10 g, 58.1 mmol) was added at room 
temperature. After 1h, the mixture was quenched by addition of NaHCO3 
saturated solution until the neutrality and, after evaporation, the residue was 
extracted with EtOAc (3×100 mL). The combined extracts were washed with 
brine, dried on Na2SO4, and evaporated to give the methyl ester 47 in quantitative 
yield. 
2,6-Lutidine (17.4 mL, 150 mmol) and tert-
butyldimethylsilyltrifluoromethanesulfonate (10.3 mL, 45 mmol) were added at 0 
°C to a solution of 47 (6.1 g, 15 mmol) in 50 mL of CH2Cl2. After 2 h stirring at 0 
°C, the reaction was quenched by addition of aqueous NaHSO4 (1M, 100 mL). 
The layers were separated and the aqueous phase was extracted with CH2Cl2 
(3×100 mL). The combined organic layers were washed with NaHSO4, water, 
saturated aqueous NaHCO3, brine and evaporated in vacuo to give protected 
methyl ester 48 in quantitative yield. To a solution of 48 (9.5 g, 15 mmol) in dry 
THF (50 mL) and dry methanol (1.82 mL, 45 mmol), LiBH4 (22.5 mL, 2M in 
THF, 45 mmol) was added at 0 °C. After stirring for 2 h at 0 °C, the mixture was 
quenched by addition of NaOH 1M and then EtOAc. The organic phase was 
washed with water, dried (Na2SO4) and concentrated. Purification on silica gel 
(hexane/EtOAc 9:1 and 0.5% TEA) gave alcohol 49 in 56% yield (5 g, 8.3 mmol). 
DMSO (6.6 mL, 92 mmol) was added dropwise for 15 min to a solution of oxalyl 
chloride (23 mL, 46 mmol) in dry CH2Cl2 (50 mL) at -78 °C under argon 
atmosphere. After 30 min, a solution of alcohol 49 (4 g, 6.6 mmol) in dry CH2Cl2 
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was added via cannula and the mixture was stirred at -78 °C for 30 min. Et3N 
(13.8 mL, 99 mmol) was added dropwise followed by NaCl saturated solution. 
The aqueous phase was extracted with Et2O (3×100 mL). The combined organic 
phase was washed with water, dried (Na2SO4) and concentrated to give aldehyde 
50 (4 g) as a colourless oil in quantitative yield. 
Compound 52. To a solution of isopropyl triphenylphosphonium iodide (5.4 g, 
12.5 mmol) in THF (2 mL), n-BuLi (5 mL, 12.5 mmol) was added dropwise at 
room temperature until the solution reached a red colour. After 30 min, a solution 
of aldehyde 50 (1.5 g, 2.5 mmol) in THF (5 mL) was added. After 1h, the mixture 
was quenched by addition of saturated aqueous NaHCO3 (50 mL) and extracted 
with EtOAc (3x50 mL). The organic phase was dried (Na2SO4) and concentrated. 
Purification on silica gel (hexane) gave the protected intermediate in 84% yield. 
To a solution of the protected intermediate (1.3 g, 2.1 mmol) in MeOH, 1 mL of 
HCl 37% v/v was added. After 1h, silver carbonate was added, the reaction 
mixture was centrifuged, and the supernatant was concentrated in vacuo to give 
compound 52 as a colourless amorphous solid (850 mg, quantitative yield). An 
analytic sample was purified by HPLC on a Nucleodur 100-5 C18 (5�m; 10 mm 
i.d. x 250 mm) with MeOH/H2O (96:4) as eluent (flow rate 3 mL/min, tR= 12 
min). Selected 1H NMR (400 MHz, CDCl3): � 5.10 (1H, t, J = 6.7 Hz, H-24), 4.08 
(1H, dt, J = 11.9, 4.6 Hz, H-6�), 3.64 (1H, m, H-3�), 1.68 (3H, s, Me-26), 1.60 
(3H, s, Me-27), 0.92 (3H, d, J = 7.0 Hz, Me-21), 0.91 (3H, s, Me-19), 0.65 (3H, s, 
Me-18); 13C NMR (100 MHz, CDCl3): � 130.9, 125.3, 71.6, 68.2, 56.2 (x 2), 48.4, 
42.9, 40.0, 39.9, 36.4, 36.2, 35.6, 35.3, 35.0, 34.9, 30.3, 29.3, 28.4, 25.7, 24.7, 
24.3, 23.3, 20.9, 18.4, 17.7, 12.1. HR ESIMS m/z 403.3576 [M+H]+, C27H46O2 
requires 403.3578.  
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Compound 57. A solution of 52 (350 mg, 0.9 mmol) in THF dry/MeOH dry (5 
mL/5 mL, v/v) was hydrogenated in presence of Pd(OH)2 5% wt on activated 
carbon. After 12 h, the catalyst was filtered through Celite, and the recovered 
filtrate was concentrated under vacuum to give a colourless amorphous solid (350 
mg, quantitative yield). An analytic sample was purified by HPLC on a Nucleodur 
100-5 C18 (5�m; 10 mm i.d. x 250 mm) with MeOH/H2O (95:5) as eluent (flow 
rate 3 mL/min, tR= 8 min). Selected 1H NMR (400 MHz, CDCl3): � 4.06 (1H, dt, J 
= 11.9, 4.6 Hz, H-6�), 3.62 (1H, m, H-3�), 0.91 (3H, s, Me-19), 0.90 (3H, d, J = 
7.0 Hz, Me-21), 0.87 (3H, d, J= 6.6 Hz, Me-26), 0.86 (3H, d, J= 6.6 Hz, Me-27), 
0.64 (3H, s, Me-18).13C NMR (100 MHz, CDCl3): � 71.6, 68.2, 56.3, 56.2, 48.4, 
42.9, 40.0, 39.9, 39.4, 36.4, 36.0, 35.9, 35.6, 35.5, 34.9, 30.4, 29.3, 28.4, 28.2, 
22.7 (x 2), 24.4, 23.9, 23.3, 20.9, 18.8, 12.1. HR ESIMS m/z 405.3733 [M+H]+, 
C27H49O2 requires 405.3735.  
Compound 53. Compound 53 (141 mg, 0.3 mmol, 20%) was prepared from 50 (1 
g, 1.7 mmol) by an analogous procedure to that detailed above for 52. An analytic 
sample was purified by HPLC on a Nucleodur 100-5 C18 (5�m; 4.6 mm i.d. x 
250 mm) with MeOH/H2O (96:4) as eluent (flow rate 3 mL/min) gave compound 
53 (tR= 17.2 min). 
Compound 58. Hydrogenation on 53 gave 58. An analytic sample was purified 
by HPLC purification on a Nucleodur 100-5 C18 (5�m; 4.6 mm i.d. x 250 mm) 
with MeOH/H2O (96:4) as eluent (flow rate 1 mL/min) gave compound 58 (tR= 16 
min). Selected 1H NMR (400 MHz, CD3OD): � 4.01 (1H, dt, J = 11.9, 4.5 Hz, H-
6�), 3.50 (1H, m, H-3�), 0.93 (3H, d, J = 6.6 Hz, Me-21), 0.92 (3H, s, Me-19), 
0.87 (6H, d, J = 6.7 Hz, Me-27 and Me-28), 0.68 (3H, s, Me-18).13C NMR (100 
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MHz, CDCl3): � 71.6, 68.1, 56.2 (x 2), 48.4, 42.8, 39.9, 39.8, 39.1, 36.0, 35.9, 
35.7, 35.5, 35.1, 34.8, 30.3, 29.1, 28.2, 28.0, 27.9, 26.3, 24.2, 23.7, 23.6, 23.5, 
20.7, 18.6, 12.0. HR ESIMS m/z 419.3889 [M+H]+, C28H51O2 requires 419.3892.  
Compound 51. Compound 51 (370 mg, 1.0 mmol, 60%) was obtained from 50 (1 
g, 1.7 mmol) by an analogous procedure to that detailed above for 52. An analytic 
sample was purified by HPLC on a Nucleodur 100-5 C18 (5�m; 10 mm i.d. x 250 
mm) with MeOH/H2O (96:4) as eluent (flow rate 3 mL/min) giving pure 
compound 51 (tR=5 min). Selected 1H NMR (400 MHz, CDCl3): � 5.80 (1H, m, 
H-24), 4.99 (1H, d, J = 17.1 Hz, H-25), 4.91 (1H, d, J = 9.8 Hz, H-25), 4.05 (1H, 
dt, J = 12.0, 4.5 Hz, H-6�), 3.62 (1H, m, H-3�), 0.91 (3H, s, Me-19), 0.92 (3H, d, 
J = 7.0 Hz, Me-21), 0.64 (3H, s, Me-18).13C NMR (100 MHz, CDCl3): � 139.6, 
113.9, 71.6, 68.1, 56.2, 56.1, 48.4, 42.8, 39.9, 39.8, 36.0, 35.5, 35.3, 35.2, 35.1, 
34.8, 30.5, 30.2, 29.2, 28.2, 24.2, 23.5, 20.7, 18.4, 12.0. 
HR ESIMS m/z 375.3263 [M+H]+, C25H43O2 requires 375.3266.  
Compound 56. Reduction of 51 (125 mg, 0.3 mmol) in the same procedure to 
that detailed above for 57, gave 87 mg of compound 56 (70%). Purification by 
HPLC on a Nucleodur 100-5 C18 (5�m; 4.6 mm i.d. x 250 mm) with MeOH/H2O 
(9:1) as eluent (flow rate 1 mL/min), (tR=18.6 min) furnished pure compound 56. 
Selected 1H NMR (400 MHz, CD3OD): � 3.99 (1H, dt, J = 12.2, 4.6 Hz, H-6�), 
3.50 (1H, m, H-3�), 0.92 (3H, s, Me-19), 0.93 (3H, d, J = 6.8 Hz, Me-21), 0.90 
(3H, t, J = 6.8 Hz, Me-25), 0.68 (3H, s, Me-18). 13C NMR (100 MHz, CDCl3): � 
71.6, 68.1, 56.2, 56.1, 48.4, 42.8, 39.9, 39.8, 35.9, 35.7, 35.5, 35.2, 35.0, 34.8, 
30.2, 29.2, 28.3, 28.2, 24.2, 23.5, 23.1, 20.7, 18.6, 14.2, 12.0. HR ESIMS m/z 
377.3420 [M+H]+, C25H45O2 requires 377.3422.  
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Compounds 54 and 55. The mixture of diasteroisomers at the side chain double 
bond (125 mg, 0.3 mmol, 67% over two steps) was prepared from 50 (250 mg, 0.4 
mmol) by an analogous procedure to that detailed above for 52. A small portion of 
the mixture was purified by HPLC on a Nucleodur 100-5 C18 (5 �m; 10 mm i.d. 
x 250 mm) with MeOH/H2O (96:4) as eluent (flow rate 3 mL/min) to give pure 
compounds 54 (tR= 13.6 min) and 55 (tR=16.2 min).  
Compound 54. Selected 1H NMR (400 MHz, CDCl3): � 7.33-7.18(5H, Ph), 6.38 
(1H, d, J = 15.7 Hz, H-25), 6.20 (1H, dt, J = 15.7, 6.8 Hz, H-24), 4.05 (1H, dt, J = 
12.1, 4.5 Hz, H-6�), 3.62 (1H, m, H-3�), 2.28 (1H, m, H-23), 2.10 (1H, m, H-23), 
0.96 (3H, d, J = 6.4 Hz, Me-21), 0.91 (3H, s, Me-19), 0.65 (3H, s, Me-18).13C 
NMR (100 MHz, CDCl3): � 138.0, 131.5, 129.3, 128.4, 126.8, 125.9, 71.6, 68.2, 
56.2 (x 2), 48.4, 42.9, 40.0, 39.9, 36.4, 35.8, 35.6, 35.5, 35.2, 35.1, 30.4, 29.8, 
29.3, 28.4, 24.4, 23.4, 20.9, 18.6, 12.1. HR ESIMS m/z 451.3576 [M+H]+, 
C31H47O2 requires 451.3580. 
Compound 55. Selected 1H NMR (400 MHz, CDCl3): � 7.33-7.21 (5H, Ph),6.39 
(1H, d, J = 11.7 Hz, H-25), 5.64 (1H, dt, J = 11.7, 7.3 Hz, H-24), 4.05 (1H, dt, J = 
12.0, 4.5 Hz, H-6�), 3.62 (1H, m, H-3�), 2.38 (1H, m, H-23), 2.22 (1H, m, H-23), 
0.91(3H, s, Me-19), 0.89 (3H, d, J = 6.8 Hz, Me-21), 0.64 (3H, s, Me-18).13C 
NMR (100 MHz, CDCl3): � 137.8, 133.6, 128.7, 128.6, 128.2, 126.4, 71.6, 68.2, 
56.2 (x 2), 48.4, 42.9, 40.0, 39.9, 36.4, 36.2, 35.6, 35.5, 35.1 (x2), 30.4, 29.3, 
28.4, 25.5, 24.4, 23.3, 20.9, 18.5, 12.1. HR ESIMS m/z 451.3576 [M+H]+, 
C31H47O2 requires 451.3579.  
Compound 59. Hydrogenation on the mixture of 54 and 55 (40 mg, 0.1 mmol) 
gave compound 59 (quantitative yield). An analytic sample was purified by HPLC 
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on a Nucleodur 100-5 C18 (5 �m; 4.6 mm i.d. x 250 mm) with MeOH/H2O (96:4) 
as eluent (flow rate 1 mL/min, tR= 7.6 min). Selected 1H NMR (400 MHz, 
CDCl3): � 7.27-7.16 (5H, Ph), 4.05 (1H, dt, J = 11.9, 4.5 Hz, H-6�), 3.62 (1H, m, 
H-3�), 2.60 (2H, m, H2-25), 0.90 (3H, s, Me-19), 0.89 (3H, d, J = 6.8Hz, Me-21), 
0.64 (3H, s, Me-18).13C NMR (100 MHz, CDCl3): � 143.0, 128.4, 128.3, 125.6, 
71.6, 68.2, 56.2 (x 2), 48.4, 42.9, 40.0, 39.9, 36.3, 36.1, 35.7, 35.6, 35.5, 35.2 (x 
2), 32.0, 30.4, 29.3, 28.4, 26.0, 24.4, 23.4, 20.9, 18.6, 12.1. HR ESIMS m/z 
453.3733 [M+H]+, C31H49O2 requires 453.3735.  
Compound 60. Compound 60 (1.9 g, 4.8 mmol) was prepared as previously 
reported133 
Compound 61. Aldehyde 61 (1 g, 1.7 mmol, 94%) was prepared from 60 (1.9 g, 
4.8 mmol) by an analogous procedure to that detailed above for 50. 
Compound 63. Compound 63 (264 mg, 0.7 mmol, 80% over two steps) was 
prepared from 61 (500 mg, 0.9 mmol) by the same procedure described for 52. An 
analytic sample was purified by HPLC on a Nucleodur 100-5 C18 (5 �m; 10 mm 
i.d. x 250 mm) with MeOH/H2O (96:4) as eluent (flow rate 3mL/min, tR=16 min) 
giving pure compound 63. Selected 1H NMR (400 MHz, CD3OD): � 5.12 (1H, 
brt, J = 6.8 Hz, H-23), 4.01 (1H, dt, J = 11.9, 4.6 Hz, H-6�), 3.50 (1H, m, H-3�), 
1.70 (3H, s, Me-26), 1.59 (3H, s, Me-25), 0.93 (3H, s, Me-19), 0.90 (3H, d, J = 
6.7 Hz, Me-21), 0.69 (3H, s, Me-18).13C NMR (100 MHz, CD3OD): � 132.8, 
124.2, 72.4, 68.6, 57.6 (x 2), 49.9, 44.1, 41.3 (x 2), 38.2, 37.0, 36.8, 36.2, 35.6, 
35.5, 31.1, 29.9, 29.5, 26.1, 25.5, 24.1, 21.9, 19.2, 18.0, 12.4. HR ESIMS m/z 
389.3420 [M+H]+, C26H45O2 requires 389.3424. 
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Compound 65. Hydrogenation on 63 (100 mg, 0.3 mmol), in the same procedure 
detailed for 57, gave 65 (90 mg, 0.2 mmol, 90%). An analytic sample was purified 
by HPLC on a Nucleodur 100-5 C18 (5 �m; 10 mm i.d. x 250 mm) with 
MeOH/H2O (96:4) as eluent (flow rate 3mL/min) giving pure compound 65 
(tR=18.4 min). Selected 1H NMR (400 MHz, CD3OD):�� 4.01 (1H, dt, J = 12.1, 
4.6 Hz, H-6�), 3.51 (1H, m, H-3�), 0.94 (3H, s, Me-19), 0.93(3H, d, J = 6.5 Hz, 
Me-21), 0.89 (3H, d, J = 6.0 Hz, Me-25), 0.87 (3H, d, J = 6.0 Hz, Me-26), 0.68 
(3H, s, Me-18).13C NMR was recorded on Varian Inova100 MHz, using CDCl3 as 
solvent: � 71.6, 68.1, 56.2 (x 2), 48.4, 42.8, 39.9, 39.8, 35.9, 35.8, 35.5, 35.3, 
35.1, 34.8, 33.5, 30.3, 29.2, 28.4, 28.2, 24.2, 23.5, 23.0, 22.4, 20.7, 18.7, 12.0. HR 
ESIMS m/z 391.3576 [M+H]+, C26H47O2 requires 391.3579. 
Compound 62. Wittig olefination on aldehyde 61 (500 mg, 0.9 mmol), as 
described for compound 52, gave 62 (290 mg, 0.8 mmol, 95% over two steps). An 
analytic sample was purified by HPLC on a Nucleodur100-5 C18 (5 �m; 10 mm 
i.d. x 250 mm) with MeOH/H2O (96:4) as eluent (flow rate 3mL/min), giving 
pure compound 62 (tR=11.0 min). Selected 1H NMR (400 MHz, CDCl3): � 5.77 
(1H, m, H-23), 5.01 (1H, ovl, H-24), 4.99 (1H, ovl, H-24), 4.06 (1H, dt, J = 12.1, 
4.6 Hz, H-6�), 3.63(1H, m, H-3�), 0.92 (3H, d, J = 6.6 Hz, Me-21), 0.91 (3H, s, 
Me-19), 0.66 (3H, s, Me-18). 13C NMR (100 MHz, CDCl3): � 137.3, 115.7, 71.6, 
68.1, 56.1, 55.8, 48.4, 42.8, 40.5, 39.9, 39.8, 35.9, 35.8, 35.5, 35.1, 34.8, 30.3, 
29.2, 28.2, 24.2, 23.5, 20.7, 18.6, 12.0. HR ESIMS m/z 361.3107 [M+H]+, 
C24H41O2 requires 361.3109.  
Compound 64. Hydrogenation on 61 (100 mg, 0.3 mmol), in the same procedure 
detailed for 57, gave 64 (88 mg, 0.2 mmol, 88%). Purification by HPLC on a 
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Nucleodur100-5 C18 (5 �m; 4.6 mm i.d. x 250 mm) with MeOH/H2O (96:4) as 
eluent (flow rate 1 mL/min), gave pure compound 64 (tR=8.0 min). Selected 1H 
NMR (400 MHz, CDCl3): � 4.06 (1H, dt, J = 12.1, 4.6 Hz, H-6�), 3.62 (1H, m, H-
3�), 0.91 (3H, s, Me-19), 0.89 (3H, d, J = 7.0 Hz, Me-21), 0.86 (3H, t, J = 7.6 Hz, 
Me-23), 0.64 (3H, s, Me-18).13C NMR (100 MHz, CDCl3): � 71.6, 68.2, 56.0, 
55.9, 48.4, 42.7, 39.9, 39.8, 38.2,36.4, 35.5, 35.4, 35.1, 34.8, 30.2, 29.3,28.2, 24.3, 
23.5, 20.8, 19.2, 18.6, 12.0, 14.5. HR ESIMS m/z 363.3263 [M+H]+, C24H43O2 
requires 363.3266.  
Compound 66. To a solution of HDCA (2 g, 5.1 mmol) in dry pyridine (100 mL), 
an excess of acetic anhydride was added. Pyridine was concentrated under 
vacuum and the residue was poured into cold water (100 mL) and extracted with 
EtOAc (3×50 mL). The combined organic phases were dried (Na2SO4) and 
concentrated. Flash chromatography on silica gel using CH2Cl2/MeOH 98:2 as 
eluent gave 66 (2.35 g, quantitative yield).  
Compound 67. Compound 66 (2.35 g, 4.9 mmol) was dissolved in toluene 
dry/pyridine dry (10 mL:100 �L, 10:1 v/v) and Cu(OAc)2 H2O (2.9 g, 14.7 mmol) 
was added in dark. After 30 min, Pb(OAc)4 (11 g, 24.5 mmol) was added. After 3 
h, the solution was heated to reflux for 1 h (no longer in the dark). The mixture 
was then cooled, and aqueous ethylene glycol was added. The resulting mixture 
was extracted with ether (3x50 mL) and the combined organic phases were 
washed with saturated solution of NaHCO3, water and brine. After drying over 
Na2SO4, the residue was evaporated under vacuum to give 67. Purification by 
flash chromatography on silica gel (Hexane/EtOAc 95:5 with 0.5% of TEA) gave 
pure 67 (360 mg, 0.8 mmol). 
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Compound 68. Compound 67 (360 mg, 0.8 mmol) was treated with CH3ONa 
(224 mg, 4.15 mmol) in CHCl3 dry/MeOH dry (10 mL:6mL, 5:3 v/v). After 
stirring for 12 h, water was added and methanol was evaporated. The residue was 
extracted with EtOAc (3x50mL). The combined organic layers were washed with 
brine, dried and evaporated to dryness to give 259 mg (90%) of 68. An analytic 
sample was purified by HPLC on a Nucleodur 100-5 C18 (5 �m; 4.6 mm i.d. x 
250 mm) with MeOH/H2O (93:7) as eluent (flow rate 1 mL/min, tR= 6 min). 
Selected 1H NMR (400 MHz, CDCl3): � 5.68 (1H, m, H-22), 4.89 (1H, d, J = 17.3 
Hz, H-23), 4.81 (1H, d, J = 10.1 Hz, H-23), 4.06 (1H, dt, J = 11.8, 4.4 Hz, H-6�), 
3.62 (1H, m, H-3�), 1.02 (3H, d, J = 6.5 Hz, Me-21), 0.91 (3H, s, Me-19), 0.66 
(3H, s, Me-18).13C NMR (100 MHz, CDCl3): � 145.3, 111.5, 71.6, 68.2, 56.3, 
55.5, 48.5, 42.7, 41.2, 40.0, 39.8, 36.4, 35.6, 35.5, 34.9, 30.4, 29.3, 28.5, 24.2, 
23.3, 20.9, 20.2, 12.1. HR ESIMS m/z 347.2950 [M+H]+, C23H39O2 requires 
347.2953.  
Compound 69. Hydrogenation on 68 (100 mg, 0.3 mmol) furnished 69 (99 mg, 
0.3 mmol, quantitative yield). An analytic sample was purified by HPLC on a 
Nucleodur 100-5 C18 (5�m; 4.6 mm i.d. x 250 mm) with MeOH/H2O (90:10) as 
eluent (flow rate 1 mL/min, tR=9.4 min). Selected 1H NMR (400 MHz, CDCl3): � 
4.07 (1H, dt, J = 12.1, 4.6 Hz, H-6�), 3.63 (1H, m, H-3�), 0.91 (3H, s, Me-19), 
0.89 (3H, d, J = 7.0 Hz, Me-21), 0.82 (3H, t, J = 7.4 Hz, Me-23), 0.64 (3H, s, Me-
18). 13C NMR (100 MHz, CDCl3): � 71.6, 68.1, 56.1, 55.7, 48.4, 42.7, 39.9, 39.8, 
37.2, 36.4, 35.5, 35.4, 35.1, 30.4, 29.3, 28.5, 28.4, 24.5, 23.5, 21.0, 18.0, 12.0, 
10.4. HR ESIMS m/z 349.3107 [M+H]+, C23H41O2 requires 349.3110.  
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Compound 70. Aldehyde 70 (1.8 g, 3.8 mmol, 72%) was prepared starting from 
LCA (2 g, 5.3 mmol), as reported for aldehyde 34.  
Compound 71. Compound 71 (653 mg, 1.8 mmol, quantitative yield over two 
steps) was obtained from 70 (900 mg, 1.9mmol) as described for 52. An analytic 
sample was purified by HPLC on a Nucleodur 100-5 C18 (5 �m; 4.6 mm i.d. x 
250 mm) with MeOH/H2O (99:1) as eluent (flow rate 1 mL/min, tR=10 min). 
Selected1H NMR (400 MHz, CDCl3): � 5.80 (1H, m, H-24), 4.99 (1H, d, J = 17.1 
Hz, H-25), 4.91 (1H, d, J = 9.8 Hz, H-25), 4.05 (1H, dt, J = 12.0, 4.5 Hz, H-6�), 
3.62 (1H, m, H-3�), 0.91 (3H, s, Me-19), 0.92 (3H, d, J = 7.0 Hz, Me-21), 0.64 
(3H, s, Me-18).13C NMR (100 MHz, CDCl3): � 139.6, 113.9, 71.6, 56.5, 56.2, 
42.7, 42.2, 40.5, 40.2, 36.5, 35.8, 35.3, 35.2, 34.8, 34.6, 30.5, 30.2, 28.3, 27.2, 
26.4, 24.2, 23.5, 20.8, 18.4, 12.0. HR ESIMS m/z 359.3314 [M+H]+, 
C25H43Orequires 359.3317.  
Compound 73. Hydrogenation on 71 (400 mg, 1.1 mmol) gave 73 (338 mg, 0.9 
mmol, 86%). An analytic sample was purified by HPLC on a Nucleodur 100-5 
C18 (5�m; 4.6 mm i.d. x 250 mm) with MeOH/H2O (99:1) as eluent (flow rate 1 
mL/min, tR=13.4 min). Selected 1H NMR (400 MHz, CDCl3): � 3.63 (1H, m, H-
3�), 0.93 (3H, s, Me-19), 0.92 (3H, ovl,Me-21), 0.89 (3H, t, J= 7.3 Hz, Me-
25).13C NMR (100 MHz, CDCl3): � 71.9, 56.5, 56.3, 42.7, 42.1, 40.5, 40.2, 36.5, 
35.9, 35.7, 35.6, 35.3, 34.6, 30.6, 28.3 (x2), 27.2, 26.4, 24.2, 23.4, 23.1, 20.8, 
18.6, 14.2, 12.0. HR ESIMS m/z 361.3470 [M+H]+, C25H45O requires 361.3472.  
Compound 72. Compound 72 (367 mg, 1.0 mmol, 40% over two steps) was 
prepared from 70 (900 mg, 1.9 mmol) as detailed for 52. An analytic sample was 
purified by HPLC on a Nucleodur 100-5 C18 (5 �m; 4.6 mm i.d. x 250 mm) with 
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MeOH/H2O (99:1) as eluent (flow rate 1 mL/min, tR=12.4 min). Selected 1H 
NMR (400 MHz, CDCl3): � 5.08 (1H, t, J = 6.6 Hz, H-24), 3.62 (1H, m, H-3�), 
1.68 (3H, s, Me-26), 1.60 (3H, s, Me-27), 0.92 (3H, ovl, Me-21), 0.92 (3H, s, Me-
19), 0.64 (3H, s, Me-18).13C NMR (100 MHz, CDCl3): � 130.9, 125.2, 71.9, 56.5, 
56.2, 42.7, 42.1, 40.4, 40.2, 36.5, 36.1, 35.8, 35.6, 35.3, 34.6, 30.6, 28.3, 27.2, 
26.4, 25.7, 24.7, 24.2, 23.4, 20.8, 18.6, 17.6, 12.0. HR ESIMS m/z 387.3620 
[M+H]+, C27H47O requires 387.3623.  
Compound 74. Hydrogenation on 72 (100 mg, 0.3 mmol) gave 74 (98 mg, 
quantitative yield). An analytic sample was purified by HPLC on a Nucleodur 
100-5 C18 (5 �m; 4.6 mm i.d. x 250 mm) with MeOH/H2O (99:1) as eluent (flow 
rate 1 mL/min, tR=16.6 min). Selected 1H NMR (400 MHz, CDCl3): � 3.63 (1H, 
m, H-3�), 0.93 (3H, s, Me-19), 0.91 (3H, d, J= 6.6 Hz, Me-21), 0.87 (6H, d, J= 
6.7 Hz, Me-26 and Me-27), 0.65 (3H, s, Me-18).13C NMR (100 MHz, CDCl3): � 
71.9, 56.5, 56.3, 42.6, 42.0, 40.5, 40.2, 39.5, 36.5, 36.2, 35.9, 35.8, 35.3, 34.7, 
30.6, 28.3 (x 2), 27.2, 26.4, 24.2, 23.8, 23.3, 22.5 (x 2), 20.8, 18.7, 12.1. HR 
ESIMS m/z 389.3783 [M+H]+, C27H49O requires 389.3786.  
Compound 76. Compound 76 (954 mg, 2.6 mmol, quantitative yield over two 
steps) was obtained from LCA (1 g, 2.7 mmol) as reported for compound 67.  
Compound 77. Compound 77 was obtained from 76 (954 mg, 2.6 mmol)as 
reported for 68. Purification on silica gel (hexane/EtOAc 97:3 and 0.5% TEA) 
gave pure 77 (228 mg, 0.7 mmol, 27% yield). Selected 1H NMR (400 MHz, 
CDCl3): � 5.68 (1H, m, H-22), 4.90 (1H, d, J= 17.2 Hz, H-23), 4.82 (1H, d, J= 
10.0 Hz, H-23), 3.63 (1H, m, H-3�), 1.03 (3H, d, J= 6.2 Hz, Me-21), 0.93 (3H, s, 
Me-19), 0.68 (3H, s, Me-18).13C NMR (100 MHz, CDCl3): � 145.3, 111.5, 71.9, 
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56.4, 55.6, 42.7, 42.1, 41.2, 40.5, 40.1, 36.4, 35.9, 35.3, 34.6, 30.5, 28.5, 27.2, 
26.4, 24.3, 23.4, 20.8, 20.2, 12.3. HR ESIMS m/z 331.3001 [M+H]+, C23H39O 
requires 331.3004.  
Compound 78. Hydrogenation on 77 (100 mg, 0.3 mmol) gave 78 (22 mg, 0.1 
mmol, 22%). HPLC purification on a Nucleodur 100-5 C18 (5 �m; 4.6 mm i.d. x 
250 mm) with MeOH/H2O (92:8) as eluent (flow rate 1 mL/min,) gave pure 
compound 78 (tR=26 min). Selected 1H NMR (400 MHz, CDCl3): � 3.62 (1H, m, 
H-3�), 0.92 (3H, s, Me-19), 0.89 (3H, d, J = 6.6 Hz, Me-21), 0.83 (3H, t, J = 7.5 
Hz, Me-23), 0.65 (3H, s, Me-18).13C NMR (100 MHz, CDCl3): � 71.8, 56.4, 56.2, 
42.6, 42.0, 40.5, 40.2, 37.2, 36.5, 35.7, 35.3, 35.0, 30.6, 28.4, 28.3, 27.1, 
26.4,24.2, 23.3, 20.8, 18.2, 12.1, 10.4.HR ESIMS m/z 333.3157 [M+H]+, C23H41O 
requires 333.3159.  
Compound 79. Compound 79 was prepared as previously described.95 
Compound 80. Compound 80 (820 mg, 1.7 mmol, 34%) was prepared from 79 (2 
g, 5.1 mmol) in the same operative conditions reported for aldehyde 50.  
Compound 82. Compound 82 (110 mg, 0.3 mmol, 34%) was prepared from 80 
(400 mg, 0.8 mmol) in the same operative conditions reported for 52. An analytic 
sample was purified by HPLC on a Nucleodur 100-5 C18 (5 �m; 4.6 mm i.d. x 
250 mm) with MeOH/H2O (99:1) as eluent (flow rate 1 mL/min), giving pure 
compound 82 (tR=20.4 min). Selected 1H NMR (400 MHz, CDCl3): � 5.10 (1H, 
brt, J = 6.9 Hz, H-24), 3.63 (1H, m, H-3�), 1.69 (3H, s, Me-26), 1.61 (3H, s, Me-
27), 0.94 (3H, d, J = 6.6 Hz, Me-21), 0.93 (3H, s, Me-19), 0.65 (3H, s, Me-18).13C 
NMR (100 MHz, CDCl3): � 130.9, 125.2, 71.4, 56.5, 56.2, 54.4, 44.8, 42.6, 40.0, 
38.2, 37.0, 36.1, 35.6, 35.5, 35.4, 32.0, 31.5, 28.7, 28.2, 25.7, 24.7, 24.2, 21.3, 
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18.6, 17.6, 12.3, 12.1. HR ESIMS m/z 387.3627 [M+H]+, C27H47O requires 
387.3630.  
Compound 84. Hydrogenation on 82 (90 mg, 0.2 mmol) afforded 84 (86 mg, 0.2 
mmol, quantitative yield). Purification by HPLC on a Nucleodur 100-5 C18 (5 
�m; 4.6 mm i.d. x 250 mm) with MeOH/H2O (99:1) as eluent (flow rate 1 
mL/min) gave pure compound 84 (tR= 25.2 min). Selected 1H NMR (400 MHz, 
CDCl3): �  3.61(1H, m, H-3�), 0.91 (3H, d, J= 6.5 Hz,Me-21), 0.87 (3H, d, J= 6.6 
Hz, Me-26), 0.86 (3H, d, J= 6.6 Hz, Me-27), 0.81 (3H, s, Me-19), 0.66 (3H, s, 
Me-18).13C NMR (100 MHz, CDCl3): � 71.4, 56.5, 56.3, 54.4, 44.9, 42.7, 40.0, 
39.4, 38.2, 37.0, 36.4, 36.0, 35.7, 35.6, 32.1, 31.5, 28.7, 28.4, 28.2, 22.5 (x 2), 
24.2, 23.9, 21.3, 18.6, 12.3, 12.1. HR ESIMS m/z 389.3783 [M+H]+, C27H49O 
requires 389.3785.  
Compound 81. Compound 81 (114 mg, 0.3 mmol, 38%) was obtained from 80 
(400 mg, 0.8 mmol) in the same operative conditions reported for 52. An analytic 
sample was purified by HPLC on a Nucleodur 100-5 C18 (5 �m; 4.6 mm i.d. x 
250 mm) with MeOH/H2O (99:1) as eluent (flow rate 1 mL/min), giving pure 
compound 81 (tR=15.4 min). Selected 1H NMR (400 MHz, CDCl3): � 5.80 (1H, 
m, H-24), 4.98 (1H, d, J = 17.0Hz, H-25), 4.90 (1H, d, J = 9.8 Hz, H-25), 
3.60(1H, m, H-3�), 0.92 (3H, d, J = 7.0 Hz, Me-21), 0.80 (3H, s, Me-19), 0.65 
(3H, s, Me-18).13C NMR (100 MHz, CDCl3): � 139.6, 113.9, 71.5, 56.5, 56.3, 
54.3, 44.8, 42.8, 39.9, 38.2, 36.9, 35.7, 35.6, 35.2, 34.8, 32.1, 31.5, 30.2, 28.7, 
28.2, 24.1, 21.3, 18.6, 12.3, 12.1. HR ESIMS m/z 359.3314 [M+H]+, C25H43O 
requires 359.3317.  
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Compound 83. Hydrogenation on 81 (100 mg, 0.3 mmol) gave 83 (98 mg, 0.3 
mmol, quantitative yield). Purification by HPLC on a Nucleodur 100-5 C18 (5 
�m; 4.6 mm i.d. x 250 mm) with MeOH/H2O (99:1) as eluent (flow rate 1 
mL/min), gave pure compound 83 (tR= 19.4 min). Selected 1H NMR (400 MHz, 
CDCl3): � 3.63 (1H, m, H-3�), 0.88 (3H, ovl, Me-21), 0.88 (3H, ovl, Me-25),0.80 
(3H, s, Me-19), 0.65 (3H, s, Me-18).13C NMR (100 MHz, CDCl3): � 71.6, 56.4, 
56.2, 54.3, 45.0, 42.7, 39.9, 38.3, 36.9, 35.9, 35.7, 35.6, 35.3, 32.1, 31.5, 28.6, 
28.4, 28.2, 24.2, 23.1, 21.2, 18.6, 14.2, 12.3, 12.0. HR ESIMS m/z 361.3470 
[M+H]+, C25H45O requires 361.3473.  
Compound 85. Compound 79 (1 g, 2.6 mmol) was hydrolyzed with NaOH (96 
mg, 2.4 mmol) in a solution of MeOH:H2O 1:1 v/v (10 mL). The mixture was 
stirred for 4 h at reflux. The resulting solution was then acidified with HCl 6N and 
extracted with ethyl acetate (3x50 mL). The collected organic phases were washed 
with brine, dried over Na2SO4 anhydrous and evaporated under reduced pressure 
to give the carboxylic acid. The intermediate was treated in the same operative 
conditions reported for 67 furnishing compound 85 (755 mg, 2.0 mmol, 78% over 
three steps). 
Compound 86. Compound 86 (413 mg, 1.3 mmol, 62%) was obtained from 85 
(755 mg, 2.0 mmol) in the same operative conditions reported for 68. An analytic 
sample was purified by HPLC on a Nucleodur 100-5 C18 (5 �m; 4.6 mm i.d. x 
250 mm) with MeOH/H2O (96:4) as eluent (flow rate 1 mL/min), giving pure 
compound 86 (tR=17.4 min). Selected 1H NMR (400 MHz, CD3OD): � 5.66 (1H, 
m, H-22), 4.89 (1H, d, J = 17.4 Hz, H-23), 4.81 (1H, ovl with solvent signal, H-
23), 3.50 (1H, m, H-3�), 1.02 (3H, d, J = 6.5 Hz, Me-21), 0.83 (3H, s, Me-19), 
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0.71 (3H, s, Me-18).13C NMR (100 MHz, CDCl3): � 145.3, 111.6, 71.4, 56.4, 
55.5, 54.4, 45.0, 42.7, 41.2, 39.9, 38.2, 36.9, 35.6, 35.5, 32.1, 31.5, 28.7, 28.3, 
24.2, 21.3, 20.2, 12.3, 12.1. HR ESIMS m/z 331.3001 [M+H]+, C23H39O requires 
331.3003.  
Compound 87. Hydrogenation on 86 (300 mg, 0.9 mmol) gave 87 (287 mg, 0.9 
mmol, quantitative yield). Purification by HPLC on a Nucleodur 100-5 C18 (5 
�m; 4.6 mm i.d. x 250 mm) with MeOH/H2O (99:1) as eluent (flow rate 1 
mL/min), gave pure compound 87 (tR=14.8 min). Selected 1H NMR (400 MHz, 
CDCl3): � 3.63 (1H, m, H-3�), 0.93 (3H, s, Me-19), 0.90 (3H, d, J = 6.7 Hz, Me-
21), 0.83 (3H, t, J = 7.5 Hz, Me-23), 0.65 (3H, s, Me-18).13C NMR (100 MHz, 
CDCl3): � 71.4, 56.5, 56.0, 54.4, 44.9, 42.6, 40.2, 38.2, 37.2, 36.9, 35.8, 35.5, 
32.0, 31.5, 28.7, 28.5, 28.3, 24.1, 21.3, 18.2, 12.2, 12.0, 10.4.  HR ESIMS m/z 
333.3157 [M+H]+, C23H41O requires 333.3159.  
Cell culture. HepG2, an immortalized human hepatocarcinoma cell line, was 
cultured and maintained at 37 °C and 5% CO2 in E-MEM added with 10% FBS, 
1% glutamine and 1%penicillin/streptomycin. HEK-293T and Glutag cells were 
cultured and maintained at 37 °C and 5% CO2 in D-MEM additioned with 10% 
FBS, 1% glutamine and 1% penicillin/streptomycin. 
Luciferase reporter gene assay and dose-response curves. To evaluate LXRα 
mediated transactivation, HepG2 cells were transfected with 200 ng of the 
reporter vector p(UAS)5XTKLuc, 100 ng of a vector containing the ligand 
binding domain of LXRα cloned upstream of the GAL4-DNA binding domain 
(i.e. pSG5-LXRαLBD-GAL4DBD) and 100 of pGL4.70 (Promega), a vector 
encoding the human Renilla gene. To evaluate GPBAR1 mediated transactivation, 
HEK-293T cells were transfected with 200 ng of human pGL4.29 (Promega), a 
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reporter vector containing a cAMP response element (CRE) that drives the 
transcription of the luciferase reporter gene luc2P, with 100 ng of 
pCMVSPORT6-human GPBAR1, and with 100 ng of pGL4.70 Renilla. To 
evaluate FXR mediated transactivation, HepG2 cells were transfected with 100 ng 
of human pSG5-FXR, 100 ng of human pSG5-RXR, 200 ng of the reporter vector 
p(hsp27)-TK-LUC containing the FXR response element IR1 cloned from the 
promoter of heat shock protein 27 (hsp27) and with 100 ng of pGL4.70 Renilla. 
At 24 h post-transfection, cells were stimulated 18 h with 10 μM GW3965, 
TLCA, or CDCA and the synthetized compounds (10 μM). Luciferase activities 
were assayed and normalized with Renilla activities. Dose-response curves were 
performed in HepG2 and HEK-293T cells transfected as described above and then 
treated with increasing concentrations of compounds selected compounds (1, 5, 
10, 25 and 50 µM). At 18 h post stimulations, cellular lysates were assayed for 
luciferase and Renilla activities using the Dual-Luciferase Reporter assay system 
(E1980, Promega). Luminescence was measured using Glomax 20/20 
luminometer (Promega). Luciferase activities (RLU) were normalized with 
Renilla activities (RRU). 
Animal model. C57BL6 mice were originally donated by Dr. Galya Vassileva 
(Schering-Plough Research Institute, Kenilworth). The colonies were maintained 
in the animal facility of University of Perugia. Mice were treated with compound 
65 (30 mg/Kg daily by oral gavage) or vehicle (distilled water) for two weeks. 
Mice were housed under controlled temperatures (22 °C) and photoperiods 
(12:12-hour light/dark cycle), allowed unrestricted access to standard mouse chow 
and tap water and allowed to acclimate to these conditions for at least 5 days 
before inclusion in an experiment. The study was conducted in agreement with the 
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Italian law and the protocol was approved by a ethical committee of University of 
Perugia and by a National committee of Ministry of Health (permission 
n.42/2014-B). The health and body conditions of the animals were monitored 
daily by the Veterinarian in the animal facility. The study protocol caused minor 
suffering, however, animals that lost more than 25% of the initial body weight 
were euthanized. At the day of sacrifice mice were deeply anesthetised with a 
mixture of tiletamine hypochoride and zolazepam hypocloride/xylazine at a dose 
of 50/5 mg/Kg. Blood, liver and terminal ileum were collected for further 
analysis. Aspartate aminotransferase (AST), Total cholesterol and Tryglicerides 
were measured by routine biochemical clinical chemistry. For histological 
examination, portions of liver lobes were fixed in 10% formalin, embedded in 
paraffin, sectioned (5 µm thin) and stained with Hematoxylin/Eosin (H&E), for 
morphometric analysis.  
RNA isolation and RT-PCR. HepG2 and Glutag cells were plated at 1x106 
cells/well in a 6 well plate. After an overnight incubation, cells were starved and 
then stimulated for 18 h with GW3965 or TLCA (10 µM), HDCA (10 µM), and 
with increasing concentrations of compound 65 (1, 5, 10, 25, 50 µM).  
Total RNA was isolated from HepG2 or Glutag cells using the TRIzol reagent 
according to the manufacturer’s specifications (Invitrogen). One microgram of 
purified RNA was treated with DNase-I and reverse transcribed with Superscript 
II (Invitrogen). For Real Time PCR, 25 ng template was dissolved in 25 μL 
containing 200 nmol/L of each primer and 12.5 μL of 2× SYBR FAST Universal 
ready mix (Invitrogen). All reactions were performed in triplicate, and the thermal 
cycling conditions were as follows: 2 min at 95 °C, followed by 40 cycles of 95 
°C for 20 s and 60 °C for 30 s in StepOnePlus (Applied Biosystems). The relative 
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mRNA expression was calculated and expressed as 2-(ΔΔCt). Forward and reverse 
primer sequences were the following, respectively:  
human GAPDH, gaaggtgaaggtcggagt and catgggtggaatcatattggaa;  
human ABCA1, gcttgggaagatttatgacagg and aggggatgattgaaagcagtaa;  
human SREBP1c, gcaaggccatcgactacatt and ggtcagtgtgtcctccacct;  
mouse GAPDH, ctgagtatgtcgtggagtctac and gttggtggtgcaggatgcattg;  
mouse Pro-glucagon, tgaagacaaacgccactcac and caatgttgttccggttcctc.  
Molecular docking. The Glide (version 7.1) software package was used to 
perform molecular docking calculations in the three-dimensional model of 
hGPBAR1 and in the crystal structure of LXRα-LBD bound to a synthetic 
benzisoxazole urea agonist (PDB code: 3IPU). 
This structure was selected among the several available using the following 
criteria: i) the higher resolution of the electron density map; ii) the presence of all 
amino acids in helix 1, which is not fully resolved in all the LXRα crystal 
structures; iii) the presence of an agonist with bulkiness comparable to bile acid 
derivatives. Missing residues in the loop connecting H1 with H3 were added and 
refined using Prime. Ligand and receptors structures were prepared as described 
in a previous paper. 
For both GPBAR1 and LXRα, a box of 30× 30× 30 Å centered on the ligand 
binding cavities was created. The standard precision (SP) mode of the GlideScore 
function was used to score the predicted binding poses.  
Molecular dynamics. All the simulations were performed with NAMD 2.10 
using the ff14SB and gaff Amber force field parameters for the protein and the 
ligand, respectively. Each complex was solvated in a 12.0 Å layer cubic water box 
using the TIP3P water model parameters. The addition of 2 Na+ ions ensured 
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neutrality. Amber charges were applied to the proteins and water molecules, 
whereas the ligand charges were computed using the restrained electrostatic 
potential (RESP) fitting procedure. The ESP was first calculated by means of the 
Gaussian09 package using a 6-31G* basis set at Hartree-Fock level of theory, and 
then the RESP charges were obtained by a two-stages fitting procedure using 
Antechamber. A 10 Å cutoff (switched at 8.0 Å) was used for atom-pair 
interactions. The long-range electrostatic interactions were computed by means of 
the particle mesh Ewald (PME) method, using a 1.0 Å grid spacing in periodic 
boundary conditions. The SHAKE algorithm was applied to constraint bonds 
involving hydrogen atoms, and thus an integration time step of 2 fs could be used. 
Each complex was heated up to 300 K while putting harmonic constraints on the 
protein and the ligand, which were gradually released along the thermalization 
process. Production runs were then performed under NPT conditions at 1 atm and 
300 K.  
All figures were rendered using PyMOL (http://www.pymol.org). 
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1H NMR (400 MHz, CDCl3) of compound 52 
 
 
 
 
 
 
1H NMR (400 MHz, CDCl3) of compound 57 
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1H NMR (400 MHz, CDCl3) of compound 53 
 
  
 
1H NMR (400 MHz, CD3OD) of compound 58 
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1H NMR (400 MHz, CDCl3) of compound 51 
 
 
 
 
 
 
1H NMR (400 MHz, CD3OD) of compound 56 
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1H NMR (400 MHz, CDCl3) of compound 54 
 
 
 
 
 
1H NMR (400 MHz, CDCl3) of compound 55 
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1H NMR (400 MHz, CDCl3) of compound 59 
 
 
 
 
 
1H NMR (400 MHz, CD3OD) of compound 63 
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1H NMR (400 MHz, CD3OD) of compound 65 
 
 
 
 
 
1H NMR (400 MHz, CDCl3) of compound 62 
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1H NMR (400 MHz, CDCl3) of compound 64 
 
 
 
 
 
1H NMR (400 MHz, CDCl3) of compound 68 
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1H NMR (400 MHz, CDCl3) of compound 69 
 
  
 
 
1H NMR (400 MHz, CDCl3) of compound 71 
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1H NMR (400 MHz, CDCl3) of compound 73 
 
  
 
 
1H NMR (400 MHz, CDCl3) of compound 72 
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1H NMR (400 MHz, CDCl3) of compound 74 
 
 
 
 
 
1H NMR (400 MHz, CDCl3) of compound 77 
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1H NMR (400 MHz, CDCl3) of compound 78 
 
  
 
 
1H NMR (400 MHz, CDCl3) of compound 82 
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1H NMR (400 MHz, CDCl3) of compound 84 
 
  
 
 
1H NMR (400 MHz, CDCl3) of compound 81 
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1H NMR (400 MHz, CDCl3) of compound 83 
 
 
 
 
 
1H NMR (400 MHz, CD3OD) of compound 86 
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1H NMR (400 MHz, CD3OD) of compound 87 
 
 
 
 V. Experimental section of SHP agonists. 
3-(2,6-dichlorophenyl)-4-carboethoxy-5-isopropyl-isoxazole (91): 1.2 g 
compound 88 (5.6 mmol) was obtained starting from 1 g of 2,6-
dichlorobenzaldehyde (5.7 mmol) using a procedure found in literature107 with a 
97.5% yield over three steps of reaction. Selected 1H NMR (400 MHz CDCl3): � 
7.4-� 7.3 (3H, m),  4.1 (2H, dd, J = 7.25 Hz), 3.88 (m),  1.44 (6H, d, J = 6.9 Hz),  
1.02 (3H, t, J = 6.98 Hz). 13C NMR (100 MHz CDCl3): � 183.31, 161.08, 158.56, 
135.4, 130.9 (2C), 127.84 (3C), 107.57, 60.44, 27.72, 20.16 (2C), 13.56. HR 
ESIMS m/z 328.1890 [M+H]+, C15H16Cl2NO3 requires 328.1894. 
3-(2,6-dichloro-phenyl)-4-carboxyl-5-isopropyl-isoxazole acid (92): Crude 
compound 91 (200 mg, 0.6 mmol) was refluxed in ca. 50 mL of methanol-water 
1:l with 30% NaOH. After stirring for 12 h, the basic aqueous solution was 
neutralized with HCl 6 N. Then methanol was evaporated and the residue was 
extracted with EtOAc (3 x 30 mL). The combined organic layers were washed 
with brine, dried and evaporated to dryness to give white solid residue, that was 
purified by silica gel chromatography, eluted with CH2Cl2 100% (154 mg, 84.3% 
yield). Selected 1H NMR (400 MHz CDCl3): � 7.36-7.3 (3H, m), 3.85 (1H, m), 
1.44 (6H, d, J = 6.95). 13C NMR (100 MHz CDCl3): � 184.81, 166.34, 158.65, 
135.33, 131.06 (2C), 127.81 (3C), 106.79, 27.82, 20.18 (2C). HR ESIMS m/z 
298.0116 [M-H]-, C13H10Cl2NO3 requires 298.0119. 
3-(2,6-dichlorophenyl)-4-hydroxymethyl-5-isopropyl-isoxazole (93): a solution 
of 3-(2,6-dichlorophenyl)-4-carbomethoxy-5-isopropyl-isoxazole (800 mg, 2.5 
mmol) in tetrahydrofurane (10 ml) was cooled to 0 °C under a nitrogen 
atmosphere while a solution of diisobutylammonium hydride (3.8 ml, 1.5 M in 
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toluene) was added dropwise. The reaction was allowed to warm slowly to 
ambient temperature over several hours and stirred at room temperature for 48 h. 
The flask was again cooled to 0 °C and methanol (4 ml) was carefully added over 
a 10 minutes period. Water (20 ml) was added dropwise and a gelatinous mixture 
formed. Sodium Hydroxide (30 ml, 2 N) was added and the mixture was filtered 
over a plug of celite. After the solids were nearly dry, they were extracted with 
ethyl acetate (3x30 ml) and the filtrates were combined. The organic layer was 
washed with water (2x30 ml) brine (30 ml), dried over anhydrous magnesium 
sulphate, filtered and condensed to give compound 3 (481 mg, 69% yield). An 
analytic sample was obtained by silica gel chromatography eluting with n-hexane: 
EtOAc 97:3. Selected 1H NMR (400 MHz CDCl3): � 7.45-7.35 (3H, m), 4.35 (2H, 
s), 3.35 (1H, m), 1.44 (6H, d, J = 7.08 Hz). 13C NMR (100 MHz CDCl3): � 
176.27, 159.05, 135.69, 131.32 (2C), 128.16 (3C), 112.53, 53.63, 26.95, 20.9 
(2C). HR ESIMS m/z 286.1520 [M+H]+, C13H14Cl2NO2 requires 286.1522. 
3-(2,6-dichlorophenyl)-4-ethylacrylate-5-isopropyl-isoxazole (94): DMSO 
(994 �l, 14 mmol) was added dropwise for 5 min to a solution of oxalyl chloride 
(3.5 ml, 7 mmol) in dry CH2Cl2 (5 ml) at −78°C under argon atmosphere. After 30 
min, a solution of 93 (400 mg, 1.4 mmol) in dry CH2Cl2 (5 ml) was added 
dropwise and the mixture was stirred at −78 °C. After 30 min, Et3N dry (1.9 ml, 
14 mmol) was added dropwise to the solution and the mixture was allowed to 
warm to room temperature. After 1 h, the reaction was quenched by addition of 
aqueous NaHSO4 (1 M, 50 ml). The layers were separated, and the aqueous phase 
was extracted with CH2Cl2 (3x30 mL). The combined organic layers were washed 
with saturated aqueous NaHSO4, saturated aqueous NaHCO3, and brine. The 
organic phase was then dried over Na2SO4 and concentrated to give the 
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corresponding aldehyde (475 mg, quantitative yield) as a colorless oil, which was 
used without any further purification. To a solution of aldehyde (1.7 mmol) in 
THF dry (10 ml) was added LiOH (94 mg, 3.9 mmol) and TEPA 
(triethylphosphonoacetate, 742 �l, 3.9 mmol). The reaction mixture was stirred 
for 45 min at room temperature and then quenched with water (10 ml). The 
mixture was then extracted with EtOAc (3×30 mL), and the organic phase was 
concentrated in vacuo. Silica gel chromatography (CH2Cl2 100%) afforded pure 
94 (415 mg, 84% over two steps). Selected 1H NMR (400 MHz CDCl3): � 7.45-
7.35 (3H, m), 7.38 (1H, d, J = 16.1 Hz), 5.51 (1H, d, J = 16.1 Hz), 4.17 (2H, dd, J 
= 7.38 Hz), 3.43 (1H, m), 1.46 (6H, d, J = 6.8 Hz), 1.27 (3H, t, J = 6.9 Hz). HR 
ESIMS m/z 354.2270 [M+H]+, C17H18Cl2NO3 requires 354.2269. 
3-(2,6-dichlorophenyl)-4-acrilic-5-isopropyl-isoxazole acid (95): A portion of 
compound 94 (100 mg, 0.3 mmol) was hydrolyzed with lithium hydroxide (14 
mg, 0.6 mmol) in a solution of THF:H2O 1:1 v/v (5 mL). The resulting solution 
was then acidified with HCl 6N and extracted with ethyl acetate (3x30 mL). The 
collected organic phases were washed with brine, dried over Na2SO4 anhydrous 
and evaporated under reduced pressure to give 95 (85 mg, 93% yield). An analytic 
sample was obtained by silica gel chromatography eluting with CH2Cl2 100%. 
Selected 1H NMR (400 MHz CDCl3): � 7.45-7.35 (3H, m), 7.41 (1H, d, J = 16.1 
Hz), 5.4 (1H, d, J = 16.1 Hz), 3.43 (1H, m), 1.46 (6H, d, J = 6.9 Hz). 13C NMR 
(100 MHz CDCl3): � 178.71, 171.63, 157.44, 133.57, 131.82 (2C), 128.42 (2C), 
127.00 (3C), 116.92, 109.64, 27.0, 20.68 (2C). HR ESIMS m/z 326.1730 [M-H], 
C15H12Cl2NO3 requires 326.1732. 
3-(2,6-dichlorophenyl)-4-prop-2-en-1-ol-5-isopropyl-isoxazole (96): a solution 
of compound 94 (300 mg, 0.9 mmol) in tetrahydrofurane (5 ml) was cooled to 0 
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°C under a nitrogen atmosphere while a solution of diisobutylammonium hydride 
(2.8 ml, 1.5 M in toluene) was added dropwise. The reaction was allowed to warm 
slowly to ambient temperature over several hours and stirred at room temperature 
for 48 h total. The flask was again cooled to 0 °C and methanol (3 ml) was 
carefully added over a 10 minutes period. Water (10 ml) was added dropwise and 
a gelatinous mixture formed. Sodium Hydroxide (30 ml, 2 N) was added and the 
mixture was filtered over a plug of celite. After the solids were nearly dry, they 
were extracted with ethyl acetate (3x50ml) and the filtrates were combined. The 
organic layer was washed with water (2x50 ml) brine (50 ml), dried over 
anhydrous magnesium sulphate, filtered and condensed to give compound 96 (201 
mg, 76% yield). An analytic sample was obtained by silica gel chromatography 
eluting with CH2Cl2 100%. Selected 1H NMR (400 MHz CDCl3): � 7.45-7.35 
(3H, m), 7.35 (1H, d, J = 16.1 Hz), 6.27 (1H, d, J = 16.1 Hz), 4.13 (1H, d, J = 
5.89 Hz), 3.55 (1H, t, J = 6.0 Hz), 3.22 (1H, m), 1.4 (6H, d, J = 7.1 Hz). HR 
ESIMS m/z 312.1900 [M+H]+, C15H16Cl2NO2  requires 312,1903. 
3-(2,6-dichlorophenyl)-4-(E)-ethyl penta-2,4-dienoate-5-isopropyl-isoxazole 
(97): DMSO (455 �l, 1.6 mmol) was added dropwise for 5 min to a solution of 
oxalyl chloride (1.6 ml, 6.4 mmol) in dry dichloromethane (5 ml) at −78 °C under 
argon atmosphere. After 30 min, a solution of 96 (100 mg, 0.3 mmol) in dry 
CH2Cl2 (5 ml) was added dropwise and the mixture was stirred at −78 °C. After 
30 min, Et3N dry (892 �l, 6.4 mmol) was added dropwise to the solution and the 
mixture was allowed to warm to room temperature. After 1 h, the reaction was 
quenched by addition of aqueous NaHSO4 (1 M, 10 ml). The layers were 
separated, and the aqueous phase was extracted with CH2Cl2 (3×20 ml). The 
combined organic layers were washed with saturated aqueous NaHSO4, saturated 
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aqueous NaHCO3, and brine. The organic phase was then dried over Na2SO4 and 
concentrated to give the corresponding aldehyde (150 mg, quantitative yield) as a 
colorless oil, which was used without any further purification. To a solution of 
aldehyde (0.5 mmol) in THF dry (5 ml) was added LiOH (24 mg, 1.0 mmol) and 
TEPA (triethylphosphonoacetate, 175 �l, 0.9 mmol). The reaction mixture was 
stirred for 30 min at room temperature and then quenched with water (5 ml). The 
mixture was then extracted with EtOAc (3×30 ml), and the organic phase was 
concentrated in vacuo. The solution was poured over a C18 silica gel column. 
Fraction eluted with n-hexane: EtOAc 99:1 gave a mixture that was further 
purified by HPLC on a Nucleodur 100-5 C18 (5 �m; 4.6 mm i.d. x 250 mm) with 
MeOH/H2O (80:20) as eluent (flow rate 1 mL/min), to give 8 mg (6% yield, over 
two steps) of compound 97 (tR=16.2 min). Selected 1H NMR (400 MHz CDCl3): � 
7.48-7.39 (3H, m), 6.56 (2H, d, J = 16.8 Hz), 5.94 (1H, t, J = 14.8 Hz), 5.67 (1H, 
d, J = 15.24 Hz), 4.19 (2H, dd, J = 7.38 Hz), 3.37 (1H, m), 1.46 (6H, d, J = 3.63 
Hz), 1.29 (3H, t, J = 7.1 Hz).HR ESIMS m/z 380.2650 [M+H]+, C19H20Cl2NO3 
requires 380.2654. 
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VI. Experimental section 2-AAQ derivatives. 
Compound 99. To a suspension of Menadione (98, 15.7 g, 89 mmol) in ethyl 
acetate (Volume: 129 ml) was added a solution of sodium hydrosulfite (36.6 g, 
179 mmol) in water (Volume: 145 ml) at rt. The resulting mixture was stirred for 
30 min at the same temperature. The organic layer was separated, washed with 
water (2×110 mL), and concentrated under reduced pressure. The residue was 
triturated with n-heptane (160 mL). The resulting crystals were collected by 
filtration, washed with n-heptane (50 mL), and dried under reduced pressure to 
give 2-methylnaphthalene-1,4-diol 99 (14.8 g, 85 mmol, 96 % yield)  as a pale 
purple crystalline powder. 
Compound 100. To a solution of 2-methylnaphthalene-1,4-diol (14.8 g, 85 
mmol) and dimethylsulfate (43.1 g, 342 mmol) in isopropanol (Volume: 231 ml), 
sodium methoxide (65.9 g of a 28 wt.% solution in methanol, 342 mmol) was 
added dropwise at rt. The resulting mixture was stirred for 30 min at 63°C and 
cooled to 20 °C. Water (500 ml) was added and the mixture was extracted using 
EtOAc (2×500 ml).  The organic layers were combined and washed successively 
with water (4×125 ml), dried with MgSO4, filtered through a glass filter (Por. 4), 
rinsed with EtOAc and concentrated under reduced pressure to give 1,4-
dimethoxy-2-methylnaphthalene 100 (17 g, 84 mmol, 98% yield) as a brown 
solid, which was used directly in further reactions without purification. 
Compound 101. To a solution of 1,4-dimethoxy-2-methylnaphthalene (17 g, 84 
mmol) in DCM (Volume: 232 ml) at 0 °C under a nitrogen atmosphere, there was 
slowly added (dropwise with a pipet) bromine (14.8 g, 92 mmol). The mixture 
was stirred under nitrogen for 1 h at 0 °C, and for an additional 1 h at room 
temperature. Then, 230 ml of water was added to the reaction mixture, the layers 
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were separated, and the aqueous phase was extracted with another 230 ml of 
CH2Cl2. The combined organic layers were washed with 230 ml brine, dried with 
MgSO4, filtered through a glass filter (Por. 4) and the solvents were removed in 
vacuo to yield 2-bromo-1,4-dimethoxy-3-methylnaphthalene 101 (23.5 g, 83 
mmol, 99% yield). 
Compound 102. In a dry 500 ml RB flask (oven dried, cooled under Ar), an ethyl 
acetate (Volume: 228 ml) solution of the 2-bromo-1,4-dimethoxy-3-
methylnaphthalene (16 g, 57.1 mmol) was added. Next, N-Bromosuccinimide 
(13.2 g, 74.3 mmol) and (E)-Azobis(isobutyronitrile) (657 mg, 4 mmol) were 
added. The reaction mixture was then stirred and heated to reflux temp. When the 
reaction was finished, the reaction mixture was concentrated in vacuo. The crude 
product was then diluted with heptane, and the resulting crystals were separated 
by filtration. The filtrate was then concentrated to obtain 2-bromo-3-
(bromomethyl)-1,4-dimethoxynaphthalene 102 (19.4 g, 53.8 mmol, 94% yield). 
Compound 103. To an oven dried Ar-filled 500 mL RB flask there was added 
Sodiumhydride (2.1 g, 86 mmol) in 190 mL DMSO. After applying a nitrogen 
blanket, N-Ethenylacetamide (7.3 g, 86 mmol) in 25 mL of DMSO was added and 
the mixture was stirred at room temperature until a clear mixture was obtained. 
The nitrogen blanket could then be removed. A solution of 2-bromo-3-
(bromomethyl)-1,4-dimethoxynaphthalene (20.6 g, 57.1 mmol) in 70 ml dry 
DMSO was added dropwise over 1 hour and the mixture was stirred further at 
room temperature for 1 hour. After completation, the reaction was poured in 500 
mL of water and extracted with (2x500 mL) EtOAc. Combined organic fractions 
were washed with water (2x300 mL) and 150 mL brine. The combined organic 
fractions were then dried with MgSO4, filtered over a glass filter (Por. size 4) and 
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the solvents were removed in vacuo to obtain N-((3-bromo-1,4-
dimethoxynaphthalen-2-yl)methyl)-N-vinylacetamide 103 (19.4 g, 5.,3 mmol, 
93% yield). 
Compound 104. N-((3-bromo-1,4-dimethoxynaphthalen-2-yl)methyl)-N-
vinylacetamide (5 g, 13.7 mmol) was loaded in a flame dried pressure tube as a 
solid. Palladium(II)acetate (154 mg, 0.7 mmol) and tert-
Butyldicyclohexylphosphonium tetrafluoroborate (470 mg, 1.4 mmol) were 
weighed each in an NMR vial and closed with a cap with a septum. Cesium 
carbonate (4.92 g, 15.1 mmol) was weighed in an NMR vial without cap and was 
oven-dried for at least one hour. The needed amount of solvent was taken with a 
syringe. This was then used to dissolve the reagents sequentially in the different 
vials by dissolving the first reagent (e.g. Pd(OAc)2), add this to the ligand, and so 
on. The mixture of all the reagents, except for Cs2CO3, was then added to the 
oven-dried MW vial under Ar atmosphere. The oven-dried cesium carbonate was, 
after cooling, added to the mixture (without Ar atmosphere). The mixture was 
then bubbled with Ar for at least ten minutes. The pressure tube was closed with a 
screw cap, and was then heated to 130 °C under an Ar atmosphere until the 
reaction was complete (overnight). The solution was then poured onto 40 g of ice 
and extracted with (3x100 ml) EtOAc. The combined layers were washed with 
water (2x200 ml) and brine (200 ml). The combined organic layers were then 
dried with MgSO4, filtered over a glass filter through a pad of celite (Por. size 4) 
and the solvents were removed in vacuo to obtain 1-(5,10-
dimethoxybenzo[g]isoquinolin-2(1H)-yl)ethanone 104 (3.9 g, 13.8 mmol, 100 % 
yield). 
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Compound 105. 1-(5,10-dimethoxybenzo[g]isoquinolin-2(1H)-yl)ethanone (3,9 
g, 13.8 mmol) in a two-necked round-bottomed flask was dissolved in Methanol 
(Volume: 332 ml), and sodiumhydroxide (83 mL of a 5 M aq. solution, 413 
mmol) was added. The mixture was heated at reflux, while pressurized air was 
bubbled through the reaction mixture until the reaction was finished (both 
deprotection and oxidation of C-N bond). After this time the mixture was made 
neutral with an aq. HCl solution and the mixture was concentrated in vacuo. The 
crude mixture was then extracted with (3x200 ml) DCM and the combined 
organic layers were washed with water (200 ml) and brine (200 ml). The 
combined organic layers were dried with MgSO4 and filtered through a glass filter 
(Por. size 4), and the solvents were removed in vacuo to obtain 5,10-
dimethoxybenzo[g]isoquinoline 105 (3.6 g, 14.9 mmol, quantitative). Purification 
by silica gel chromatography eluting with heptane: ethyl acetate 8:2 afforded 1.8 g 
of pure 105. 
Compound 106. To a solution of 5,10-dimethoxybenzo[g]isoquinoline (1.8 g, 7.5 
mmol) in a mixture of ACN/H2O (2:1) was added Cerium(IV)diammoniumnitrate 
(8.7 mg, 15.8 mmol) portionwise over 5 minutes at 0 °C. The mixture was stirred 
at 0 °C until the reaction was complete. Next, the solution was quenched with 
water (200 ml), ACN was removed in vacuo and the mixture was then extracted 
with DCM (3x200 ml). The combined organic phases were dried over MgSO4, 
filtered over a glass filter (Por. 4) through a pad of Celite and the solvents were 
removed in vacuo to obtain benzo[g]isoquinoline-5,10-dione 106 (1.6 g, 7.5 
mmol, 87 % yield) . 
Compound 107. To a solution of benzo[g]isoquinoline-5,10-dione (1.6 g, 7.5 
mmol) in DCM (Volume: 75 ml), m-Chloroperbenzoicacid (75% wt, 2.1 g , 9.0 
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mmol) was added at room temperature while stirring. The reaction mixture was 
stirred at room temperature until the reaction was complete. When the reaction 
was finished, the solvent was removed in vacuo, after which a saturated NaHCO3 
solution (400 ml) was added and was allowed to stir for about 1 hr. The water 
layer was then separated and extracted with DCM (2x400 ml) and the combined 
organic layers were washed with brine (200 mL), dried with MgSO4, filtered 
through a glass filter (Por. 4) and the solvents were removed in vacuo furnishing 
compound 107 (1.5 g, 6.6 mmol, 88%yield).  
1H NMR (400 MHz CDCl3): � 8.89 (1H, s), 8.43 (1H, d, J = 6.8 Hz), 8.33 (2H, 
m), 8.14 (1H, d, J = 6.7 Hz), 7.8 (2H, m).  
13C NMR (100 MHz CDCl3): � 180.4, 179.6, 143.7,137.4, 135.3, 134.8, 133.1, 
132.9, 131.1, 128.0, 127.7, 127.6, 123.9. HR ESIMS m/z 226.2030 [M+H]+, 
C13H7NO3 requires 226.2033 
 
General amination procedure 
 
To a solution of compound 107 (30 mg, 0.1 mmol) in the choosen solvent (0.1 
M), CuI (2.5 mg, 10% mmol) was added (when required). The reaction was 
capped and an oxygen balloon was insert. Then, piperidine was added and the 
reaction was let stir for the selected time. After completion, the mixture was 
cooled down to room temperature, then H2O (10 ml) was added and the mixture 
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was extracted with DCM (3x30 ml). The combined organic layers were dried over 
MgSO4 and evaporated to give the desired product.  
Entry 1. Following the general procedure, toluene was used as solvent. 
Piperideine (91 mg, 1.1 mmol) was added and the reaction was let stir for 16 h. 
Purification by silica gel chromatography (from 100% heptane to 50% 
heptane:ethyl acetate) yielded compound 108 (3.7 mg, 0,012 mmol, 9%) and 
compound 110 (1.5 mg, 0.004 mmol, 2%). 
Entry 2. Following the general procedure, DMSO was used as solvent. 
Piperideine (91 mg, 1.1 mmol) was added and the reaction was let stir for 16 h. 
Purification by silica gel chromatography (from 100% heptane to 50% 
heptane:ethyl acetate) yielded compound 108 (9 mg, 0,029 mmol, 16%) and 
compound 110 (2.8 mg, 0.007 mmol, 4%). 
Entry 3. Following the general procedure, DMF was used as solvent. Piperideine 
(91 mg, 1.1 mmol) was added and the reaction was let stir for 16 h. Purification 
by silica gel chromatography (from 100% heptane to 50% heptane:ethyl acetate) 
yielded compound 108 (18 mg, 0.045 mmol, 34%) and compound 110 (5 mg, 
0.017 mmol, 13%). 
Entry 4. Following the general procedure, CH3CN was used as solvent. 
Piperideine (91 mg, 1.1 mmol) was added and the reaction was let stir for 16 h. 
Purification by silica gel chromatography (from 100% heptane to 50% 
heptane:ethyl acetate) yielded compound 108 (4 mg, 0.013 mmol, 10%). 
Entry 5. Following the general procedure, toluene was used as solvent. 
Piperideine (91 mg, 1.1 mmol) was added and the reaction was let stir for 10 days. 
Purification by silica gel chromatography (from 100% heptane to 50% 
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heptane:ethyl acetate) yielded compound 108 (4 mg, 0.013 mmol, 10%) and 
compound 110 (3 mg, 0.007 mmol, 5%). 
Entry 6. Following the general procedure, an excess of piperideine was added and 
the reaction was let stir for 16 h. Purification by silica gel chromatography (from 
100% heptane to 50% heptane:ethyl acetate) yielded compound 110 (2 mg, 0.006 
mmol, 4%). 
Entry 7. Following the general procedure, toluene was used as solvent. Cs2CO3 
(43 mg, 0.1 mmol) was used as additive and piperideine (91 mg, 1.1 mmol) was 
added and the reaction was let stir for 16 h. Purification by silica gel 
chromatography (from 100% heptane to 50% heptane:ethyl acetate) yielded 
compound 108 (13 mg, 0.04 mmol, 32%) and compound 110 (31 mg, 0.08 mmol, 
60%).  
Entry 8. Following the general procedure, without adding CuI, toluene was used 
as solvent. Cs2CO3 (43 mg, 0.1 mmol) was used as additive and piperideine (91 
mg, 1.1 mmol) was added and the reaction was let stir for 5h.  
Entry 9. Following the general procedure, without adding CuI, toluene was used 
as solvent. Cs2CO3 (43 mg, 0,.1 mmol) was used as additive and piperideine (23 
mg, 0.3 mmol) was added and the reaction was let stir for 16 h.  
Entry 10. Following the general procedure, without adding CuI, toluene was used 
as solvent. Cs2CO3 (43 mg, 0.1 mmol) was used as additive and piperideine (45 
mg, 0.5 mmol) was added and the reaction was let stir for 16 h.  
Entry 11. Following the general procedure, without adding CuI, toluene was used 
as solvent. Cs2CO3 (43 mg, 0.1 mmol) was used as additive and piperideine (91 
mg, 1.1 mmol) was added and the reaction was let stir for 72 h. Purification by 
silica gel chromatography (from 100% heptane to 50% heptane:ethyl acetate) 
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yielded compound 108 (11 mg, 0.03 mmol, 23%) and compound 110 (2 mg, 
0.0065 mmol, 5%). 
Entry 12. Following the general procedure, toluene was used as solvent. Cs2CO3 
(43 mg, 0.1 mmol) was used as additive and piperideine (91 mg, 1.1 mmol) was 
added and the reaction was let stir for 5 h. Purification by silica gel 
chromatography (from 100% heptane to 50% heptane:ethyl acetate) yielded 
compound 108 (4 mg, 0.014 mmol, 10%), compound 109 (6 mg, 0.018 mmol, 
14%) and compound 110 (28 mg, 0.07 mmol, 53%).  
Entry 13. Following the general procedure, toluene was used as solvent. Cs2CO3 
(43 mg, 0.1 mmol) was used as additive and piperideine (91 mg, 1.1 mmol) was 
added and the reaction was let stir for 5 h. Purification by silica gel 
chromatography (from 100% heptane to 50% heptane:ethyl acetate) yielded 
compound 108 (5 mg, 0.016 mmol, 9%), compound 109 (19 mg, 0.062 mmol, 
32%) and compound 110 (20 mg, 0.05 mmol, 26%).  
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GENERAL REDUCTION PROCEDURE 
 
To a stirred mixture of The N-oxide in toluene (0.2 M), was dropwise added 
Phosphorustrichloride (1.2 eq.). The reaction mixture was stirred for 1h at room 
temperature. Saturated solution of NaHCO3 (5 mL) was added and then stirred for 
additional 5 min. The aqueous layer was then washed with CH2Cl2 (3x20 ml). The 
combined organic layers were dried over MgSO4, filtered, and concentrated under 
reduced pressure to give the de-oxygenated product in quantitative yields. 
 
SPECTROSCOPIC DATA 
 
Compound 108. 
 1H NMR (400 MHz CDCl3): � 8.88 (1H, s), 8.28 (2H, broad t), 7.82 (2H, m), 7.6 
(1H, s), 3.52 (4H, t, J = 5.0 Hz), 1.82 (4H, m), 1.73 (2H, m). 
13C NMR (100 MHz CDCl3): � 180.9, 180.0, 139.5, 134.6, 134.4, 133.5, 133.4, 
129.4, 127.5, 127.3, 122.3, 110.2, 49.5 (2-C), 25.6 (2-C), 24.3. HR ESIMS m/z 
309.3370 [M+H]+, C18H16N2O3 requires 309.3372 
Compound 109.  
1H NMR (400 MHz CDCl3): � 8.48 (1H, s), 8.27 (1H, d, J = 7.75 Hz), 8.22 (1H, 
d, J = 7.75 Hz), 8.18 (1H, d, J = 1.67 Hz), 7.83 (1H, t, J = 7.12 Hz), 7.77 (1H, t, J 
= 7.35 Hz), 3.18 (4H, t, J = 5.1 Hz), 1.77 (4H, m), 1.69 (2H, m). 
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13C NMR (100 MHz CDCl3): � 181.5, 178.9, 150.4, 135.0, 134.9, 134.7, 133.6, 
132.9, 131.6, 130.2, 127.7, 126.8, 118.0, 53.5 (2-C), 25.6 (2-C), 23.7. HR ESIMS 
m/z 309.3371 [M+H]+, C18H16N2O3 requires 309.3374 
Compound 110 
1H NMR (400 MHz CDCl3): � 8.6 (1H, s), 8.18 (2H, m), 7.79 (1H, t, J = 7.3 Hz), 
7.74 (1H, t, J = 7.3 Hz), 3.34 (4H, broad d), 1.77-1.68 (12H, m). 
13C NMR (100 MHz CDCl3): � 181.4, 180.6, 157.9, 148.3, 135.9, 134.7, 133.8, 
133.4, 132.6, 127.0 (2-C), 126.6, 124.4, 52.1 (2-C), 49.0 (2-C), 26.6 (2-C), 26.1 
(2-C), 24.0, 23.9. HR ESIMS m/z 391.4710 [M+H]+, C23H25N3O3 requires 
391.4709 
Compound 111. 
1H NMR (400 MHz CDCl3): � 9.12 (1H, s), 8.32 (1H, d, J = 7.5 Hz), 8.26 (1H, d, 
J = 7.7 Hz), 7.81 (1H, t, J = 7.6 Hz), 7.28 (1H, s), 3.83 (4H, t, J = 4.9 Hz), 1.74 
(2H, m), 1.69 (4H, m). 
13C NMR (100 MHz CDCl3): � 183.8, 180.8, 161.1, 151.4, 134.7, 134.5, 1343.6, 
133.2, 127.1 (2-C), 116.1, 100.9, 46.4 (2-C), 25.6, 24.6 (2-C). HR ESIMS m/z 
293.3380 [M+H]+, C23H25N3O3 requires 293.3383 
Compound 112. 
1H NMR (400 MHz CDCl3): � 9.01 (1H, s), 8.83 (1H, s), 8.25 (2H, m), 7.8 (2H, 
m), 3.27 (4H, t, J = 5.4 Hz), 1.88 (4H, q, J = 5.6 Hz), 1.77 (2H, q, J = 5.7 Hz). 
13C NMR (100 MHz CDCl3): � 184.1, 181.7, 148.4, 145.2, 140.0, 134.8, 134.5, 
133.6, 132.2, 127.4, 127.3, 126.5, 126.8124.5, 53.5, 25.8, 24.1. HR ESIMS m/z 
293.3382 [M+H]+, C23H25N3O3 requires 293.3385 
Compound 113. 
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1H NMR (400 MHz CDCl3): � 8.95 (1H, s), 8.19 (1H, m), 8.09 (1H, m), 7.73 (2H, 
m), 3.57 (4H, t, J = 5.1 Hz), 3.11 (4H, broad t), 1.75-1.69 (12H, m). 
13C NMR (100 MHz CDCl3): � 185.6, 182.2, 164.8, 143.0, 138.0, 133.8, 133.6, 
133.4, 133.2, 126.4, 126.3, 121.5, 50.3 (2-C), 49.7 (2-C), 26.3, 26.1, 24.6 (2-C), 
24.1 (2-C). HR ESIMS m/z 376.4720 [M+H]+, C23H25N3O3 requires 376.4724 
Compound 114. 
1H NMR (400 MHz CDCl3): � 8.15 (1H, d, J = 7.6 Hz), 7.93 (1H, d, J = 7.6 Hz), 
7.66 (1H, dt, J = 7.6 Hz, J = 0.8 Hz), 7.57 (1H, dt, J = 7.5 Hz, J = 1.0 Hz), 3.71 
(4H, broad t), 3.57 (4H, broad t), 2.91 (4H, broad t), 1.68-1.62 (18H, m). 
13C NMR (100 MHz CDCl3): � 190.6, 176.6, 161.7, 155.5, 140.9, 135.5, 134.7, 
133.5, 131.6, 129.1, 126.3, 124.9, 101.9, 50.6 (2-C), 50.2 (2-C), 49.9 (2-C), 26.5, 
26.4, 26.3 (2-C), 24.9 (2-C), 24.8, 24.0 (2-C). HR ESIMS m/z 459.6060 [M+H]+, 
C23H25N3O3 requires 459.6063. 
 
 1H NMR (400 MHz, CDCl3) of compound 107 
 
 
1H NMR (400 MHz, CDCl3) of compound 108 
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1H NMR (400 MHz, CDCl3) of compound 109 
 
1H NMR (400 MHz, CDCl3) of compound 110 
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1H NMR (400 MHz, CDCl3) of compound 111 
 
1H NMR (400 MHz, CDCl3) of compound 112 
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1H NMR (400 MHz, CDCl3) of compound 113 
 
1H NMR (400 MHz, CDCl3) of compound 114 
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